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Abstract 
Cardiovascular disease (CVD) remains a leading cause of premature death worldwide. 
Despite advances in treatment of ischemic diseases including myocardial infarction and 
peripheral arterial disease (PAD), there remains a need for effective revascularization 
therapies. Although early cell therapy trials investigated use of mononuclear cells from 
autologous bone marrow, emerging evidence indicates that purified progenitor cell 
populations are required to induce optimal vascular regeneration. In addition, autologous 
cells show reduced efficacy due to CVD-related progenitor dysfunction. This thesis presents 
preclinical studies characterizing several blood-derived cell types for the development of 
cellular therapies to treat PAD, focusing on the use of allogeneic umbilical cord blood (UCB) 
hematopoietic progenitor cells (HPC) and bone marrow multipotent stromal cells (MSC). 
First, I demonstrated that human UCB cells prospectively purified based on high aldehyde 
dehydrogenase activity (ALDHhi), promote the recovery of perfusion and vascularization in 
mice with acute unilateral hindlimb ischemia. Unfortunately, the rarity of ALDHhi cells 
impedes clinical implementation for patients with PAD. To address this issue, I developed ex 
vivo culture protocols to increase the number of ALDHhi cells available for therapy. I 
demonstrated that after a 20-fold increase in total cell number, expanded HPC maintained 
robust vascular regenerative functions. Indeed, expanded UCB promoted endothelial cell 
survival and endothelial cell tubule formation by paracrine mechanisms. Notably, 
intramuscular injection of HPC significantly augmented recovery of perfusion and increased 
vascularization in the injured limb, and increased recovery of limb usage within one week of 
therapy. MSC have been widely investigated for vascular regenerative cellular therapies, 
however substantial variability between donor sources indicating a need for better markers to 
select pro-angiogenic MSC subsets for clinical applications. I demonstrated that MSC 
retaining high ALDH activity after expansion effected increased endothelial cell 
proliferation, survival, and tubule formation using in vitro systems. Taken together, my work 
establishes the value of ALDH as a marker of cells with increased vascular regenerative 
potential. My work also reveals that UCB ALDHhi cells, their ex vivo expanded HPC 
progeny, and MSC retaining high ALDH-activity after expansion represent promising 
candidates for future development of vascular cell therapies for PAD and CVD. 
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Chapter 1 
1 Introductioni 
1.1 Cardiovascular disease 
Despite significant progress and advances to improve treatments and management, 
cardiovascular disease (CVD) remains the leading cause of premature death worldwide 
and represents a huge burden on the health care systems in North America1,2.  Broadly, 
CVD includes a diverse array of conditions and affecting the heart and blood vessels.  
Common classifications of CVD include both chronic conditions such as ischemic heart 
disease, peripheral vascular disease, cerebrovascular disease and heart failure and acute 
conditions like myocardial infarction and stroke. CVD accounts for roughly one third of 
all deaths and it is estimated that CVD and stroke-related healthcare costs for patients are 
now in excess of $300 billion in the US alone1-3.  
1.1.1 Atherosclerosis 
One common risk factor of CVD is atherosclerosis1,4-6.  Atherosclerosis is characterized 
by the progressive development of complex lesions or plaques that protrude from the 
vascular lumen effectively narrowing the blood vessel1,3-5,7.  In response to stressors like 
dyslipidemia, hypertension and inflammation, arterial blood vessel endothelial cells 
(ECs), which normally do not adhere circulating white blood cells, begin to express 
adhesion molecules, effectively attracting monocytes to the vessel intima8.  These 
monocytes differentiate into tissue resident macrophages, which engulf lipoprotein from 
                                                
i Parts of this chapter have been previously published:  
Putman, D. M., Bell, G. I. & Hess, D. A. Blood-Derived ALDHhi Cells in Tissue Repair in Regenerative 
Therapy Using Blood-Derived Stem Cells (Allan, D. S. S. & Strunk, D.) 21–34 (Humana Press, 2012). 
doi:10.1007/978-1-61779-471-1_3 
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the interstitium and become foam cells. This stage is called the fatty streak, named for the 
appearance of the accumulated lipid filled foam cells in the developing lesion8.  In the 
developing atheroma, SMC are recruited from the medial layer to the intima where they 
proliferate with the foam cells.  Lipid pools form in the core of the lesion between the 
ECs and the accumulating foam cells and SMC comprising the pathologic intimal layer9.  
The lipid core becomes increasingly apoptotic and necrotic as SMC and foam cells die 
and release accumulated intracellular lipids and cholesterol. Advancing plaques become 
increasingly fibrotic and calcified as the lumen of the blood vessel becomes narrowed7. 
As the lesion becomes larger and more fibrotic there is increased risk of developing what 
is called the vulnerable plaque, characterized by a thin fibrous cap, a large lipid-rich 
necrotic core, more inflammation and possible neovascularization and haemorrhage.  The 
vulnerable plaque is more prone to initiating thrombosis where a part of the plaque breaks 
off and enters the circulation10, or the lesion may become complicated resulting in a 
hematoma if it becomes vascularized by recruiting new blood vessels8. Plaque rupture or 
thrombosis can lead to the acute ischemic events of myocardial infarction or stroke7. 
Chronic reduction in blood flow to the heart or peripheral tissues due to severe 
narrowing, or stenosis, leads to overt tissue ischemia. Broadly, it has been shown that 
many factors influence the risk and development of atherosclerotic CVD including 
physical activity, cigarette smoking, cholesterol levels and blood pressure11,12. 
1.1.2 Chronic vascular diseases 
Ischemia is characterized by insufficient blood flow to a given tissue or organ.  Chronic 
ischemia due to atherosclerosis in the limbs or extremities, like the lower leg, is called 
peripheral arterial disease (PAD)13.  In contrast, coronary artery disease (CAD) presents 
where there are atheromatous lesions stenosing the coronary arteries feeding the 
myocardium of the heart which can lead to heart failure14.   The epidemiology of vascular 
disease is relatively well described and is associated with increased age, and major risk 
factors for the development and progression of vascular disease include, smoking and 
diabetes mellitus15,16.   More than half of patients with CAD have type 2 diabetes mellitus 
associated with insulin resistance and the severity and rate of progression of vascular 
disease complications is increased in patients with diabetes16.  Furthermore, diabetes is 
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associated with increased risk for developing PAD.  Patients with diabetes have higher 
rates of PAD and higher rates of intermittent claudication and poor wound healing in the 
peripheral extremities17,18.  
1.1.2.1 Coronary artery disease 
CAD is a major component of CVD, contributing to millions of deaths each year due to 
myocardial infarction and affecting many more people who a debilitated by permanent 
disability due to progressive heart failure5.  The treatment of CAD has improved greatly 
since the Coronary Artery Surgery Study (CASS) clinical trial first demonstrated the use 
of coronary artery bypass surgical intervention19.   It is estimated that 1% of the Western 
world is affected by congestive heart failure and the mortality in late stage heart failure is 
very high, estimated to be above 60% within 10 years in patients above 6514,20.  Currently, 
the best treatment for end stage heart failure is heart transplantation21.  Unfortunately, 
heart transplantation is only an option for a very small subset of patients as there are too 
few donors to meet the demand for potential recipients. Furthermore many patients do not 
meet the eligibility criteria for transplantation and do not have any remaining viable 
medical or surgical options22.  In these patients there is a need for alternative therapeutic 
strategies as well as preventative therapies to reduce progression to end stage heart 
failure.   
1.1.2.2 Peripheral arterial disease 
Peripheral vascular or peripheral arterial disease (PAD), like CAD, is generally caused by 
macrovascular atherosclerotic plaque progression leading to arterial stenosis13,23-25. Other 
major factors related to PAD incidence are advanced age, smoking and diabetes26,27. PAD 
of varying severity is extremely widespread and is estimated to affect more than 27 
million people in North America and Europe28. The most common symptom in the 
diagnosis of PAD that presents in patients is intermittent claudcation, or limping 
associated with muscle cramping after moderate exertion and tends to present first in the 
distal extremity of the calf muscle24.  As the arteries of the lower extremities become 
more severely narrowed the symptoms in the patient worsen.  PAD is graded by severity 
based on degree of tissue ischemia, commonly using the Rutherford scale29.   The most 
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common therapy for PAD has focused on smoking cessation, increasing exercise to 
induce improved collateralization by arteriogenesis, pharmacological vasodilatation, and 
surgical revascularization30.  Unfortunately, the progression of PAD severity advances 
aggressively culminating in the most severe form of PAD, critical limb ischemia 
(CLI)24,31,32.   CLI is characterized by pain at rest and/or tissue loss in the ischemic limb24.   
Patients with PAD and concomitant diabetes and atherosclerosis often show endothelial 
dysfunction in the microcirculation in addition to the stenosis further complicating 
treatment in CLI as vascular regeneration is impaired23,24. In CLI there is a significant 
mismatch in the metabolic demand of the affected area and the ability of the vasculature 
to adequately perfuse the tissue23,33.  This perfusion insufficiency causes pain at rest and 
can lead to persistent non-healing ulcers increasing the risk for co-infection of the 
wounds23.   CLI patients have poor prognosis, leg amputation is required in 30% of 
patients after 1 year with CLI and mortality at 1 year is greater than 20%28. Notably, CLI 
patients have very poor psychological quality of life indices, about the same level as 
terminally-ill cancer patients32.   Despite the benefit of surgical revascularization and 
endovascular catheterization, it is estimated that more than 50% of patients are ineligible 
for these treatments due to co-morbidity or anatomic complexity34. The lack of effective 
therapy for many CLI patients indicates a need for improved revascularization strategies.  
1.2 Vascular biology 
Blood vessels are the primary conduits though which blood flows to carry oxygen, carbon 
dioxide, nutrients, hormones, and blood cells to and from every organ of the body35.  The 
fundamental structural unit of the blood vessel is the EC.   The endothelium comprises 
the single inner layer of the blood vessel surrounding the central lumen through which the 
blood flows. ECs play an important role in the regulation of blood flow and serve as a 
barrier between the blood and interstitium.  Because of a short diffusion distance (0.1 to 
0.2mm) the entire body must be highly vascularised with a branching network of blood 
vessels36,37.  
Capillaries are the smallest blood vessels and consist solely of a single layer of ECs 
surrounded by occasional pericytes.  In larger vessels, arterioles and venules, the 
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endothelium is surrounded by pericytes and connective tissue. Larger and more complex, 
in arteries and veins the inner layer of ECs is surrounded by a basement membrane and 
supportive perivascular cells including pericytes and a thick layer of smooth muscle cells 
(SMC)37. The heart pumps oxygenated blood from the lungs at high pressure through 
arteries to arterioles and finally to capillaries where nutrient and gas exchange occurs.  
From the arterial capillaries flow continues into venous circulation and passes from 
capillaries to venules to larger veins and back to the heart at lower pressure and speed. To 
accommodate higher pressure of arterial circulation, arteries have thicker layers of SMC 
compared to veins35,38,39.  
ECs help mediate local responses to injury and inflammation by modulating thrombosis 
and by permitting blood-derived immune cells to pass through to the interstitium40-42.   
ECs are a heterogeneous cell type and display phenotypic differences between arterial 
and venous circulation and between organ source and size of vessel35,38,39,42.  In the 
healthy adult, ECs are primarily quiescent and have low turnover within the vessel.  They 
are protected from injury by autocrine survival and maintenance signals, such as vascular 
endothelial growth factor-A (VEGF-A), angiopoietin-1 (ANG-1) and fibroblast growth 
factors (FGFs) 42-44.  Due to their involvement in oxygen supply, blood vessels express 
oxygen sensors like prolyl hydroxylase domain 2 (PHD2) and hypoxia inducible factors 
like hypoxia-inducible factors 1α and 2α (HIF-1α and HIF-2α)36,45-47. These permit the 
ECs to respond appropriately to changes in oxygen levels36.  In the perfused vessel, 
adjacent ECs form a tight monolayer interconnected by junctional molecules like VE-
cadherin.  The pericytes that surround the vessel share a basement membrane with the 
ECs and express factors like VEGF-A and ANG-1 that normally maintain homeostatic 
quiescence in the ECs36,48. 
1.2.1 Vascular development 
The formation of the vasculature is an important early step in organogenesis during 
development of the embryo because as an organism grows it needs a more advanced 
system for oxygen and nutrient exchange and to remove metabolic waste37,49.  In the 
developing embryo the vasculature forms by two primary processes, vasculogenesis and 
angiogenesis.  In vasculogenesis, mesodermal precursor cells migrate, aggregate and 
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differentiate de novo into a hemangioblast, a common precursor of both blood and 
ECs37,49,50.  These hemangioblasts create new blood vessels and form the primary vascular 
plexus of capillaries. Subsequent expansion and remodeling of the primary capillary 
plexus occurs by angiogenesis which encompasses many steps including adhesion, 
migration, proliferation, differentiation and tube formation from the already existing 
vessel36,44,49.    
1.2.1.1 Vasculogenesis in development 
Vasculogenesis is the de novo formation of blood vessels from mesodermal progenitor 
cells.  In the mouse the earliest marker of the hemangioblast is Flk1 also known as 
vascular endothelial growth factor 2 (VEGFR2).  VEGFR2 is the primary receptor for 
VEGF-A. Flk1 marks a subset of Brachyury-positive (mesodermal) cells in the primitive 
streak which migrate to the extra-embryonic endoderm and form the vascular plexus, part 
of which will form blood islands.  The outer cells in the blood islands are ECs while the 
inner cells become hematopoietic progenitor cells49.  The hemangioblast theory has been 
supported by findings from human embryonic stem cell in vitro differentiation studies51 
and in vitro differentiation of isolated hemangioblasts from mouse embryos52.  After the 
formation of the vascular plexus, angiogenesis becomes the primary mechanism by which 
blood vessels develop and remodel in the embryo proper. 
1.2.2 Angiogenesis 
Angiogenesis is defined as the growth of new blood vessels from the preexisting 
vasculature44.  There are two main types of angiogenesis that occur, intussusceptive and 
sprouting angiogenesis.  The primary difference is that sprouting angiogenesis is 
relatively slow and involves proliferation of ECs and subsequent invasion of vascularized 
tissues by the growing EC pool44. Intussusceptive angiogenesis involves preexisting, 
perfused blood vessels which remodel into new vessels and occurs without need for EC 
proliferation53. Sprouting angiogenesis occurs when ECs become activated by increased 
levels of angiogenic growth factors like VEGF-A, angiopoietin-2 (ANG-2), and 
FGFs43,54,55. Chemokines which are released by hypoxic or inflammatory cells will also 
initiate pro-angiogenic activation in ECs56.  Broadly, angiogenesis includes extracellular 
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matrix and basement membrane remodeling, increased EC migration, and induction of 
EC proliferation leading to the formation of new blood vessel branches.  
1.2.2.1 VEGF and NOTCH signaling in angiogenesis 
VEGF signaling causes ECs to reduce VE-cadherin expression and EC-EC junctions 
loosen, increasing permeability allowing plasma proteins access to the interstitium 
around the vessel, laying down a scaffold for EC migration57.  Single EC are selected to 
become the tip cell which lead the growing endothelial tube towards the angiogenic 
signal58. In response to a VEGF-A gradient, tip cells upregulate expression of Delta-like 
ligand 4 (DLL4) which activates NOTCH signaling in adjacent EC cells leading to 
downregulation of VEGFR-2 and establishment of a stalk cell phenotype58.  This makes 
stalk cell less responsive to VEGF signaling compared to tip cells and the stalk cells 
become proliferative, causing the growing vessel sprout to lengthen by cell division.  The 
tip cells develop filopodia enabling them to sense environmental signals and guidance 
cues to direct the growing vessel branch towards an angiogenic stimulus. Macrophages 
have been shown to act as myeloid bridge cells that help fuse the sprouting vessels with 
other growing branches enabling contiguous blood flow in a process known as vascular 
anastomosis36,59,60. Although initiated by activated ECs, complete angiogenesis is a 
complex process requiring the integration multiple cell types and signaling pathways. 
1.2.2.2 Angiogenesis in hypoxia  
Hypoxia, or low oxygen tension, is an important mediator of angiogenesis47,61. The HIFs 
are transcription factors composed of an oxygen-sensitive α-subunit (HIFα) and a stable 
β-subunit (HIFβ), also called the aryl hydrocarbon nuclear translocator (ARNT) which 
together regulate expression hypoxia-responsive elements47,62.  Under normal oxygen 
tension, or normoxia, HIFα is hydroxylated by prolyl-hydroxylase domain (PHD)–
containing enzymes and subsequently ubiquitinated, tagging it for proteasomal 
degredation62.   PHD requires oxygen to hydroxylate HIFα and is therefore are unable to 
initiate degradation of HIFα during hypoxia63.  Stable HIFα forms heterodimers with 
HIFβ and translocates to the nucleus where is regulates expression of hundreds of genes 
that regulate angiogenesis including VEGF-A45,46,64.  Many other angiogenesis-related 
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genes have been shown to be regulated by hypoxia, further increasing the complexity of 
the angiogenic process65-69.  
1.2.2.3 Angiopoietin and FGF signaling in angiogenesis 
The angiopoietins, ANG1 and ANG2, are important regulators of EC quiescence and 
angiogenesis55. Homeostasis and response to angiogenic activation is regulated by 
angiopoietin signaling through the TIE receptors TIE-1 and TIE-2.  ANG-1 is the primary 
agonist of TIE-2 and depending on signaling context, ANG-2 is a generally considered a 
competitive antagonist of ANG-1/TIE-2 signaling axis70. Recently ANG-2 has also been 
shown to be a context-dependent TIE-2 agonist. Quiescence in EC is maintained by 
ANG-1 signaling through TIE271.  ANG1 also promotes mural cell/pericyte coverage and 
increases deposition of basement membrane, further increasing vessel stability55. In 
response to angiogenic stimuli, the tip cells and sprouting EC release ANG-2.  ANG-2 
competitively inhibits TIE-2 signaling thereby increasing pericyte detachment, vessel 
permeability and endothelial branch formation70,72.  In response to ANG-2, pericytes 
initiate proteolytic degradation of the basement membrane by releasing matrix 
metalloproteinases (MMPs) and detach from the vessel wall36.  FGF signaling induces 
angiogenesis directly in ECs or indirectly by activating secretion of other angiogenic 
factors from neighboring cell types43.  Furthermore, low levels of active FGF signaling is 
necessary in quiescent blood vessels as inhibition of FGFR signaling leads to vessel 
regression73.   
1.2.2.4 Extracellular matrix modification in angiogenesis 
In vascular homeostasis the basement membrane between the ECs and perivascular cells 
helps maintain EC quiescence. During angiogenesis the basement membrane is degraded 
and the ECM begins to be remodeled by proteases like the MMPs44,74. Proteolytic 
degradation of the extracellular matrix (ECM) liberates further VEGF and FGF release 
from deposits in the ECM as it is remodeled to be more accommodating to migrating and 
proliferating ECs44,74,75.  Matrix remodeling by MMP activity promotes EC migration and 
tube formation by creating a pro-angiogenic microenvironment74,76. 
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1.2.2.5 Chemokine signaling in angiogenesis 
Chemokines have been demonstrated to play a role in the regulation of angiogenesis in a 
number of pathophysiological conditions including ischemia36,56.  Chemokines can exert 
their role in angiogenesis both directly via actions on ECs and indirectly by recruiting 
leukocytes and modulating growth factor signaling.  Chemokines are a family of secreted 
proteins classified into subgroups based on the spacing and presence of four conserved 
cysteine residues, C, CC, CXC, and CX3C chemokines77.  Several members of the CXCL 
family have been demonstrated to promote angiogenesis including CXCL1 (GRO-α), 
CXCL5 (ENA-78), CXCL8 (IL-8), and CXCL12 (SDF-1)78-80. The mechanism by which 
CXCL12 promotes angiogenesis is particularly well established81,82.   Angiogenic VEGF 
signaling has been demonstrated to induce EC and perivascular expression of the 
chemokine SDF-1/CXCL12 which in turn recruits circulating pro-angiogenic myeloid 
progenitor cells to the vasculature83.  These bone marrow (BM) derived angiogenic 
hematopoietic cells are proposed to provide critical paracrine support enhancing both 
inflammation and angiogenesis81-84.    
Of the CC family cytokines, CC2L (MCP-1, monocyte chemoattractant protein-1)85 and 
CCL5 (RANTES)86,87, have been notably demonstrated to be angiogenic85,88. MCP-1 is 
highly upregulated in vascular smooth muscle cell after injury to the blood vessel89,90.   
MCP-1 signaling induces recruitment and transendothelial migration of monocytes and 
into the intima of the injured vessel91.  MCP-1 has been demonstrated to be an important 
mediator of monocyte-EC adherence which were shown to increase vascular regeneration 
and revascularization in a balloon-mediated endothelial injury model92.  Other studies 
have also implicated MCP-1 in recruitment of monocytes and macrophages and 
mediation of angiogenesis during wound repair93,94.  MCP-1 has also been implicated in 
directly promoting angiogenesis by activating chemokine receptors on ECs95. RANTES 
has been shown to be necessary for angiogenesis to occur in rats with peripheral ischemia 
through proposed recruitment of myeloid cells to the site of injury87. RANTES, which 
stands for regulated upon activation, normal T-cell expressed and secreted, also plays an 
important role in recruitment of monocytes and circulating angiogenic hematopoietic 
progenitor cells which modulate angiogenesis and vascular repair86,96,97. CX3CL1 has 
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been demonstrated to promote angiogenesis directly in ECs from skin by recruiting 
angiogenic lymphocytes98.   In a similar fashion, other chemokines have been shown to 
modulate vascular repair and interact differentially with endothelium in various organs 
further underscoring the phenotypic differences in ECs by tissue residence and location in 
the vascular network.    
1.2.2.6 Vascular remodeling and resolution of angiogenesis 
Most of the newly formed blood vessel networks formed during angiogenesis after 
vascular trauma are chaotic, tortuous and form many dead ends not forming a complete 
loop from arterial to venous circulation99.  As such, these vessels are poorly perfused and 
considered immature, as they lack tight EC-EC VE-cadherin junctions and are 
consequently leaky.  Furthermore, most newly sprouted vessels contain very few 
pericytes to stabilize them100,101.   For the new vessel to become functional and stable it 
must resume its quiescent state and recruit pericyte support102. The recruitment of 
pericytes to the newly formed vessel is mediated primarily by the platelet derived growth 
factors (PDGFs), angiopoietins and transforming growth factor-β (TGF-β) 55,102-104. In the 
growing vessel branch ECs secrete PDGF-B to recruit pericytes to stabilize the nascent 
vessel103.  
As blood flow is restored to a tissue the hypoxic stress is reduced and consequently, there 
is a decrease in secretion of angiogenic growth factors and activation of ECs.  As the 
peak of vessel density is reached in the wound bed of ischemic tissue, anti-angiogenic 
signals begin to outweigh angiogenic stimuli and further sprouting is stopped as the 
vascular network begins to be pruned back to homeostatic levels105,106.    Fluid flow forces 
or shear stress in newly perfused branches initiates pro-survival mechanisms helping to 
prune the branching network to ensure optimal blood flow107.   While only a minority of 
vessels newly perfused by blood flow will mature and recruit perivascular support and 
ECM remodeling108, the majority of vessel branches which are not adequately perfused 
will undergo regression107.  The generally accepted mechanism by which regression and 
vascular network pruning occurs is through apoptosis, programmed cell death109,110.  
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During maturation and regression of the vascular network after injury or hypoxia the 
ECM is concurrently remodeled and new basement membrane components must be 
deposited surrounding the vessels to be stabilized.  MMP-mediated remodeling during 
this stage can lead to dissociation of EC-ECM contacts and this has been postulated to 
promote regression of unstable non-perfused vessels111. In contrast, tissue inhibitors of 
metalloproteinases (TIMPs) and plasminogen activator inhibitor-1 (PAI-1) promote the 
deposition of new basement membrane around vessels that undergo subsequent 
functional maturation36.    
1.2.3 Arteriogenesis 
During arteriogenesis pre-existing arterioles undergo considerable remodeling to form 
larger, functional collateral blood vessels112. Arteriogenesis is stimulated by increased 
shear stress induced by narrowing in major arteries shunting increased flow into the 
smaller collateral arterioles113,114. Commonly this occurs as an effect of arterial stenosis 
during pathological atherosclerotic arterial disease115. The process of arteriogenesis is 
regulated by cytokines like MCP-1 which recruits hematopoietic support cells, and FGF 
which is mitogen of both ECs and smooth muscle cells116.  Collectively, the effects 
modulated during arteriogenesis stimulate extracellular matrix remodeling, and 
subsequent formation of multilayered arteries, inclusive of the intima (endothelium, 
basement membrane and pericytes) the media (smooth muscle cells and their ECM) and 
adventitia (fibroblasts and their extracellular matrix)112.    
Arteriogenesis is mechanically driven by increased pressure which increases stress on the 
vessel wall; the vessel enlarges until the stress is normalized117,118.  The increased shear 
stress causes the endothelium of the arterioles to increase expression of adhesion 
molecules leading to increased recruitment of monocytes and macrophages which help 
drive arteriogenesis119. In addition to recruitment of monocytes, circulating BM-derived 
hematopoietic progenitor cells are recruited to growing arteriole and promote further 
arteriogenesis81,120-124.   In order to accommodate the growing diameter of the arterioles 
the ECM must be remodeled in a process similar to that in angiogenesis115,116,125.  Despite 
an increase in collateral size after arteriogenesis is resolved, the collaterals still do not 
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recapitulate the full conductance of the artery they’ve replaced allowing for the refinenent 
of endogenous repair by other pro-angiogenic processes114,115,126.   
1.2.4 Postnatal vasculogenesis  
Vasculogenesis was originally thought to be restricted solely to embryonic development 
until 1997 when Asahara et al. demonstrated evidence for peripheral blood-derived cells 
which were termed endothelial precursor cells (EPC)127.  Asahara et al. postulated that 
since angioblasts and hematopoietic cells arise in development nearly simultaneously in 
extra-embryonic blood islands and share expression of many cell surface antigens that 
they may share a common progenitor cell (the hemangioblast), which might persist in the 
adult organism, as is the case with hematopoietic stem cells.  They isolated cells from 
human blood based on CD34 expression and from murine blood by Flk-1 (VEGF-R2) 
expression and showed some engraftment of transplanted EPC in close association with 
the injured endothelium. Because integrated EPC co-stained for mature EC marker they 
postulated that this was evidence of a postnatal vasculogenic process.   Many of the 
findings of this paper became some of the defining and often controversial characteristics 
of a circulating EPC128. Many subsequent studies have shown that several cell types that 
have been termed EPC are in fact hematopoietic cells with proangiogenic function and 
phenotype128-132.  Many of these pro-angiogenic hematopoietic cells facilitate robust 
vascular regeneration without stable integration into the endothelium, in effect supporting 
the literature on angiogenesis and arteriogenesis, and raising questions on the clinical 
applicability of postnatal vasculogenesis during vascular repair in the adult81,82,124,133-138.  In 
2007, Yoder et al. defined endothelial colony forming cells129 (ECFC) as putative EPC, 
which are rare blood-derived cells that form late-outgrowth adherent colonies of 
proliferative cells when propagated under strict EC growth conditions, and can be 
isolated at extremely low frequency from human peripheral blood, BM, and umbilical 
cord blood (UCB).  ECFC are distinguished from pro-angiogenic hematopoietic cell 
types in human blood as they were exclusively CD45-, and represented the only cell type 
that could integrate directly into perfused vessels in vivo128,130-132,139.  It has been proposed 
that pro-angiogenic hematopoietic cells and vessel-resident ECFC cooperatively 
coordinate the vascular regenerative niche140. 
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1.3 Cell therapy for vascular regeneration 
The identification of molecular mediators, cells and genes involved in angiogenesis and 
arteriogenesis has presented the possibility of new therapeutic approaches to promote 
vascular regeneration during CVD3,21,23,33,115,141-143.  Many different cell types, including 
blood-derived angiogenic cells have been previously implicated in vascular repair and 
have been recently investigated in preclinical animal models and in recent human clinical 
trials as potential cell therapies for CVD21,23.    
1.3.1 Stem cell therapy 
A stem cell is defined a cell that can both self renew indefinitely, creating more stem 
cells, and differentiate into different, more specialized cell types144-146.  Stem cells can be 
further classified by their potency, or more specifically their differentiation potential.  A 
pluripotent cell is capable of differentiating and forming all tissues in the adult organism.  
These cells are found during development in the inner cell mass of a blastocyst147. 
Pluripotent cells are absent in postnatal tissues but recently Yamanaka et al. 
demonstrated that terminally differentiated cells like fibroblasts can be transcriptionally 
reprogramed to a pluripotent state148. These cells, called induced pluripotent stem cells, 
hold promise in terms of potential ability to make any cell type with one’s one genetics 
for possible therapeutic applications149.  
In the postnatal, adult organism many tissues contain resident cells that demonstrate stem 
cell characteristics.  These multipotent stem or progenitor cells, can form multiple 
different cell types, but are generally restricted to one tissue type or germ layer from 
which they are derived.  An example of the best-characterized multipotent stem cell is the 
hematopoietic stem cell which can form all lineages of blood cells found in circulation150.   
A progenitor cell can form multiple (multipotent) or one (unipotent) type of more 
specialized cell, but has lost the capacity to self-renew over the life of the organism.  An 
example of a unipotent progenitor cell that has been widely studied in the context of 
postnatal vasculogenesis is the endothelial progenitor cell (EPC/ECFC) which can 
differentiate into mature ECs129.    
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Bone marrow, mobilized peripheral blood and UCB have been intensely studied as easily 
accessible and readily-available sources of adult progenitor cells for cell therapy for 
CVD21,23. Adult or postnatal progenitor cells obtained from human BM or UCB are 
comprised of a heterogeneous array of regenerative cell subtypes and represent 
transplantable cells used to reconstitute hematopoiesis in hematological malignancies or 
to facilitate the repair of damaged or diseased tissues via paracrine effects128,151-154. 
However, with the exception of hematopoietic stem cells (HSC) with the phenotype lin-
CD34+CD38-CD45RA-Thy1+RholoCD49f+, prospective purification of infrequent BM- or 
UCB-derived stem and progenitor cells for use in targeted regenerative therapies is 
currently underutilized129,150,154. Indeed, non-hematopoietic stem and progenitor cell 
subtypes from BM and UCB demonstrate a paucity of specific markers of differentiation 
in situ155, and stem cell surface markers can also vary between species, source, and cell 
cycle progression156. As described in terms of postnatal vasculogenesis, circulating 
EPC/ECFC which can integrate into repairing vasculature or support angiogenesis show 
much promise as potential cell therapies for vascular regeneration128.  Many 
hematopoietic cells types thought to be EPC in fact represent pro-angiogenic 
hematopoietic cells124,140.    
Asahara et al. originally identified endothelial precursor cells (EPC) as a population of 
circulating progenitor cells in human peripheral blood that differentiate into mature 
endothelial cells (EC) in vitro and contribute to vessel formation after transplantation into 
SCID mice 127. Later studies showed that these cells expressed the primitive cell markers 
CD34, CD133, and KDR (VEGFR-2)157 and can be obtained from other sources such as 
BM and UCB158,159. However, this cell phenotype was shared by hematopoietic progenitor 
cells, making discrimination of hematopoietic versus endothelial lineage commitment 
controversial. Because both myeloid hematopoietic and endothelial progenitor cells have 
been shown to promote angiogenesis in mouse models138,160 Yoder et al. functionally 
demonstrated that true EPC are plastic-adherent blood-derived cells propagated in strict 
EC growth conditions that form proliferative colonies of CD45− ECs capable of forming 
perfused vessels in gel implants in vivo, termed ECFC 129. In contrast, the nonadherent 
CD45+ blood-derived cells that co-expressed typical EC markers (CD31) were not actual 
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EC precursors but myeloid/macrophage lineage cells, which did not incorporate into 
newly formed vessels, yet can contribute to angiogenesis through proposed paracrine 
signaling to activated vessel-derived EC124,129,134-136,138. 
With accumulating evidence indicating the promise of multiple BM-derived cell 
populations for vascular regeneration, clinical trials were initiated investigating the 
transplantation of heterogeneous BM mononuclear cells (MNCs) to treat limb 
ischemia23,161,162 and to promote cardiac repair21,153,163-165. However, while many of these 
trials demonstrated promising results in promoting revascularization, scientists have 
undertaken studies to take a closer look at the specific progenitor cell fractions that show 
vascular regenerative promise166.   
Using nude mice and femoral artery ligation with complete excision of the femoral artery 
and vein, López-Holgado et al. demonstrated that treatment with both CD14+ monocytes 
and CD133+ cells from mobilized peripheral blood demonstrate significantly improved 
perfusion in the surgical limb compared to vehicle treated mice. That research group 
showed furthermore that these hematopoietic cell population do not transdifferentiate into 
true endothelial cells or EPC167.  Lai et al. demonstrated that various sources of EC 
support recovery of perfusion in a similar hindlimb ischemia model in SCID mice168.  
They showed that human umbilical vein EC (HUVEC), EC derived from embryonic stem 
cells, EC derived from induced pluripotent stem cells, and EC derived from patient BM 
supported augmented recovery of perfusion compared to vehicle control mice.  They 
derived EC from BM by plating MNC in endothelial growth media (EGM2) and selecting 
adherent cells similar to ECFC derivation as published by Yoder.   Notably they also 
demonstrated derivation of EC from human BM was more challenging from patients with 
CVD indicating the value of allogeneic transplantation strategies to treat CVD168.  
Recently, using a model of very severe induction of ischemic injury by burning the 
femoral artery whereby some untreated mice completely lose the surgical limb, Vu et al. 
demonstrated that treatment with heterogeneous UCB MNC or ex vivo expanded CD34+ 
CD133+ cells prevented limb loss and improved recovery of limb function and reduced 
necrosis169.  Vu et al. termed their cells EPC however they did not show that the CD34+ 
CD133+ cells they used were non-hematopoietic or that they could directly integrate into 
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newly formed vessels making it likely that their “EPC” were in fact a mixture of 
endothelial and angiogenic hematopoietic cells as shown by others134,167. Notably, there is 
evidence that there is significant variation in the basal recovery rate of perfusion after 
femoral artery ligation surgery between different mouse strains, an important caveat for 
comparing the magnitude of perfusion recovery results between studies170,171.  
1.3.1.1 Mesenchymal stromal cells 
Mesenchymal stromal/stem cells (MSC), also refered to as multipotent stromal cells, can 
be isolated from bone marrow and other tissues and have been demonstrated to be a 
multipotent mesenchymal cell type that differentiate in bone, fat, and cartilage.  MSC are 
defined by their ex vivo culture method; they must be plastic adherent, express the 
markers CD73 (ecto 5’ nucleotidase), CD90 (Thy-1), and CD105 (endoglin) after culture 
and must not express hematopoietic markers like CD45, CD14172.  In addition, MSC need 
to demonstrate the definitive multipotential differentiation into osteocytes, adipocytes and 
chondrocytes173. Strictly speaking, MSC should properly be called multipotent 
mesenchymal progenitor cells as they have not been demonstrated to display full self-
renewal capacity to meet the full criteria of a stem cell174.   
MSC are widely considered as good candidates for allogeneic cell therapy applications 
because of their low immunogenicity; they do not express MHC class II (HLA-DR) nor 
costimulatory molecules like CD40, CD80 and CD86175.    Furthermore, MSC have been 
shown to demonstrate low levels of engraftment and little proliferative capacity after 
transplantation, reducing risk of transplant malignancy, but also potentially limiting long 
term therapeutic efficacy176.  In light of low levels of engraftment the currently hypothesis 
regarding MSC contibutions towards regenerative therapy is primarily through the 
modulation of the tissue microenvironment as opposed to cell replacement154,177.   
MSC have been shown to augment cardiomyocyte178 and EC176,179 survival.  MSC have 
also been shown to secrete many angiogenic factors including, VEGF-A, FGF-2, ANG-1, 
and MCP-1176,179-182. MSC have also been recently identified as a component of vascular 
pericytes in multiple human organs that express CD146 in situ and help stabilize newly 
formed vessels when co-transplanted with ECs in vivo183,184. MSC have furthermore been 
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shown to play an important role in immunomodulation presenting interesting potential 
paracrine applications in auto-immune disease and inflammatory conditions185. Taken 
together these findings show the considerable promise of MSC from human BM or UCB 
as a potential source for vascular regenerative cell therapies.  
1.4 Aldehyde dehydrogenase: a functional marker of stem 
cells for cell therapy 
In order to simultaneously isolate stem and progenitor cells from multiple lineages, BM 
or UCB mononuclear cells (MNC) can be purified based on a conserved stem cell 
characteristic, high levels of aldehyde dehydrogenase (ALDH) activity, an intracellular 
enzyme first reported to be highly expressed in primitive hematopoietic186, and neural 
progenitor cells 187. 
ALDH1A1 activity is involved in oxidation of vitamin A to retinoic acid and is 
predominantly implicated in the protection of long-lived cells from oxidative damage186. 
Most notably, ALDH activity is downregulated as primitive cells differentiate towards 
maturity, making ALDH activity a unique function to distinguish essential regenerative 
precursors from expendable cells. Our group and others have recently shown that high 
ALDH activity is also a property shared by regenerative progenitors of endothelial and 
mesenchymal lineages134,188. Purification of BM or UCB cells based on high ALDH-
activity can be used to simultaneously isolate adult stem and progenitor cell subtypes for 
the preclinical development of regenerative therapies inducing tissue repair. Focusing on 
transplantation studies using human ALDH-expressing progenitor cells for hematopoietic 
reconstitution, blood vessel formation, and islet regeneration in immunodeficient mice, 
the Hess laboratory aims to understand how the multiple progenitor subtypes act together 
to formulate a regenerative niche and to coordinate complex regenerative processes. 
1.4.1 FACS purification of multiple human progenitor subtypes using 
ALDH activity 
Intracellular ALDH activity can be quantified using a fluorescent substrate for ALDH, 
termed Aldefluor reagent 186. First synthesized by Clayton Smith’s group in 1999, 
Aldefluor reagent is a Bodipy fluorochrome conjugated to an aminoacetaldehyde 
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molecule, an uncharged moiety that can freely cross through the cell membrane. Once 
inside the cell, cytoplasmic ALDH1A1 converts Aldefluor into a metabolized by ALDH 
into an anion that becomes trapped in the cell due to its negative charge. Under 
pharmacological inhibition of ABC transporters contained within Aldefluor buffer, cells 
with high ALDH activity retain Aldefluor substrate and fluoresce brightly, while cells 
with lower ALDH activity are more dimly fluorescent. Thus, high-speed fluorescence-
activated cell sorting (FACS) can efficiently purify UCB or BM MNC with low side 
scatter and low versus high ALDH activity. The integrity and function of the isolated 
cells are not compromised by this procedure since upon removal of the Aldefluor buffer, 
ATP-binding cassette transporters become reactivated, and Aldefluor is actively effluxed, 
returning the cell to its original state. Thus, the Aldefluor purification procedure is 
clinically applicable for the efficient sorting of multiple functional human progenitor cell 
types based on a highly conserved stem cell function. The amount of ALDH activity in 
all viable cells falls along a spectrum from low ALDH activity (ALDHlo) to high ALDH 
activity (ALDHhi), where ALDHlo versus ALDHhi cells are distinguished by cluster gating 
using diethylaminobenzaldehyde or DEAB, a pharmacological inhibitor of ALDH1A1. 
The basic premise of the Aldefluor assay to assess ALDH activity with FACS is 
summarised in Figure 1.1.  
It has previously been shown that purified ALDHhi cells from BM and UCB highly co-
expressed stem cell-associated surface markers (CD34, CD133, c-kit) and were enriched 
for multipotent hematopoietic and mesenchymal stromal progenitors, as well as precursor 
cells with endothelial colony forming cell (ECFC) capacity in vitro134,156,188,189. In contrast, 
ALDHlo cells were primarily comprised of mature leukocytes (primarily T- and B-cells) 
and demonstrated little progenitor function in vitro134. Therefore, high ALDH activity 
simultaneously purifies multiple progenitor cell subtypes ideal for lineage-specific 
expansion in vitro. Subsequently, purified ALDH-purified mixed progenitor cells or their 
ex vivo expanded progeny can be assayed for regenerative functions after 
xenotransplantation into a variety of immunodeficient models of tissue damage. 
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Figure 1.1. Schematic overview of FACS isolation of ALDHhi cells using Aldefluor. 
(A) Aldefluor passively diffuses into cells where is metabolized by ALDH into an anion 
which can no longer diffuse out of the cell, this leads to accumulation of a fluorescent 
signal that can be detected and selected by FACS.  (B) DEAB inhibition of ALDH 
activity identifies ALDHlo population for gating.  (C) Aldefluor labeling allows efficient 
selection of ALDHhi cells from a heterogenous population of UCB MNC by FACS. 
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1.4.2 Cells with high ALDH activity possess hematopoietic 
repopulating capacity 
Hematopoietic stem cells (HSC) and lineage-specific hematopoietic progenitors are 
responsible for the replenishment and maintenance of blood after BM 
transplantation190,191. These cells can be isolated from BM, cytokine-mobilized peripheral 
blood, or UCB based on expression of the cell surface markers CD34 and CD133, and 
assayed for hematopoietic repopulating function after transplantation into sublethally 
irradiated nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice192-194. 
Storms et al. first established that the ALDHhi fraction of human UCB was enriched for 
primitive hematopoietic progenitors in vitro and was depleted of lineage-committed 
hematopoietic cells186. Subsequently, prospective lineage depletion in combination with 
the commercially available Aldefluor reagent (Stemcell Technologies, Vancouver, 
Canada) was used by our group to demonstrate that transplantation of human UCB 
ALDHhi cells into NOD/SCID mice resulted in multilineage human hematopoietic 
engraftment156. Greater than 70% of the UCB ALDHhi cell population co-expressed the 
HSC-associated cell surface markers CD34 and CD133156. ALDHhi CD34+ cells were 
highly enriched for short-term myeloid progenitors while ALDHhi CD34− cells 
represented precursors to the CD34+ population that also demonstrated NOD/SCID-
repopulating cell (SRC) capacity195-197. 
Our laboratory has also demonstrated that while both ALDHhi CD133− and ALDHhi 
CD133+ cells demonstrated clonogenic hematopoietic progenitor function in vitro, only 
the ALDHhi CD133+ population was able to engraft the murine BM after intravenous 
injection198. Furthermore, prospective selection based on both high ALDH activity and 
CD133 increased the frequency of SRC by tenfold compared to selection by CD133 
alone. Notably, ALDHhi CD133+ cells demonstrated enhanced hematopoietic 
repopulating function in serial secondary transplants while maintaining primitive 
hematopoietic phenotypes (CD34+CD38−)198. In addition to long-term hematopoietic 
repopulating function, human UCB ALDHhiCD133+ cells also showed previously 
unrecognized engraftment in nonhematopoietic tissues such as the liver, lung, heart, 
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brain, pancreas using the highly sensitive human cell-tracking NOD/ SCID MPSVII 
model199. 
Later studies established that hematopoietic engraftment after human UCB 
transplantation in immunodeficient mice occurs faster with increasing ALDHhi cell doses 
200. Similar to CD34 expression, clinical reconstitution rates following transplantation of 
BM or mobilized peripheral blood can be directly correlated with the number of ALDHhi 
cells infused201,202. As a result of these promising preclinical data and direct potential for 
clinical translation, recently completed clinical trials designed to assess the safety and 
efficacy of transplanted allogeneic human UCB ALDHhi cells to enhance the rate of 
engraftment in the treatment of haematological dysfunction (www.clinicaltrials.gov trial 
no. NCT00692926) have been reported. In summary, high ALDH activity is now well 
established as a functional characteristic of repopulating hematopoietic cells, and ALDH 
activity appears to be a superior indicator of the quality of BM or UCB samples for 
transplantation compared to standardized CD34+ counts201. 
1.4.3 Cells with high ALDH activity for vascular regeneration  
Although the ALDHhi population from human BM or UCB is more than 90% 
hematopoietic in origin, it has been shown that the ALDHhi fraction of BM is also 
significantly enriched for ECFC compared to ALDHlo cells and that high ALDH activity 
was downregulated as a result of differentiative culture in vitro134. Thus, consistent with 
the classification by Yoder et al., true ECFC initially possesses elevated ALDH activity. 
Nagano et al. expanded EPC in culture from UCB and subsequently sorted the CD45- 
EPC progeny based on ALDH activity203. Interestingly, they found that the more 
differentiated ALDHlo outgrowth population was more proliferative in vitro and showed 
higher expression of hypoxia-inducible factors (HIF1α), VEGF, and the chemokine 
receptor CXCR4 under hypoxic conditions. They further showed that the cultured 
ALDHlo outgrowth represented more mature EC that recruited effectively to the site of 
ischemia and reduced necrosis in a mouse skin flap model of ischemic wound repair203. 
Consistent with the idea that high ALDH activity simultaneously purifies stem and 
progenitor cells from multiple lineages, our group and others have shown that in addition 
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to HSC and tubule-forming EPC, the BM ALDHhi fraction was highly enriched for MSC 
that efficiently differentiated into fat, cartilage, and bone in differentiation cultures in 
vitro 134,189. Capoccia et al. went on further to describe that transplanted human BM 
ALDHhi mixed progenitor cells transiently recruited to areas of ischemia and augmented  
the recovery of blood flow (perfusion ratio of ischemic/control limb of 0.7±0.1) by 
stimulating the endogenous revascularization of ischemic limbs in immunodeficient 
NOD/SCID/β2microglobulin null and NOD/SCID/MPSVII mice with acute unilateral 
hind limb ischemia induced by femoral artery ligation compared to vehicle control treated 
mice at 21 days after treatment (0.3±0.1)134. Even without permanent engraftment at the 
site of ischemia, a low dose of ALDHhi cells were more effective at inducing 
revascularization than transplantation of unsorted BM nucleated cells containing the 
equivalent of fourfold more ALDHhi cells. Recent work by Sondergaard et al. has shown 
that intravenously transplanted UCB ALDHhi cells recruited specifically to the ischemic 
myocardium where they augmented vascular density in a murine model of myocardial 
infarction204. 
Although the detailed mechanisms by which ALDHhi cells induced endogenous 
revascularization remains an active area of investigation in the Hess lab, our working 
hypothesis describes that high ALDH activity simultaneously depletes for inflammatory 
immune cells and enriches for multiple proangiogenic progenitor subtypes. After 
transplantation, ALDHhi progenitor subtypes recruit transiently to areas of regional 
hypoxic damage and contribute to the generation of a proangiogenic microenvironment 
by potentially providing both structural and paracrine support. 
Despite the paucity of mechanistic details regarding the vascular regenerative potential of 
ALDHhi cells, clinical trials have been initiated to explore the safety and efficacy of the 
use of autologous BM ALDHhi cells in many CVD conditions205,206. The FOCUS-Br trial 
was undertaken to investigate intramyocardial injection of autologous ALDHhi cells for 
therapeutic angiogenesis (www.clinicaltrials.gov trial no. NCT00314366).  The results of 
the trial showed evidence that transplantation intramyocardial transplantation of ALDHhi 
cells is safe and supported possible functional benefits in the setting of chronic 
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myocardial ischemia indicating need for further clinical testing in a larger cohort to fully 
assess efficacy207.   
BM ALDHhi cells have also been investigated in clinical trials for treatment of critical 
limb ischemia (NCT00392509).  Intramuscular transplantation of autologous BM 
ALDHhi cells were directly compared to unfractionated autologous BM MNC in PAD 
patients with a Rutherford score of 4 (resting pain) or 5 (ulceration or necrosis)208.  
Results of the study demonstrated safety and patients that received autologous BM 
ALDHhi cells showed improved Rutherford category and reduced resting pain.  
Furthermore patients in the ALDHhi treatment group showed improved ankle to brachial 
index scores more rapidly than the MNC group indicating improved perfusion of the 
lower limb.  However, patients in both cohorts reported significantly improved quality of 
life indices.208 More recently, a phase 2 placebo-controlled randomized clinical trial has 
been initiated to investigate transplantation of BM ALDHhi cells to improve symptoms of 
intermittent claudication (NCT01774097).  Another phase 2 clinical trial is currently 
underway to investigate intracarotid infusion of BM ALDHhi cells for patients after and 
ischemic stroke (NCT01273337).   
1.4.4 ALDH-purified cells stimulating islet revascularization and repair 
The Hess laboratory focuses on the development of pre-clinical models to study the 
potential utility of post-natal stem cells for the treatment of diabetes and its vascular 
complications. Indeed, the successful induction of angiogenesis or revascularization is a 
central process in tissue repair. In the context of regenerative therapies for diabetes, the 
contributions of transplanted stem cells are not limited to the direct replacement of 
damaged beta cells. As an alternative, the endogenous repair of damaged islets or the 
generation of new islets in situ has also been proposed209. Hess and colleagues were the 
first to show that transplantation of murine BM-derived MNC or further purified c-kit+ 
progenitor cells stimulate the recovery of streptozotocin (STZ)-damaged islets by 
inducing proliferation of recipient beta cells and augmenting glycemic control via the 
endogenous regeneration of beta cell function210. Donor cells with both hematopoietic and 
EC phenotypes were recruited to ductal regions and surrounded damaged islets, 
subsequently stimulating beta cell proliferation and insulin production in recipient-
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derived beta cells. Several groups have extended these findings to show that islet 
recovery can be induced by the induction of hematopoietic chimerism in overtly diabetic 
NOD mice211 and that simultaneous infusion of murine BM MNC with allogeneic MSC 
optimize islet repair and protection against T-cell-mediated beta cell deletion 212. 
Although transplantation of murine BM-derived cells have shown proof of principle that 
BM-derived progenitor can impact endogenous beta cell regeneration, further purification 
and transplantation of human progenitor subtypes from multiple sources is underway in 
our lab to study the actions of specific cellular populations relevant to islet regeneration. 
Toward this end, Hess et al. have transplanted human ALDH-purified BM stem cells into 
STZ-treated hyperglycemic NOD/SCID mice to promote islet regeneration. 
Transplantation of BM ALDHhi cells led to a significant reduction in blood glucose and 
increased serum insulin due to an increase in endogenous beta cell proliferation resulting 
in increased islet size and total beta cell mass213. Notably, transplanted BM ALDHhi cells 
recruited to damaged islets and stimulated beta cell proliferation associated with 
functional capillary formation in regenerating islets. Similar to hyperglycemic mice 
transplanted with human BM cells, mice transplanted with human UCB ALDHhi cells 
also demonstrated increased islet size and vascularization compared to controls. 
However, blood glucose reductions were transient, returning to severe hyperglycemia 
several weeks after transplantation. Furthermore, direct intra-pancreatic delivery of UCB 
ALDHhi cells increased peri-islet engraftment and stimulated a permanent reduction in 
hyperglycemia compare to ALDHlo cell controls via the induction of an islet proliferative 
and revascularization program in recipient islets214. Unlike ALDH-purified BM 
progenitor populations, ALDH-purified UCB drawn by venipuncture did not consistently 
establish expandable MSC in culture, indicating a potential requirement for MSC to 
maintain islet regeneration. Fortunately, adherent MSC can be liberated from UCB after 
collagenase treatment215, and inclusion of these cells within the transplanted population 
may further improve islet regeneration. 
In the past, clinical applications of UCB-derived stem cells have been limited to 
transplantation in the fields of hematology or oncology; however, an increasing number 
of studies support the use of these cells for nonhematopoietic disorders, including 
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diabetes216,217. UCB MNC transplantation into diabetic mice has shown delayed onset of 
autoimmunity and insulitis in a model of type 1 diabetes and improved in hyperglycemia 
and survival rates post-transplantation 218,219. A clinical trial using autologous UCB cells 
is currently underway in children with recently diagnosed type 1 diabetes 217. Delayed 
loss of endogenous insulin production and enhanced glucose control have been reported 
due to a highly functional population of regulatory T-cells within UCB220,221. However, 
the functional mechanisms conferring beta cell protection and potential mechanisms for 
the expansion of beta cell mass and vascularization after UCB transplantation require 
further preclinical experimentation. 
1.4.5 Roles of ALDH-Purified MSC in Islet Regeneration 
MSC possess properties beneficial in the repair of tissues damaged by autoimmunity. 
MSC have been shown to modulate the microenvironment after injury and stimulate a 
shift from an inflammatory to a regenerative response222, and to aid in tissue repair by 
exerting antifibrotic and neoangiogenic effects223. MSC have also been shown to migrate 
toward areas of hypoxia and or tissue damage through their expression of a variety of 
chemokine receptors and adhesion molecules. Islets attract MSC in vitro and in vivo by 
CX3CL1-CX3CR1 and CXCL12-CXCR4 interactions224,225. MSC may also play an 
important role in modulating the immune response, an important consideration in the 
treatment of type 1 diabetes. In damaged tissues, MSC stimulate reduced T-cell226 and B-
cell proliferation227, inhibit maturation as well as differentiation of dendritic cells228, and 
decrease the production of inflammatory cytokines by immune cells229. MSC can exert 
these effects by secreting immunosuppressive effectors such as TGF-β, IDO, or PGE2229. 
Collectively, these characteristics make transplanted MSC an attractive target for the 
development of cellular therapies for autoimmune diabetes230. As proof of principle, Lee 
et al. have shown that multiple high-dose intracardiac infusion of human BM-derived 
MSC into STZ-treated immune-deficient NOD/ SCID mice repaired islets and improved 
hyperglycemia with only minimal engraftment in the pancreas231. Transplantation of 
ALDH-purified MSC into the tail vein of STZ-treated hyperglycemic mice also stably 
reduced blood glucose and increased serum insulin. Rather than stimulating increased 
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islet size and vascularization, MSC transplantation stimulated an increase in the number 
of small islets present in the pancreas. Newly formed beta cell clusters were small in size 
with direct proximity to the ductal epithelium. These unique regenerative characteristics 
suggested the induction of a islet neogenic mechanism, whereby transplanted ALDH-
purified MSC stimulated new islet formation213. Similar to findings by Lee et al., 
transplanted ALDH-purified MSC showed low-level or transient recruitment to the 
pancreas, but initially lodge in the liver and lung capillaries199, presumably exerting their 
effects on islet regeneration via the release of unknown paracrine regenerative factors 
into the bloodstream.   
1.4.6 Future perspectives for use of ALDHhi cells in cell therapy 
BM- or UCB-derived ALDH-purified mixed progenitor cells and ALDH-purified MSC 
demonstrate a variety of regenerative functions that impact tissue repair and 
revascularization. However, differences in progenitor frequencies and functions should 
not be overlooked when considering the optimal progenitor cell populations for 
regenerative therapies. In addition, the regenerative mechanisms induced by ALDH-
expressing progenitors and the paracrine mediators that comprise the regenerative niche 
require further elucidation. Provided with this foundation of critical information, 
scientists will be able to design rational regenerative therapies using a combination of 
regenerative small molecules or directed administration of multiple progenitor cell 
subtypes to synergize endogenous blood vessel and subsequent tissue repair. 
1.5 Thesis Overview and Hypotheses 
Recently, our lab has shown that human BM ALDHhi mixed progenitor cells transiently 
recruit to areas of ischemia and augment blood flow by stimulating the endogenous 
revascularization of ischemic limbs in transplanted immune-deficient mice after 
induction of unilateral hindlimb ischemia by femoral artery ligation/transection134. 
However, in patients with CVD, pro-angiogenic cell content or function may be 
compromised due to chronic diabetes or vascular disease-related pathologies rendering 
autologous BM transplantation strategies less effective129,232-235.  Readily available and 
early in ontogeny, human umbilical cord blood (UCB) represents a promising allogeneic 
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source of functional pro-angiogenic progenitor cells.  During my thesis work I have 
investigated the vascular regenerative potential of human UCB and BM-derived 
hematopoietic and multipotent-stromal progenitor cells for the pre-clinical development 
of rational allogeneic cell-based therapies for ischemic diseases focusing on PAD. 
Furthermore, I have focused on global molecular approaches, and functional assays in 
vitro (Figure 1.2) and in vivo (Figure 1.3) to determine the paracrine signals elaborated 
from these pro-angiogenic cell sources that positively impact microvascular endothelial 
cell activation and function Our working model for transplanted progenitor cell 
involvement in vascular regeneration as investigated in this thesis is summarised in 
Figure 1.4.  The central hypothesis of my studies is that high ALDH activity identifies 
populations of progenitor cells from blood or BM that will demonstrate augmented 
support of vascular regeneration. Thus, the specific objectives of my studies were as 
follows. 
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Figure 1.2. in vitro models for determination of progenitor cell contribution to 
endothelial cell function.  
Co-culture assays to assess cell-mediated effects on survival, proliferation, and tube 
forming capacity of endothelial cells. (A) Schematic overview of hanging transwell co-
culture and cell-conditioned medium assays to assess endothelial cell proliferation or 
survival. (B) Representative photomicrograph of human endothelial cells cultured on 
plastic. (C) Representative photomicrograph of human endothelial cells growing on a thin 
layer of Matrigel to assess modulation of tube-like structure formation. 
Adapted from: Putman DM, Hess DA. Isolation of human umbilical cord blood aldehyde 
dehydrogenase-expressing progenitor cells that modulate vascular regenerative functions 
in vitro and in vivo. Curr Protoc Stem Cell Biol. 2013;Chapter 2:Unit 2A.10 
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Figure 1.3 Transplantation model of acute unilateral hindlimb ischemia.  
(A) Diagram of the vasculature of the mouse hindlimb from the inguinal crease to the 
bifurcation of the femoral artery into the saphenous and popliteal arteries that descend 
into the calf and lower limb. Ligation sites for femoral artery ligation surgery are 
indicated. Representative laser Doppler perfusion images of mouse hindquarters before 
and after ligation and transection of femoral artery and vein. Regions of interest are 
selected from ankle to toe to quantify relative perfusion in the surgical limb. (B) Outline 
and timing for tracking recovery of perfusion in the ischemic limb after surgical 
induction of acute ischemia. Number in lower left quadrant of each laser Doppler 
perfusion image is the ratio of perfusion in the ischemic limb to the perfusion in the 
control limb. 
Adapted from: Putman DM, Hess DA. Isolation of human umbilical cord blood aldehyde 
dehydrogenase-expressing progenitor cells that modulate vascular regenerative functions 
in vitro and in vivo. Curr Protoc Stem Cell Biol. 2013;Chapter 2:Unit 2A.10 
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Figure 1.4. Umbilical cord blood and bone marrow-derived stem and progenitor 
cells support an angiogenic niche.   
The ALDHhi subpopulation of cells in UCB and BM is enriched for progenitors from the 
hematopoietic, endothelial, and mesenchymal lineages.  Each of these progenitor cell 
types recruit to and help co-ordinate a pro-angiogenic regenerative microenvironment in 
ischemic tissues.   
Adapted from: Putman, D. M., Bell, G. I. & Hess, D. A. Blood-Derived ALDHhi Cells in 
Tissue Repair, in Regenerative Therapy Using Blood-Derived Stem Cells (Allan, D. S. S. 
& Strunk, D.) 21–34 (Humana Press, 2012). 
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Figure 1.4. 
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1.5.1 Aim 1  
• To characterise the capacity of umbilical cord blood-derived ALDH-purified cells 
to modulate endothelial cell functions in vitro 
• To assess the effects on vascular regeneration after intra-venous transplantation of 
UCB ALDHhi cells into immune-deficient mice with unilateral hindlimb ischemia 
induced by femoral artery ligation surgery. 
In Aim 1, I hypothesized that selection of UCB cells based on high ALDH activity will 
select a population of cells with augmented capacity to promote recovery from ischemic 
injury. 
1.5.2 Aim 2  
Due to the relative rarity of ALDHhi cells from UCB or BM, in Aim 2 I sought to 
determine if it was possible to expand UCB-derived ALDHhi cells ex vivo to generate 
more cells for therapeutic applications without losing beneficial vascular regenerative 
effect. Therefore the objectives of Aim 2 were two-fold: 
• To optimize the ex vivo expansion of UCB ALDHhi hematopoietic cells under 
clinically relevant serum-free conditions and to characterize vascular regenerative 
functions of the expanded progenitor cells in vitro.  
• To investigate the paracrine mechanisms by which expanded hematopoietic 
progenitor cells derived from UCB ALDHhi contribute to revascularization after 
direct intramuscular injection into the ischemic limb. 
In Aim 2, I hypothesized that ex vivo expansion of UCB ALDHhi cells would increase the 
number of pro-angiogenic hematopoietic progenitor cells for application in vascular 
regeneration without decreasing EC-supportive functions. 
1.5.3 Aim 3 
BM MSC are a population of progenitor cells that expand readily in ex vivo cultures with 
underutilized potential for vascular regenerative cellular therapies. However, our lab has 
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demonstrated in our beta cell regeneration model studies that different MSC lines from 
different donors showed variable efficacy to promote regeneration213,236. Furthermore, it 
has been previously shown that selection of high ALDH activity in BM cells selected for 
cells with increased regenerative potential. Therefore the objective in Aim 3 was as 
follows: 
• To characterize the differentiative and vascular regenerative functions of MSC 
subpopulations selected after expansion for low versus high ALDH activity. 
In Aim 3, I hypothesized that selection of MSC subpopulations with high ALDH activity 
would identify a population of MSC with increased vascular regenerative potential.  
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Chapter 2 
2 Umbilical Cord Blood-Derived Aldehyde 
Dehydrogenase-Expressing Progenitor Cells Promote 
Recovery from Acute Ischemic Injuryii 
This study focused on the characterization of UCB as a source of ALDHhi cells for 
development of cell therapy for CVD. My objective was to characterize the capacity of 
umbilical cord blood-derived ALDH-purified cells to modulate endothelial cell functions 
in vitro and to augment revascularisation after intra-venous transplantation into immune-
deficient mice with unilateral hindlimb ischemia induced by femoral artery ligation 
surgery. 
  
                                                
ii A version of this chapter has been published:  Putman, D. M., Liu, K. Y., Broughton, H. C., Bell, G. I. & 
Hess, D. A. Umbilical cord blood-derived aldehyde dehydrogenase-expressing progenitor cells promote 
recovery from acute ischemic injury. Stem Cells 30, 2248–2260 (2012). 
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2.1 Introduction 
Ischemic disease is characterized by the reduction of blood flow to the heart or peripheral 
tissues and encompasses life-threatening disorders such as ischemic heart disease and 
critical limb ischemia. Despite advances in pharmacological and surgical management, 
ischemic disease remains one of the leading causes of morbidity and mortality 
worldwide1,2. Thus, novel therapies to promote the regeneration of damaged vasculature 
are under intense pre-clinical investigation3-5.  
Angiogenesis, the sprouting of new blood vessels from pre-existing vessels, is a central 
process for tissue repair, allowing the delivery of circulating pro-angiogenic cells that 
form a vascular regenerative microenvironment5. Asahara et al. first described human 
bone marrow (BM)-derived cells that promoted the recovery of blood flow, and co-
localized with new vessels after transplantation in vivo6. Later studies have shown that 
these rare cells, termed endothelial precursor cells (EPC), express the cell markers CD34, 
CD133, and VEGFR27. Because these markers were also expressed on clonally distinct 
cell types of both hematopoietic and non-hematopoietic lineages, there has been 
considerable controversy over which cell subtypes best promote vascular regeneration. 
Endothelial colony forming cells (ECFC) are rare blood-derived cells that form late-
outgrowth adherent colonies of proliferative cells when propagated under strict 
endothelial cell growth conditions, and can be isolated at increasing frequency from 
human peripheral blood, BM, and umbilical cord blood (UCB). ECFC are distinguished 
from pro-angiogenic hematopoietic cell types in human blood as they are exclusively 
CD45–, and can integrate directly into perfused vessels in vivo. Recently, it has been 
demonstrated that many of the cell types previously referred to as EPC are not endothelial 
cell precursors per se, but represent myeloid/macrophage lineage cells that promote 
vascular repair through proposed paracrine signaling to vessel-derived EC8,9,10-12. In 
mouse models, circulating CXCR4+/VEGFR1+ hematopoietic cells are recruited to 
sprouting vessels by secretion of stromal-derived factor (SDF-1) or vascular endothelial 
growth factor-A (VEGF-A) produced by damaged vasculature4,13. Studies examining 
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tumor metastasis have demonstrated that even small numbers of these hematopoietic cells 
play a major role in establishing a permissive niche for tumor vascularization14-16.  
Numerous studies have established that a decreased frequency or impaired function of 
circulating CD133+ or CD34+ cells is associated with increased cardiovascular risk in 
patients with ischemic heart disease and diabetes2,9,17-20. This, in addition to preclinical 
data showing the pro-angiogenic potential of BM-derived cells, has led to a number of 
clinical trials investigating treatment of cardiac21-23 and limb ischemia24,25 by 
transplantation of heterogeneous human BM MNC. Although these studies have 
demonstrated safety in the autologous setting, they have shown only modest 
improvements in clinical endpoints compared to other approved therapies26. Thus, 
purification of specific pro-angiogenic cellular sub-types from non-autologous sources, 
and further characterization of specific sub-type contribution during the coordination of 
vascular repair is warranted to improve current cell-based therapies for ischemic diseases. 
Cord blood represents a promising source of regenerative progenitor cells.  Early in 
ontogeny, UCB has been shown to contain a higher frequency of ECFC28, and UCB-
derived ECFC have more robust vessel forming capacity than ECFC from adult blood9,29. 
Due to recent widespread initiatives to HLA-phenotype and cryopreserve this material, 
UCB now represents a readily available source of progenitor cells for cell therapy 
applications. In addition, allogeneic UCB progenitor cell transplantation may have 
distinct advantages over autologous BM in patients with obesity, chronic diabetes, or 
vascular disease-related pathologies due to compromised progenitor cell content and 
function30-33.  
Using high aldehyde dehydrogenase (ALDHhi) activity, a cytosolic enzyme involved in 
retinoic acid metabolism and cellular self-protection from oxidative damage34-39, 
fluorescence activated cell sorting strategies to simultaneously enrich for progenitor cells 
from hematopoietic, endothelial, mesenchymal lineages40. It has been demonstrated that 
transplanted ALDHhi progenitors reconstitute hematopoiesis34,35, exhibit widespread tissue 
distribution41, and recruit to areas of ischemia after transplantation40. Furthermore, BM-
derived ALDHhi cells can augment revascularization and blood flow of ischemic limbs in 
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transplanted mice with acute ischemic injury40. Recently, we proposed a model of 
coordinated neovascularization after human progenitor cell transplantation wherein 
hematopoietic and non-hematopoietic progenitors act in concert to formulate a pro-
angiogenic niche for vascular regeneration (Appendix 1)27.  
Here we show that selection of human UCB cells with high ALDH activity 
simultaneously purifies a mixed population of primitive hematopoietic and endothelial 
colony-forming cells with potent pro-angiogenic functions. UCB ALDHhi progenitors 
demonstrated a pro-angiogenic transcription profile and supported endothelial cell (EC) 
survival in liquid culture and tube-like cord formation in growth factor–reduced matrigel. 
Transplanted ALDHhi cells improved recovery of blood flow after femoral artery ligation 
in NOD/SCID mice. Thus, UCB progenitors purified by high ALDH-activity represents 
an allogeneic population of pro-angiogenic cells for the revascularization of ischemic 
tissues. 
2.2 Methods 
2.2.1 Progenitor cell isolation from human umbilical cord blood 
UCB was collected after informed consent by venipuncture at the London Health 
Sciences Birthing Centre. The human research ethics committee at the University of 
Western Ontario approved all studies. After hypaque-ficoll centrifugation, mononuclear 
cells (MNC) were depleted of erythrocytes by ammonium chloride lysis and assayed for 
ALDH activity using Aldefluor™ reagent (Stemcell Technologies, Vancouver, BC) as 
previously described40. FACS was performed to isolate cells with low side scatter, and 
high (ALDHhi) vs. low (ALDHlo) ALDH activity to >99% purity. Sorted cells were 
washed in PBS to allow efflux of Aldefluor™ substrate via reactivation of inhibited 
ABC-transporters. 
2.2.2 Cell surface phenotype analysis 
UCB MNC, ALDHhi or ALDHlo cells were labeled with anti-human antibodies against 
pan-leukocyte marker CD45, and co-labeled with CD4 and CD8 (T cells), or CD19 and 
CD20 (B cells), or CD33 (myeloid) and CD14 (monocytes), or CD31 (PECAM-1) and 
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CD144 (VE-cadherin, GeneTex, Irvine, CA), or CD34 and CD38, or CD117 (c-kit) and 
CD133 (Miltenyi Biotec, Auburn, CA), or CXCR4 and VEGFR2. All antibodies were 
from BD Biosciences unless otherwise indicated. Cell surface marker expression was 
measured using a FACSCalibur cytometer (BD Biosciences), and analyzed using FlowJo 
software.  
2.2.3 Colony forming cell assays 
UCB MNC, ALDHhi or ALDHlo cells were cultured in methylcellulose (Methocult® 
H4434, Stemcell Technologies) for 14 days and hematopoietic colony formation was 
enumerated based on cell morphology identifying burst-forming units of erythrocytes 
(BFU-E), colony-forming units of granulocytes (CFU-G), macrophages (CFU-M), 
granulocytes and macrophages (CFU-GM), or multilineage mixed colonies (CFU-Mixed) 
containing cells of all 3 types. ECFC were enumerated after adherent culture for 14 days 
in complete endothelial growth media (EGM-2 + 2%FBS + EGF, VEGF-A, FGF, IGF-1, 
Lonza) counting colonies of cells with cobblestone morphology as previously described9. 
2.2.4 mRNA isolation and microarray analyses  
mRNA was isolated from three sample-matched UCB ALDHhi  and ALDHlo cell cohorts 
using mRNeasy Mini kits (Qiagen, Mississauga, ON). Microarrays were performed in 
triplicate using 18 human gene array chips (Affymetrix, Santa Clara, CA) at the London 
Regional Genomics Facility. Transcripts differentially expressed by UCB ALDHhi versus 
ALDHlo cells were analyzed using Partek Genomics Suite (Partek Inc., St Louis, MO).  
2.2.5 Co-culture assays with human umbilical vein endothelial cells 
(HUVEC)  
To assess paracrine functions of UCB cells on human umbilical vein endothelial cell 
(HUVEC) survival and proliferation during co-culture in vitro, 40x103 HUVEC were 
cultured in endothelial basal media (EBM2, Lonza) with or without growth factors (EGF, 
VEGF-A, FGF, IGF-1) and serum (2%) supplementation. Under each condition, 105 
ALDHhi or 105 ALDHlo cells were seeded into porous (5µm pore size) hanging transwells 
suspended above the HUVEC. The number of trypan blue excluding HUVEC present 
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after 72 hours co-culture was enumerated by blinded hemocytometer counts. For tube-
like cord formation assays, 50x103 HUVEC, or HUVEC supplemented with 20x103 
ALDHhi or ALDHlo cells were seeded on growth factor reduced Matrigel (BD 
Biosciences) and cultured for 72 hours. The number of complete branch points in the 
cord structures formed by HUVEC was enumerated on an inverted microscope by 
blinded manual counts of four fields of view at 24, 48, and 72 hours after plating. All co-
culture experiments were performed in triplicate.  
2.2.6 Murine femoral artery ligation surgery and transplantation of 
human UCB cells 
Right femoral and saphenous artery and vein ligation with complete excision of the 
femoral artery and vein was performed on anesthetised NOD/SCID (Jackson Laboratory, 
Bar Harbor, ME) or NOD/SCID/MPSVII mice as previously described40. Within 24 hours 
of surgery, non-irradiated or sublethally irradiated (300cGy) mice were transplanted by 
tail-vein injection with PBS, 2x105 ALDHhi cells, 10x106 ALDHlo cells, or 20x106 MNC. 
Cell doses were chosen based on the relative frequency of each cell type within UCB 
MNC. NOD/SCID mice were used for functional studies to monitor the recovery of 
perfusion and to quantify blood vessel density as described below. NOD/SCID/MPSVII 
mice were used to detect human cell engraftment kinetics and localization in muscle 
sections from ischemic limbs using β-glucuronidase (GUSB) staining as described below. 
2.2.7 Quantification of hindlimb perfusion using laser Doppler 
perfusion imaging  
For laser Doppler perfusion imaging (LDPI; MoorLDI-2; Moor Instruments, Devon, 
UK), anesthetized NOD/SCID mice were placed at 37°C for 5 minutes following shaving 
of the hindquarters to remove hair.  Blood flow was quantified within the hindquarters of 
live mice after surgery, and at 3, 7, 14, 21, and 28 days post-transplantation. Perfusion 
ratios (PR) comparing blood flow in the ischemic versus non-ischemic limb were 
quantified by averaged units of flux from the ankle to toe in each limb using Moorflow 
software.  
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2.2.8 Quantification of blood vessel density  
Adductor muscles from transplanted mice were embedded and frozen in optimum cutting 
temperature medium (Sakura Finetek, Torrance, CA), cryosectioned, fixed in 10% 
formalin (Sigma), and blocked with mouse-on-mouse reagent (Vector Labs, Burlingame, 
CA). Murine blood vessel density in ischemic and non-ischemic limbs was quantified at 
day 28 by counting mouse CD31+ capillaries and mouse von Willebrand factor (vWF+) 
blood vessels using rat-anti mouse CD31 (1:100, BD Biosciences) or rabbit anti-mouse 
vWF antibody (1:200, Millipore, Temecula, CA) and peroxidase-labelled anti-rat or anti-
rabbit immunoglobulin G (IgG) secondary antibodies (Vector) visualised using 3, 3'-
diaminobenzidine (DAB) substrate, and counterstained with hematoxylin. Blood vessel 
density was counted in a blinded fashion from 9 photomicrographic fields using light 
microscopy. 
2.2.9 Quantification of human cell engraftment by flow cytometry 
BM and adductor muscles from the ischemic and non-ischemic limbs were analyzed for 
human cell engraftment at 3, 7, and 28 days after transplantation by flow cytometric 
detection of human CD45 and HLA-A,B,C in combination with 7-aminoactinomycin D 
(7-AAD) viability dye (BD Biosciences). Muscle samples were digested with type II 
collagenase (Worthington Biomedical, Lakewood, NJ) prior to antibody labelling. 
2.2.10 Detection of human cells by GUSB-activity 
Transplanted NOD/SCID/MPSVII mice with unilateral hindlimb ischemia were 
sacrificed at 3, 7 and 28 days after transplantation to allow histochemical detection of 
single human cell engraftment in ischemic muscle sections (GUSB-deficient) based on 
the detection of ubiquitous GUSB activity in human cells as previously described42. 
Muscle sections were co-stained with vWF to assess the distribution of engrafted human 
cells with respect to murine vasculature, and with human CD45 to assess the lineage of 
engrafted cells.  
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2.2.11 Statistics 
Analysis of significance was performed by one-way ANOVA for cell-surface marker and 
progenitor frequency assays, and by two-way ANOVA with Bonferroni post-hoc tests for 
all other assays using Graphpad Prism software.  
2.3 Results 
2.3.1 UCB ALDHhi cells were enriched for myeloid progenitor cell 
surface phenotypes  
Human UCB MNC were collected without prior lineage depletion34, and purified based 
on cells with low side scatter (non-granular) and with low (ALDHlo, 41.36±3.6%) vs. 
high (ALDHhi, 0.4±0.1%) ALDH activity compared to ALDH-inhibited 
(diethylaminobenzaldehyde, DEAB) controls (n=10, Figure 2.1A,B). Compared to 
unpurified UCB MNC (97.7±0.8% CD45+) or ALDHlo cells (99.1±0.5% CD45+), ALDHhi 
cells showed lower expression of the pan-leukocyte marker CD45 (93.3±1.9% CD45+, 
*p<0.05, n=4). Thus, sorted cell populations were gated into hematopoietic (CD45+) and 
non-hematopoietic (CD45-) subsets, and further analyzed for primitive vs. mature 
hematopoietic or endothelial cell surface marker expression.  
CD45+ ALDHhi cells showed reduced expression lineage-specific markers for T- (CD4 
and CD8, Figure 2.1C) and B-lymphocytes (CD19 and CD20, Figure 2.1D) compared to 
unsorted MNC or ALDHlo cells (**p<0.01, Table 2.1). Over 90% of CD45+ ALDHhi cells 
expressed CD33, an early myeloid lineage marker, but co-expression of the mature 
monocyte marker CD14 was low (3.3±1.0%, Figure 2.1E; Table 2.1). Similarly, ALDHhi 
cells showed near homogeneous expression of CD31 or PECAM-1 (96.7±2.9%) but low 
co-expression of CD144/VE-cadherin (3.2±1.0%, Figure 2.1F; Table 2.1). Notably, the 
CD45+ ALDHhi cells were highly enriched for the co-expression of the progenitor 
markers CD34 (89.6±5.9%, Figure 2.1G), CD117 (80.2±4.9%), and CD133 (61.5±2.3%, 
Figure 2.1H) compared to unsorted UCB MNC or ALDHlo cells (*p<0.05, Table 2.1). 
CD45+ ALDHhi cells were enriched for SCID repopulating progenitor phenotype 
(CD34+CD38–, Figure 2.1G)43, and ALDHhiCD34+ cells showed co-expression of the 
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homing marker CXCR4 (14.2±2.9%, Figure 2.1I), but low expression of VEGFR2 
(0.5±0.1%, Figure 2.1J).  
CD45– cells, representing approximately 7% of the ALDHhi population, also showed 
enriched expression of CD34 (65.0±14.8%), CD117 (64.9±12.4%), and CD133 
(22.5±3.9%) progenitor markers (*p<0.05), but did not show increased expression of the 
mature EC-associated adhesion molecules (CD31 and CD144) compared to UCB MNC 
or ALDHlo cells (Table 2.2). Collectively these data indicate that the hematopoietic 
fraction of ALDHhi cells was depleted of mature lymphocytes and monocytes yet 
enriched for primitive myeloid progenitor phenotype, and the CD45– portion of the 
ALDHhi cells similarly retained a primitive non-hematopoietic cell phenotype.  
2.3.2 UCB ALDHhi cells demonstrated hematopoietic and endothelial 
colony formation 
UCB MNC, ALDHlo or ALDHhi cells were plated under lineage-specific growth 
conditions for 14 days to assess hematopoietic and endothelial CFC frequency. After 
culture in methylcellulose, ALDHhi cells were highly enriched for myeloid-lineage 
colony forming cells (1 HCFC in 3.6 cells) compared to ALDHlo cells (1 HCFC in 
6.6x103 cells, **p<0.01, n=4). ALDHhi HCFC demonstrated multipotent lineage 
differentiation with increased production of erythroid, macrophage, granulocyte and 
mixed morphologies (***p<0.001, Figure 2.1K). To assess ECFC function in vitro, 
ALDH-purified UCB cells were cultured under stringent conditions established by Yoder 
and colleagues9. Colony enumeration revealed increased ECFC content in ALDHhi cells 
(1 ECFC in 4.6x104 cells) compared to ALDHlo cells (1 ECFC in 2.2x105 cells, *p<0.05, 
Figure 2.1L). ECFC progeny were highly proliferative, did not express hematopoietic 
markers (CD45, CD14), and expressed EC markers (CD31, CD105, CD144). Unlike 
human BM40, MNC or ALDH-sorted cohorts from UCB did not establish plastic adherent 
multipotent stromal cell colonies in vitro (n=10). Thus, UCB ALDHhi cells represented a 
mixture of cells with enriched HCFC and ECFC function. 
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Figure 2.1 Purification of UCB ALDHhi cells enriches for hematopoietic and 
endothelial colony forming cells.  
(A,B) Human UCB MNC were sorted for low side scatter (SSC) and low 
(ALDHlo=41.2±3.6%) versus high (ALDHhi=0.4±0.1%) ALDH activity with or without 
DEAB inhibitor. Representative flow cytometry plots show that UCB ALDHhi cells were 
depleted of cells expressing mature (C) T-lymphocyte (CD4, CD8), (D) B-lymphocyte 
(CD19, CD20), (E) monocyte  (CD14), and (F) endothelial (VE-cadherin, CD144) cell 
surface markers, were enriched for cells expressing (E) early myeloid (CD33), (F) 
adhesion (PECAM-1, CD31), and (G,H) primitive progenitor (CD34, CD1117, CD133) 
markers. (I,J) CD34+ALDHhi cells showed low co-expression of chemokine receptors 
(CXCR4, VEGFR2). (K) After culture for 14 days in Methylcellulose media (n=7), UCB 
ALDHhi cells were highly enriched for multipotent HCFC.  (L) After culture for 14 days 
in complete endothelial growth media (EGM-2 + IGF, EGF, bFGF, VEGF-A + 2% 
serum, n=5), UCB ALDHhi were also enriched for ECFC. Scale bar = 200μm. Data are 
expressed as mean ± SEM, *p<0.05, **p<0.01, ***p<0.001. 
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Table 2.1  Cell surface marker expression for the hematopoietic (gated CD45+) 
component of human UCB MNC, ALDHhi cells, and ALDHlo cells. 
Lineage Markers (%) MNC ALDHhi ALDHlo 
T-Lymphocyte 
CD4 47.6±3.2a 3.5±0.6**b 47.8±2.1a 
CD8 24.9±0.9a 2.5±0.3**b 26.1±3.5a 
B-Lymphocyte 
CD19 20.3±1.8a 0.6±0.1**b 21.1±1.4a 
CD20 23.6±1.8a 1.8±0.9**b 21.1±1.7a 
Myeloid/ 
Monocyte 
CD33 20.9±0.9a 90.4±4.8**b 1.4±0.3**c 
CD14 17.7±1.2a 3.3±1.1**b 0.6±0.2**b 
Adhesion 
CD31 86.5±1.2a 96.7±2.9*b 81.0±3.5a 
CD144 21.5±2.0a 3.2±1.0**b 4.9±2.9**b 
Progenitor 
CD34 5.1±1.9a 89.6±5.9**b 0.3±0.1a 
CD117/c-kit 15.9±2.8a 80.2±4.9**b 12.5±5.3a 
CD133 0.7±0.3a 61.5±2.3**b 0.2±0.1a 
Homing 
CXCR4 47.3±6.1a 17.7±2.5*b 37.8±5.8a 
KDR/VEGFR2 0.6±0.3a 0.9±0.3a 0.3±0.1a 
Data represents mean ± SEM (n=4), different letters denote different expression patterns 
at *p<0.05, **p<0.01 compared to unpurified MNC. 
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Table 2.2. Cell surface marker expression for the non-hematopoietic (gated CD45-) 
component of human UCB MNC, ALDHhi cells, and ALDHlo cells. 
Lineage Markers (%) MNC ALDHhi ALDHlo 
Adhesion 
CD31 50.8±24.9a 38.7±16.6a 20.3±13.2a 
CD144 20.0±12.5a 17.8±11.3a 6.5±3.8a 
Progenitor 
CD34 17.9±9.2a 65.0±14.8*b 1.3±0.6**c 
CD117/c-kit 22.1±9.8a 64.9±12.4*b 12.8±3.5a 
CD133 6.9±1.5a 22.5±3.9*b 0.4±0.3a 
Homing 
CXCR4 33.9±10.1a 8.8±3.4*b 7.4±1.1*b 
KDR/VEGFR2 1.8±0.8a 1.9±1.0a 1.4±1.1a 
Data represents mean ± SEM (n=4), different letters denote different expression patterns 
at *p<0.05, **p<0.01 compared to unpurified MNC. 
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2.3.3 UCB ALDHhi cells demonstrated a pro-angiogenic transcription 
profile 
Affymetrix microarray identified 1253 transcripts with significantly increased (*p<0.05) 
expression in 3 UCB ALDHhi cell samples compared to sample-matched ALDHlo cells. 
These transcripts were first filtered to include unique genes translating to plasma 
membrane bound (196 hits) or extracellular (108 hits) locations, and subsequently filtered 
for documented angiogenic biological functions (Tables 2.3 and 2.4). As a control for the 
selection of cells with high ALDH-activity, ALDH1A1 mRNA expression was increased 
42-fold in ALDHhi vs ALDHlo cells (p=2.08x10-5). Furthermore, significantly increased 
CD34, PROM1, and KIT mRNA expression in ALDHhi cells (Table 2.3) correlated with 
increased CD34, CD133, and c-kit/CD117 cell surface protein expression previously 
observed by FACS (Figure 2.1, Table 2.1). Transcripts associated with early myeloid 
progenitor differentiation (FLT3, CSF3R, CD33), integrin-mediated cell adhesion 
(ITGA9, ITGAV, ITGA2B), and vascular cell signaling (TIE1, TIE2, FGFR1, endoglin) 
were also highly expressed by UCB ALDHhi cells (Table 2.3). Interestingly, transcripts 
for secreted cytokines associated with vascular functions (ANGPT1, FGF16, VEGFA), 
immune cell migration (IL-18, IL-1b, IL-8, CSF1, CXCL2), and modulators of EGF and 
IGF signaling (EREG, AREG, HBEGF, IGFBP7) were also increased in UCB ALDHhi 
cells (Table 2.4). Collectively, these data suggested that UCB ALDHhi cells possessed a 
pro-angiogenic transcription profile compared to ALDHlo cells. 
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Table 2.3 Angiogenesis-associated transcripts encoding cell surface proteins with 
increased expression in UCB ALDHhi versus ALDHlo cells. 
Gene 
Symbol 
Common  
Names 
Biological  
Function 
Molecular 
Function  
FC  
vs Alo 
p-value  
vs Alo 
PROM1 prominin 1, CD133 
hematopoiesis, vascular 
development / remodeling 
MAPK and Akt 
signaling 109.8 1.9x10-6 
CD34 
transmembrane 
sialomucin 
hematopoiesis, vascular 
development / remodeling 
adherence to BM 
matrix and cells 89.7 3.7x10-5 
KIT c-kit, CD117 
HPC survival, maintenance 
and migration, HPC marker 
tyrosine-protein 
kinase signaling 67.9 7.1x10-6 
FLT3 
FLT3 receptor tyrosine 
kinase, CD135 
myeloid progenitor 
proliferation / differentiation 
fms-related 
tyrosine kinase 
signaling 27.4 3.1x10-5 
IRAK3 
IL-1 receptor 
associated kinase 3 
stimulates EC proliferation 
and angiogenesis 
regulates IL-1 
receptor signaling 27.0 1.5x10-6 
ITGA9 integrin, alpha 9 
cell-cell and cell-matrix 
adhesion  
α9/β1 dimer 
binds VCAM1 26.8 2.8x10-6 
CSF3R 
colony stimulating 
factor receptor, CD114 
granulocyte and neutrophil 
survival / differentiation 
GCSF receptor 
signaling 20.0 3.4x10-3 
CD109 
TGF-beta-1-binding 
protein 
cell division, differentiation, 
motility, adhesion 
heterodimer with 
TGFB1 receptor 17.6 9.9x10-6 
CD302 
type 1 transmembrane 
C-type lectin receptor 
phagocytosis, cell adhesion 
and migration 
carbohydrate 
binding / adhesion 17.0 4.1x10-4 
EMR2 
EGF-module receptor 2 
CD312 mucin-like cell adhesion 
G-protein coupled 
receptor signaling 9.2 1.4x10-5 
CD33 
myeloid cell surface 
antigen 
adhesion molecule on 
monomyelocytic cells 
tyrosine kinase, 
binds sialic acid 7.3 3.7x10-5 
TIE1 
tyrosine kinase with 
immunoglobulin-like 
and EGF-like domain 1  
regulation of angiogenesis and 
vasculogenesis 
modulates TEK / 
TIE2 binding to 
angiopoietins 4.9 3.6x10-3 
ITGAV integrin, alpha V cell-cell, cell-matrix adhesion 
αV/β3 binds 
vitronectin 4.6 3.0x10-3 
ENG endoglin, CD105 
vascular system development 
and remodeling, EC migration 
complexes with 
TGF-beta, activin, 
BMP molecules 2.8 1.8x10-3 
FGFR1 
fibroblast growth factor 
receptor 1, CD331 
angiogenesis, embryonic 
development, cell 
proliferation, differentiation 
tyrosine kinase 
activity, binds 
FGF molecules 2.8 2.1x10-3 
ITGA2B integrin, alpha 2b 
cell-cell and cell-matrix 
adhesion 
α2B/β3 binds 
fibronectin 2.2 5.9x10-4 
TMEFF1 
transmembrane protein 
with EGF-like and 
follistatin-like domains 
unknown function during 
embryonic development 
modulates 
Nodal and BMP 
signaling 2.1 2.4x10-3 
TEK/TIE2 
tyrosine kinase with 
immunoglobulin-like 
and EGF-like domain 2 
angiogenesis, EC survival, 
proliferation, migration, 
adhesion 
tyrosine kinase 
activity, binds 
angiopoietins 2.0 1.8x10-3 
FC, fold change; BMP, bone morphogenic protein; EC, endothelial cell, EGF, epidermal 
growth factor; GCSF, granulocyte colony stimulating factor, HPC, hematopoietic 
progenitor cell; IL-1, interleukin 1; MCSF, macrophage colony stimulating factor; TGF, 
transforming growth factor; VCAM, vascular cell adhesion molecule 
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Table 2.4 Angiogenesis-associated transcripts encoding secreted cytokines with 
increased expression in UCB ALDHhi versus ALDHlo cells.  
Gene 
Symbol 
Common  
Name 
Biological  
Function 
Molecular 
Function  
FC  
vs Alo 
p-value  
vs Alo 
ANGPT1 angiopoietin-1 
vascular development / 
remodeling, angiogenesis 
TIE2 receptor 
activation 17.3 3.6x10-5 
IL18 
interleukin 18 (IFNγ-
inducing molecule) 
inflammation, EC migration, 
angiogenesis 
IL 18 receptor 
activation 16.7 7.7x10-6 
IL1β interleukin-1 beta 
inflammation, EC 
differentiation / proliferation  
IL-1β receptor 
activation 16.5 3.8x10-4 
EREG epiregulin EC proliferation, angiogenesis 
EGF receptor 
activation 12.1 2.6x10-4 
IL 8 
(CXCL8) interleukin 8 
chemoattraction of angiogenic 
and inflammatory cells 
CXCR1 and 
CXCR2 activation 8.5 3.1x10-5 
AREG amphiregulin EC proliferation, angiogenesis 
EGF receptor 
activation 5.9 1.4x10-4 
IGFBP7 
insulin-like growth 
factor binding protein 7 
implicated in tumor 
angiogenesis 
binds IGF1 and 
IGF2 4.7 1.5x10-4 
BMP6 
bone morphogenic 
protein 6 
EC development, 
proliferation, angiogenesis 
BMP receptor 
activation 3.9 3.4x10-3 
CSF1 
colony stimulating 
factor 1, M-CSF 
macrophage differentiation, 
migration and function 
M-CSF receptor 
activation 3.4 3.4x10-4 
FGF16 
fibroblast growth factor 
16 
angiogenic factor during 
development 
FGFR1 and 
FGFR2 activation 2.9 3.4x10-3 
FBLN5 fibrulin 5 
EC adhesion during vascular 
development / remodeling 
vascular ligand 
for integrins 2.5 5.8x10-3 
CXCL2 
chemokine (C-X-C 
motif) ligand 2 
chemoattraction of angiogenic 
and inflammatory cells CXCR2 activation 2.2 2.4x10-3 
 HBEGF 
heparin-binding EGF-
like growth factor 
endothelial cell proliferation, 
angiogenesis 
EGF receptor  
activation 2.1 8.0x10-3 
VEGFA 
vascular endothelial 
growth factor A 
regulation of angiogenesis and 
vasculogenesis 
VEGFR1 and R2 
activation 1.7 4.8x10-3 
FC, fold change; EC, endothelial cell 
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2.3.4 UCB ALDHhi cells augment the survival of HUVEC in vitro 
To assess the paracrine functions of ALDH-purified UCB cells on endothelial cell 
survival and proliferation in vitro, 40x103 HUVEC were seeded into transwell co-cultures 
for 72 hours using a 5μm pore hanging insert containing 105 UCB ALDHhi or ALDHlo 
cells (or basal media control) suspended above HUVEC. Under optimal conditions 
containing growth factors (GF+) and serum, non-contact co-culture with ALDHlo or 
ALDHhi cells did not impact the 5-fold expansion of HUVEC observed over 72h (Figure 
2.2A,E). Conversely, in GF-/serum-free conditions with or without ALDHlo cell 
supplementation, HUVEC invariably died within 72 hours (Figure 2.2B,E). In contrast, 
co-culture with ALDHhi cells under GF-/serum-free conditions promoted HUVEC 
viability for 72 hours (*p<0.05, Figure 2.2B,E). Under GF+/serum-free conditions, 
ALDHhi cell co-culture promoted a modest expansion (1.7-fold) of HUVEC 
(67.4±7.1x103 cells), compared to >3-fold HUVEC loss with basal media (12.4±2.6x103 
cells) or ALDHlo cell supplementation (14.4±2.8x103 cells, *p<0.05, Figure 2.2C,E). 
Under GF-/serum+ conditions, ALDHlo or ALDHhi co-culture did not significantly alter 
HUVEC numbers (Figure 2.2D,E). Thus, non-contact co-culture with human ALDHhi 
cells promoted HUVEC survival under GF-/serum-free conditions. These effects were 
consistent with the pro-survival stimulus in HUVEC provided by VEGF-A treatment44, a 
central pro-angiogenic cytokine with increased mRNA-expression in UCB ALDHhi cells 
(Table 2.4). 
  
70 
 
Figure 2.2 UCB ALDHhi cells promote endothelial cell survival under growth factor 
and serum-free conditions.  
(A-D) Representative photomicrographs of HUVEC density after 72h co-culture with 
UCB ALDHlo or ALDHhi cells in hanging transwells with or without growth factor or 
serum supplementation. Scale bar = 200μm. (E) Non-contact co-culture with human UCB 
ALDHhi cells promoted the survival of HUVEC under growth factor-free, serum-free 
conditions (n=5). Data are expressed as mean ± SEM, *p<0.05. 
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2.3.5 UCB ALDHhi cells augment tube-like cord formation by HUVEC 
in vitro 
HUVEC were cultured alone at 50x103 per well, or co-cultured with 20x103 ALDHhi or 
ALDHlo cells on growth factor reduced Matrigel. HUVEC established partially completed 
cord networks within 24 hours (Figure 2.3A). Although co-culture of HUVEC with UCB 
ALDHlo cells did not significantly alter cord formation, supplementation with ALDHhi 
cells increased the number of HUVEC tube-like cord formed at 24 hours after plating 
(Figure 2.3B and C). Although UCB ALDHhi cells established ECFC in liquid culture 
(Figure 2.1L, inset), UCB ALDHlo or ALDHhi cells seeded alone on growth factor 
reduced Matrigel did not spontaneously align to form cord networks (Figure 2.3D), and 
tube-like cord stability of HUVEC was not enhanced by co-culture with UCB ALDHlo or 
ALDHhi at 72 hours (Figure 2.3E-H). Enumeration of completed branch points at 24 and 
48 hours revealed that co-culture with UCB ALDHhi cells augmented cord formation by 
HUVEC compared to media controls (n=6, *p<0.05, Figure 2.3H). Therefore, co-culture 
with UCB ALDHhi cells promoted the cord-forming function of HUVEC in vitro. 
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Figure 2.3 UCB ALDHhi cells augmented tube-like cord formation by HUVEC.  
Representative photomicrographs of tubule formation by HUVEC after 24 (A-C) and 72 
(E-G) hours co-culture with ALDHlo or ALDHhi cells or media control. Scale bar = 
500μm. (D) ALDHhi cells plated without HUVEC did not form cord structures. (H) Co-
culture with ALDHhi cells augmented the formation of complete tubule networks formed 
by HUVEC at 24 and 48 hours, but did not augment tubule stability after 72 hours co-
culture. Data are expressed as mean ± SEM, *p<0.05. 
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2.3.6 Transplanted UCB ALDHhi cells enhanced the recovery of 
hindlimb perfusion 
To determine whether ALDH-purified human UCB cells could support blood vessel 
regeneration after intravenous transplantation in vivo, we induced acute unilateral 
hindlimb ischemia in NOD/SCID mice by right femoral artery ligation with complete 
excision of a 0.5cm section of the femoral artery and vein. Blood flow was assessed by 
LDPI and the perfusion ratio (PR) in the ischemic versus control limb was decreased 
>10-fold (PR=0.08±0.02) post-surgery confirming consistent induction of unilateral 
hindlimb ischemia (Figure 2.4). Within 24 hours of surgery mice were tail vein injected 
with PBS vehicle control, unsorted UCB MNC, ALDHhi cells, or ALDHlo cells. The 
representative LDPI shown in Figure 2.4 documents the recovery of limb perfusion after 
transplantation. PBS-injected control mice showed recovery of PR from 0.07±0.01 after 
surgery to 0.36±0.05 by day 7 post-surgery without subsequent improvement at later time 
points (Figure 2.4A,E). This baseline recovery of perfusion was sufficient to prevent 
excess morbidity or limb loss in PBS transplanted mice. Mice transplanted with 20x106 
MNC or 10x106 ALDHlo cells showed equivalent recovery of limb perfusion similar 
compared to PBS controls (Figure 2.4B,D-E). In contrast, mice transplanted with 50-100-
fold fewer ALDHhi cells (2x105) showed increased perfusion by day 14 post-
transplantation (PR=0.58±0.07) compared to all other treatments and augmented 
perfusion was maintained for 28 days post-transplantation (PR=0.64±0.06, **p<0.01, 
Figure 2.4C,E). Thus, intravenous-transplantation of human UCB ALDHhi cells improved 
the limb perfusion in mice with acute unilateral hindlimb ischemia. 
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Figure 2.4 Transplanted UCB ALDHhi cells augmented perfusion in ischemic 
hindlimbs.  
Representative LDPI following right femoral artery ligation and tail vein injection of (A) 
PBS vehicle control (n=7), (B) 20x106 unsorted UCB MNC (n=7), (C) 2x105 ALDHhi 
cells (n=7), or (D) 10x106 ALDHlo cells (n=7). Numbers in lower left of each image 
indicate perfusion ratio of the ischemic versus the non-ischemic hindlimb. (E) Compared 
to all other treatments, transplantation of UCB ALDHhi cells promoted improved 
recovery of perfusion in ischemic mouse hindlimbs by day 14 and augmented perfusion 
was maintained to day 28. Data are expressed as mean ± SEM, **p<0.01. 
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2.3.7 Transplanted UCB ALDHhi cells increased capillary density in 
the ischemic limb 
To address the recovery of blood vessels in the ischemic hindlimb, sections from the 
adductor muscle at the site of artery ligation were stained for both murine CD31+ 
capillary (Figure 2.5A-C) and vWF+ blood vessel (Figure 2.5D-F) density. Compared to 
the non-ischemic limb at day 28 (65.3±6.1 CD31+/mm2, 8.1±1.2 vWF+/mm2), PBS-
injected mice showed significant reduction (*p<0.05) of both CD31+ capillaries 
(53.5±4.8/mm2, Figure 2.5G) and vWF+ blood vessels (5.5±1.4/mm2, Figure 2.5F) within 
the ischemic hindlimb. However, mice transplanted with UCB ALDHhi cells 
(73.7±10.5/mm2) had significantly more CD31+ capillaries compared to mice transplanted 
with ALDHlo cells (61.1±12.4/mm2, *p<0.05) or PBS (65.3±6.1/mm2,**p<0.01, Figure 
2.5G). Similarly, mice transplanted with ALDHhi cells (8.8±1.8/mm2) showed higher 
vWF+ blood vessel density than mice injected with ALDHlo cells (5.8±1.2/mm2, *p<0.05), 
or MNC (5.8±0.9/mm2, *p<0.05), or PBS-injected controls (8.1±1.2 vWF+/mm2, 
***p<0.001, Figure 2.5H). Despite only partial recovery of perfusion, CD31+ and vWF+ 
vessel density in the ischemic limbs of ALDHhi cell-treated mice was equivalent to the 
vessel density of the non-ischemic control limb at day 28 (Figure 2.5G,H). Thus, UCB 
ALDHhi cell transplantation increased both CD31+ capillary and vWF+ blood vessel 
density in the ischemic hindlimb after femoral artery ligation. 
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Figure 2.5. Transplanted UCB ALDHhi cells augmented blood vessel density within 
ischemic hindlimbs.  
Representative photomicrographs of adductor muscle sections from the ischemic and 
non-ischemic limbs of mice injected with PBS or UCB ALDHhi cells stained for (A-C) 
CD31+ capillaries or (D-F) vWF+ blood vessels at day 28 post-transplantation. Scale bar = 
100μm. Compared to all other treatments, (G) CD31+ capillary density, and (H) vWF+ 
blood vessel density was increased in the ischemic limb of mice transplanted with human 
UCB ALDHhi cells. Data are expressed as mean ± SEM, *p<0.05, **p<0.01, ***p<0.001 
as determined by two way ANOVA and Bonferroni post-tests to compare multiple 
means. 
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2.3.8 Transplanted UCB ALDHhi cells recruited to the ischemic 
muscle at low frequency 
In order to correlate the recovery of perfusion with human cell engraftment, murine BM 
and adductor muscle were collected at 3, 7, and 28 days after transplantation, and 
analyzed for the presence of human CD45+ or HLA-A,B,C+ cells by flow cytometry. 
Despite consistent human cell hematopoietic chimerism in the BM of mice transplanted 
with ALDHhi cells (Figure 2.6A,C) or MNC (Figure 2.6C), human cells were not 
significantly detected in the adductor muscle of ischemic limbs by flow cytometry 
(Figure 2.6B,D) at day 28. In addition, mice processed for engraftment at earlier time 
points showed no evidence of human cells in the ischemic limb at 3 (n=3) or 7 days (n=3) 
post-transplantation by FACS. Therefore, we repeated engraftment experiments using 
identical cell doses in the GUSB-deficient NOD/SCID/MPSVII recipient to permit the 
detection of transplanted human cells at single cell resolution. At 3 and 7 days post-
transplantation, the detection of GUSB expressing cells confirmed the recruitment of 
human cells to the ischemic hindlimbs of mice that received MNC (n=4, Figure 2.6E-F) 
or ALDHhi cells (n=4, Figure 2.6H-I). However, human cells were not detected in the 
ischemic limbs of mice that received ALDHlo cells (n=4). Although transplanted cells 
were never detected in the non-ischemic limb, engrafted MNC and ALDHhi cells were 
observed in ischemic muscle sections surviving out to 28 days (Figure 2.6G, J). Staining 
for GUSB-activity combined with murine vWF showed engraftment of single human 
cells between muscle fibres (Figure 2.6K) and in association with the connective tissue 
surrounding blood vessels (Figure 2.6L). Also, the majority of GUSB+ human cells 
surviving at day 28 co-stained for CD45 (Figure 2.6M). Despite low frequency 
engraftment in the ischemic region, early recruitment of ALDHhi progenitor cells to the 
site of ischemic injury was sufficient to augment blood vessel density and improve limb 
perfusion.  
  
82 
 
Figure 2.6 Transplanted human UCB ALDHhi cells recruited to the ischemic 
hindlimb.  
Representative flow cytometry plots illustrating the detection of human cells 
(CD45+/HLA-A,B,C+) cells within (A) the bone marrow and (B) ischemic hindlimbs of 
mice transplanted with UCB ALDHhi cells. (C,D) Despite engraftment of human cells in 
the mouse bone marrow, human cells were rarely detected in the ischemic hindlimb by 
flow cytometry. Representative photomicrographs showing the detection of transplanted 
human cells (red) in the adductor muscle of the ischemic hindlimb of mice transplanted 
with (E-G) UCB MNC or (H-J) UCB ALDHhi cells at 3, 7 and 28 days post-
transplantation. GUSB+ human cells (arrows) were detected in the ischemic limb of mice 
injected with UCB MNC or ALDHhi cells, but not in mice injected with UCB ALDHlo 
cells. Co-staining for GUSB-activity with murine vWF at day 28 showed (K) engraftment 
of single GUSB+ cells between muscle fibres, and (L) associated with vWF+ blood 
vessels. (M) GUSB+ human cells surviving at day 28 co-stained for CD45. Scale bars = 
100μm. 
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2.3.9 Sublethal irradiation did not improve perfusion in the ischemic 
hindlimb 
The requirement for preparative irradiation is an important consideration in the design of 
clinically applicable cell therapies for ischemic diseases. In an attempt to improve human 
cell engraftment in the ischemic limb, transplantation experiments were repeated after 
sublethal irradiation (300cGy) administered as a means to reduce xenorejection by 
residual innate immunity or NK-cell activity in the NOD/SCID model. Surprisingly, in 
mice receiving UCB ALDHhi cells, perfusion at early time points (days 3, 7, and 14) was 
similar for all transplanted groups (Figure 2.7A-E). Although perfusion improved in the 
ALDHhi cell transplanted cohort at day 21, perfusion was reduced to baseline by day 28 
(Figure 2.7E), indicating that only a transient improvement in limb perfusion was 
observed. Compared to mice transplanted without preparative irradiation (Figure 2.4), 
irradiated mice receiving an equal dose of UCB ALDHhi cells actually showed delayed 
recovery of perfusion at day 14 (PR300cGy = 0.40±0.05 vs PR0cGy = 0.58±0.07). 
Nonetheless, at day 28, irradiated mice injected with ALDHhi cells still showed improved 
vWF+ blood vessel density (Figure 2.8) similar to non-irradiated mice.  
Irradiated mice also showed enhanced recruitment of ALDHhi cells to the BM at day 7 
(1.3±0.2%, Figure 2.9A,C), resulting in extensive hematopoietic repopulation by day 28 
(44.7±2.0%, Figure 2.9A,C). Unexpectedly, human cells in the ischemic limb were not 
detected by FACS or GUSB staining at day 7 (Figure 2.9B,D,E), and were only rarely 
detected at day 28 (Figure 2.9F). Thus, irradiation prior to ALDHhi cells transplantation 
did not augment engraftment or the recovery of perfusion in the ischemic limb. 
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Figure 2.7 Transplanted UCB ALDHhi cells induced transient recovery of perfusion 
in the ischemic limbs of mice that received preparative irradiation.  
Representative LDPI following right femoral artery ligation, 300 cGy sublethal 
preparative irradiation to suppress immune rejection, and tail vein injection with (A) PBS 
vehicle control (n=6), (B) 20x106 unsorted UCB MNC (n=7), (C) 2x105 UCB ALDHhi 
cells (n=8), or (D) 10x106 ALDHlo cells (n=8), and monitored for 28 days. Numbers in 
lower left of each LDPI image indicate perfusion ratio of the ischemic versus the non-
ischemic hindlimb from ankle to toe. (E) Summary of mean perfusion ratios in all 
transplanted mice as described above. Compared to all other treatments, transplantation 
of UCB ALDHhi cells promoted a transient recovery of perfusion in ischemic mouse 
hindlimbs at day 21 post-transplantation. Data are expressed as mean ± SEM, **p<0.01. 
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Figure 2.8 Transplanted UCB ALDHhi cells augmented blood vessel density in the 
ischemic hindlimb of irradiated mice. 
Representative photomicrographs of adductor muscle sections from the non-ischemic and 
ischemic hindlimbs of mice injected with (A, B) PBS or (C) UCB ALDHhi cells or (D) 
UCB ALDHlo cells stained for vWF+ blood vessels at day 28 post-transplantation. Scale 
bar = 100µm. (E) Summary of vWF+ blood vessel density for each transplanted cohort at 
28 days post-transplantation. Compared to all other treatments, blood vessel density was 
increased in the ischemic limb of mice transplanted with human UCB ALDHhi cells. Data 
are expressed as mean ± SEM, ***p<0.001. 
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Figure 2.9 Transplanted UCB ALDHhi cell showed reduced engraftment in the 
ischemic limb and increased engraftment in the bone marrow of irradiated mice.  
(A,B) Representative flow cytometric detection of human cells in (A) bone marrow or 
(B) ischemic muscle (B) of mice transplanted with UCB ALDHhi cells after sublethal 
(300cGy) preparative irradiation. (C-D) Summary of human cell (CD45+/HLA-A,B,C+) 
engraftment in (C) the bone marrow or (D) ischemic muscle of all transplanted mice at 7 
and 28 days–post transplantation. (E, F) Representative photomicrographs showing the 
detection of transplanted human cells (red) in the adductor muscle of the ischemic 
hindlimb of mice transplanted with UCB ALDHhi cells at 7 and 28 days post-
transplantation. GUSB+ human cells (arrows) were detected in the ischemic limb of mice 
at 28 days post-transplantation, Scale bar = 100μm. 
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2.4 Discussion 
In the present study we demonstrate that ALDH-expressing cells from human UCB, 
representing <0.5% of total UCB cells and primarily comprised of primitive myeloid 
progenitor cells, demonstrated increased expression of mRNA transcripts for several 
angiogenic cytokines, and stimulated the survival and tubule forming functions of EC 
during co-culture in vitro. Intravenous transplantation of UCB ALDHhi cells also 
augmented recovery of limb perfusion induced by femoral artery ligation and transection. 
Although the engraftment of human cells within ischemic muscle was infrequent, UCB 
ALDHhi cells specifically recruited to the ischemic limb within 3 days of transplantation, 
and stimulated the recovery of blood vessel and capillary density. Furthermore, ALDHhi 
cells function within the pancreas to promote islet revascularization after transplantation 
into streptozotocin-treated mice45,46. Collectively, these data suggest that UCB ALDHhi 
progenitor cells represent a readily available population of pro-angiogenic cells for the 
development of cellular therapies to promote endogenous revascularization. 
The UCB ALDHhi population was significantly enriched for human hematopoietic 
progenitor function. Approximately 1 in 4 ALDHhi cells demonstrated multipotent CFU 
capacity in methylcellulose cultures. UCB ALDHhi cells also showed increased 
expression of primitive cell surface markers (CD34, c-kit/CD117, and CD133), and 
>90% of UCB ALDHhi cells expressed the early myeloid marker CD33, indicating a 
substantial enrichment of early myeloid progenitors. At the same time, UCB ALDHhi 
cells were depleted of mature T- and B-lymphocytes as well as CD14 expressing 
monocytes. This is notable as CD14+ monocytes have been specifically implicated in the 
paracrine support of angiogenesis47. However, transplantation of UCB ALDHhi cells, 
containing only 3% CD14+ monocytic cells significantly improved perfusion and blood 
vessel density in the ischemic limb, whereas transplantation of mice with 100-fold higher 
doses of unsorted MNC, containing over 17% CD14+ monocytes, failed to promote 
recovery from hindlimb ischemia. Recent studies have demonstrated that murine 
common myeloid progenitors preferentially differentiate into pro-angiogenic monocytes 
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that support neovessel formation in vivo48. Although UCB ALDHhi cells may be capable 
of differentiating into monocytes in vivo, our data indicates that primitive UCB ALDHhi 
myeloid progenitors play a significant role in support of angiogenesis in vivo.  
UCB ALDHhi cells also possessed enriched ECFC capacity in vitro. In contrast to the 
dominant myeloid progenitor composition, ECFC were infrequent at approximately 1 
ECFC in 50,000 ALDHhi cells. Although this represents a significant ECFC enrichment 
from unpurified UCB MNC9, it is unlikely that the few ECFC within 40x103 ALDHhi 
cells make a major contribution towards the maintenance of HUVEC survival and the 
induction of tubule forming function that we observed under growth factor and serum 
starved conditions in vitro. However, paracrine contributions of the non-hematopoietic 
component of the ALDHhi population should not be overlooked in vivo. Approximately 
7% of the UCB ALDHhi population were CD45-, and these cells demonstrated high co-
expression of primitive endothelial precursor markers (CD34 and CD133). Therefore, we 
propose that UCB ALDHhi cells represents a heterogeneous mixture of primitive 
hematopoietic and non-hematopoietic progenitors that may act in synergy to generate a 
supportive microenvironment to promote EC survival and revascularization function.  
After intravenous transplantation, UCB ALDHhi cells induced stable recovery from acute 
ischemic injury within 2 weeks of transplantation into mice with unilateral hindlimb 
ischemia. However, permanent engraftment of ALDHhi cells within the ischemic muscle 
was below the threshold of detection by flow cytometry. Notably, transplantation of 50-
100-fold greater cell doses of unpurified UCB MNC or ALDHlo cells also showed little 
engraftment by FACS. Using NOD/SCID/MPSVII mice, a unique cell tracking model 
capable of detecting GUSB-expressing human cell at the single cell level, we 
demonstrate that intravenous-injected UCB ALDHhi cells specifically recruited into the 
ischemic limb at 3 and 7 days after transplantation, and these cells survived in ischemic 
muscle tissue, albeit at low frequencies, for up to 28 days. Nonetheless, this low 
frequency engraftment of ALDHhi cells in the ischemic region at early time points was 
sufficient to augment the revascularization of ischemic muscle indicating a vascular 
stabilization was mediated by the ALDHhi cells.  
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Recent models have proposed a transient role for pro-angiogenic hematopoietic cells in 
the stabilization of injured vasculature, and in the activation and recruitment of vessel 
resident endothelial precursors to the sprouting vessel branch8. In support of this concept 
we show that sublethal irradiation prior to transplantation of ALDHhi cells reduced 
recruitment of human cells to the ischemic region, increased engraftment of ALDHhi cells 
in the murine BM, and delayed the functional recovery of perfusion. Therefore, we 
propose that early recruitment of ALDHhi cells to the ischemic region is critical for 
vascular recovery, allowing ALDHhi cells to release pro-angiogenic stimuli that activate 
an endogenous program for collateral vessel formation resulting in improved limb 
perfusion. Thus, strategies to improve the efficiency ALDHhi progenitor cell delivery, or 
to prolong survival at or near the site of ischemic injury, is expected to further augment 
vascular regeneration via paracrine or contact dependent mechanisms.  
2.4.1 Conclusion and Summary 
Strategies that purify pro-angiogenic cell subtypes from alternate human sources are 
required to improve the efficacy of human cell therapy trials26. Our studies outline several 
important caveats relevant to the development of cellular therapies to treat ischemic 
diseases. First, we have identified a mixed population of hematopoietic/myeloid and non-
hematopoietic/endothelial ALDHhi progenitor cells from human UCB as a readily-
available and clinically applicable cell population with potent pro-angiogenic function. 
Second, the potential use of allogeneic UCB cells will open new avenues towards clinical 
cell based therapies for ischemic disease, as mounting evidence indicates the potential for 
progenitor deletion and dysfunction of autologous BM cells in patients with severe 
diabetes and cardiovascular disease2,18-20. Third, we have shown that neither high-level 
nor permanent engraftment of human cells were necessary to mediate augmentation of 
perfusion and improved vessel density in vivo. In an allogeneic context, such as 
intramuscular delivery of UCB ALDHhi cells in patients with ischemic heart disease or 
critical limb ischemia49,50, future clinical transplantation strategies employing UCB may 
require only short-term immune suppression to initiate potent revascularization. Future 
studies will increase our understanding of the cellular constituents and paracrine 
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pathways that modulate regenerative angiogenesis, and will lead to novel therapies to 
improve tissue vascularization during ischemic diseases.  
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Chapter 3 
3 Ex Vivo Expanded Hematopoietic Progenitor Cells Promote 
Endothelial Cell Survival and Ischemic Limb Revascularization 
Due to the relative rarity of ALDHhi cells from UCB or BM, I aimed in Chapter 3 to 
determine if it was possible to expand UCB-derived ALDHhi cells ex vivo to generate 
more cells for therapeutic applications without losing beneficial vascular regenerative 
effect. Therefore the objectives of this chapter 3 were two-fold:  
• To optimize the ex vivo expansion of UCB ALDHhi hematopoietic cells under 
clinically relevant serum-free conditions and to characterize vascular regenerative 
functions of the expanded progenitor cells in vitro.  
• To investigate the paracrine mechanisms by which expanded hematopoietic 
progenitor cells derived from UCB ALDHhi contribute to revascularization after 
direct intramuscular injection into the ischemic limb. 
The studies presented in this chapter used HMVEC as the EC source as minor adjustment 
compared to the HUVEC used in Chapter 2 to more closely model the phenotype of the 
EC thought be involved in angiogenesis and vascular regeneration. Vascular regeneration 
tends to affect the capillary microcirculation more so than a large vessel venous EC like 
HUVEC.  The work presented in this chapter build directly upon the findings presented 
in Chapter 2. Specifically, it demonstrates that UCB ALDHhi cells can be efficiently 
expanded ex vivo without loss of vascular regenerative phenotype. Moreover, it 
introduces further refinement of the in vivo and in vitro models of vascular regeneration 
from those used in Chapter 2.  The in vitro model used in this chapter introduces further 
mechanistic characterizing of the effects of HPC on cultured EC in terms of cell survival 
and death as measured by flow cytometry.  Building on the in vivo murine hindlimb 
ischemia model from the previous chapter, here I present techniques to measure limb 
usage in addition to blood perfusion data.  Quantitation of limb usage in addition to 
simple measurement of perfusion indicates that mice regain functional usage of the limb 
in addition to recovery of simple blood flow, strengthening the model. Furthermore,  the 
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transplantation method was changed to intramuscular injection to more closely model the 
transplantation strategy from most PVD and CLI trials as well as to decrease delays in 
therapeutic benefit due to delayed and inefficient recruitment of cells transplanted 
intravenously.   
3.1 Introduction 
Ischemia, caused by insufficient blood flow to a given tissue, represents a widespread 
burden on human health. Cardiovascular disease (CVD) is the leading cause of death in  
North America, and accounts for roughly one third of all deaths and related healthcare 
costs for patients with CVD and stroke is now estimated to be in excess of $300 billion in 
the US alone1,2. Since Asahara et al. first described a role for circulating bone marrow-
derived cells in vascular regeneration, cell therapy has emerged as an important strategy 
to treat ischemic diseases3-7. Thus, the development of novel cellular therapies for the 
management of acute cardiovascular diseases such as myocardial infarction and stroke, as 
well as chronic ischemic disease such as coronary and peripheral arterial disease, remain 
the focus of intense preclinical research.  
Early clinical trials building upon the preclinical promise shown by bone marrow and 
umbilical cord blood-derived endothelial and hematopoietic progenitor cells showed that 
transplantation in humans was well-tolerated and safe6-8. Unfortunately, many of these 
therapies showed mixed results in improving cardiovascular disease outcomes, leading 
researchers to refocus on better understanding of the role of circulating progenitor cells in 
vascular repair9. As such, several cell types have been implicated in vascular regeneration 
including multiple cell types from the hematopoietic lineage10-13. 
Recent cell-based approaches for vascular regeneration have focused on better functional 
characterization of purified cellular subpopulations and the mechanisms by which 
transplanted progenitor cells mediate vascular regeneration. Several groups have 
demonstrated that cells of the myeloid lineage recruit to areas of ischemia and support 
vessel regeneration though paracrine signaling to vessel-resident endothelial cells14-17. 
Our lab has demonstrated that transplantation of primitive hematopoietic progenitor cells 
with high aldehyde dehydrogenase (ALDH) activity, derived from human bone marrow 
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or umbilical cord blood, promote recovery from acute ischemic injury in immune 
deficient mice with hindlimb ischemia more effectively than unpurified, more 
heterogeneous populations (Chapter 2)18,19. However, implementation of a cell-based 
therapy using UCB or BM-derived ALDHhi cells is hindered by the rarity of the ALDHhi 
cell population as it accounts for less than 1% of total MNC in BM or UCB samples. 
However, interest in developing strategies to increase the number of hematopoietic stem 
and progenitor cells for transplantation into patients with hematological disorders has led 
to identification of clinically-applicable culture strategies for hematopoietic progenitor 
expansion using defined, xeno-free conditions supplemented with stem cell factor (SCF), 
thrombopoietin (TPO) and fms-related tyrosine kinase 3 ligand (FLT3L) 20-22.  
In this study we characterize serum-free ex vivo expansion of UCB-derived ALDHhi 
hematopoietic progenitor cells as a transplantable cell population for vascular 
regenerative cell therapies. We demonstrate that intramuscular transplantation of 
expanded ALDHhi cells can accelerate the recovery of perfusion and limb use after 
femoral artery ligation-induced ischemic injury. Even after a 20-fold increase in the total 
number of myeloid cell progeny available for transplantation, expanded HPC prevented 
capillary loss as effectively as freshly isolated UCB ALDHhi cells. In addition, the 
secretion of pro-angiogenic and pro-inflammatory effectors from expanded ALDHhi cells 
correlated with improved survival and tube formation by human microvascular 
endothelial cells (HMVEC) during co-culture in vitro. We propose that ex vivo-expanded 
myeloid progeny derived from the ALDHhi subset of UCB represent a readily available, 
clinically applicable population for future development of cell therapies to prevent limb 
loss in patients with severe peripheral artery disease.   
3.2 Methods 
3.2.1 Purification of human umbilical cord blood cells based on 
aldehyde dehydrogenase activity 
Human umbilical cord blood samples were collected with informed consent immediately 
after scheduled, full-term Cesarean sections by venipuncture at the London Health 
Sciences Birthing Centre. The Human Research Ethics Committee at the University of 
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Western Ontario approved all studies. Cord blood samples were labeled with RosetteSep 
human cord blood progenitor cell enrichment tetrameric antibody complexes to 
prospectively deplete cells expressing lineage specific (Lin-) markers CD2, CD3, CD14, 
CD16, CD19, CD24, CD56, CD66b and glycophorin. After hypaque-ficoll centrifugation 
(Stem Cell Technologies, Vancouver, Canada) Lin– MNC were further depleted of 
erythrocytes by ammonium chloride lysis and assayed for ALDH activity using Aldefluor 
reagent (Stem Cell Technologies) as previously described (Appendix 1, Chapter 
2)18,19,23,24. Fluorescence activated cell sorting was performed to isolate cells with low side 
scatter and high (ALDHhi) versus low (ALDHlo) ALDH activity. Before use in 
experiments, sorted cell population of >98% purity were washed in phosphate-buffered 
saline (PBS) to allow the efflux of Aldefluor substrate via ATP-binding cassette-
transporters, leaving the cells unmodified for subsequent functional characterization and 
transplantation experiments. 
3.2.2 Ex vivo expansion of hematopoietic progenitors from UCB 
ALDHhi cells 
After fluorescence activated cell sorting, UCB ALDHhi cells were plated on recombinant 
human fibronectin coated (1 hour coating with 0.0125 mg/mL fibronectin in PBS 
followed by sterile water rinse) dishes in X-vivo 15 (Lonza, Basel, Switzerland) 
supplemented with stem cell factor (SCF, 10ng/mL), Fms-related tyrosine kinase 3 ligand 
(FLT3LG, 10ng/mL), and thrombopoietin (TPO, 10ng/mL). All growth factors were from 
Life Technologies, Burlington, ON. Growth media was changed every 3 days and 
conditioned media was collected after 3 and 6 days of expansion. Ex vivo expanded 
hematopoietic progenitors (HPC) were harvested and enumerated by Trypan blue 
viability at day 6.  
3.2.3  Assessment of ALDH-activity and cell surface marker 
expression after ex vivo expansion 
After 6 days ex vivo expansion, HPC were first assayed for the retention of high ALDH 
activity using Aldefluor reagent by flow cytometry to compare fluorescence levels to 
DEAB-inhibited control samples. Freshly isolated UCB ALDHhi cells and day 6 ex vivo-
expanded HPC progeny were labeled with anti-human antibodies for lineage-specific 
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markers for T lymphocytes (CD3, Biolegend, San Diego, CA), macrophages (CD11b, BD 
Biosciences), monocytes (CD14, BD Bioscience), B lymphocytes (CD19, BD 
Bioscience), myeloid cells (CD33, BD Bioscience), and with antibodies for primitive 
progenitor-specific markers CD34 (Biolegend), CD38 (BD Biosciences), CD133 
(Miltenyi Biotech, Auburn CA) and CD117 (BD Bioscience). Viable, 7-amino-
actinomycin D (7AAD, BD Bioscience)-excluding cells were assessed for ALDH-activity 
and cell surface marker expression using an LSRII flow cytometer at the London 
Regional Flow Cytometry Facility and analyzed using FlowJo software (Treestar, 
Ashland, OR).  
3.2.4 Quantitation of hematopoietic colony forming capacity in vitro 
Freshly isolated UCB ALDHhi or 6-day ex vivo-expanded HPC were cultured in semi-
solid methylcellulose media (Methocult® H4434, SCT) at limiting dilution. 
Hematopoietic colony formation at 14 days was enumerated by manual counting under 
bright field light microscopy, based on cell morphology identifying burst-forming units 
of erythrocytes (BFU-E), colony-forming units of granulocytes (CFU-G), macrophages 
(CFU-M), granulocytes and macrophages (CFU-GM), or multilineage mixed colonies 
(CFU-Mixed) containing cells of all 3 myeloid cell types listed above.  
3.2.5 Microarray assessment of gene transcription after ex vivo 
expansion  
mRNA was isolated from 6 day culture expanded HPC or freshly-isolated (uncultured) 
UCB ALDHhi cells using the mRNeasy Mini kits (n=3, Qiagen, Mississauga, ON). 
Microarray analysis was performed in triplicate using human array chips (Affymetrix, 
Santa Carla, CA) at the London Regional Genomics Centre (London, ON). Genes 
differentially expressed by uncultured UCB ALDHhi cells versus ex vivo-expanded HPC 
were analyzed using the Partek Genomic Suite and angiogenesis associated-transcripts 
coding for secreted proteins were identified (Partek, Inc., St. Louis, MO).  
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3.2.6 HMVEC survival when exposed to HPC-secreted factors 
For endothelial cell growth and survival assays, 4x104 HMVEC (adult, dermal source) 
were cultured in endothelial basal media (EBM2-MV, Lonza) with or without growth 
factors (EGF, VEGF-A, FGF, IGF-1) and serum (5%) supplementation. To assess 
whether co-culture with expanded HPC could support HMVEC survival under serum-
starved, growth factor depleted conditions, 8x104 HPC were seeded into porous (1µm) 
hanging transwells suspended above the HMVEC. The number of trypan blue excluding 
HMVEC present after 72 hours co-culture was enumerated by blinded hemocytometer 
counts. To assess HPC-conditioned media could support endothelial cell survival, 3x103 
HMVEC were plated in endothelial basal media with or without growth factors, or in 
serum-free HPC-conditioned media collected after 3 or 6 days of expansion. The number 
of HMVEC present after 72 hours of culture was quantified using the CyQUANT cell 
proliferation assay (Life Technologies) performed as described by the manufacturers 
protocol. Briefly, total lysed-cell DNA content was quantified by a fluorescence plate 
reader (SpectraMax M5, Molecular Devices, Sunnyvale, CA) and cell number was 
interpolated by a standard curve. To quantify HMVEC apoptosis rates during co-culture 
or after exposure to HPC-conditioned media, HMVEC were also harvested after 24 hours 
and labelled with viability dye 7AAD and co-stained with anti-human annexin V and 
assayed using flow cytometry. Annexin V is expressed on the external cell membrane 
early during the apoptotic cascade and identified apoptotic cells and 7AAD staining was 
used to identify live versus dead cells. The frequency of live (7AAD−/annexin V−), 
apoptotic (7AAD−/annexin V+), and dead HMVEC (7AAD+) was quantified using FlowJo 
analysis software. 
3.2.7 HMVEC tubule network formation when exposed to HPC-
secreted factors 
To assess endothelial cell tubule formation, 1.4x104 HMVEC were cultured on growth 
factor-reduced Matrigel (BD Biosciences) for up to 48 hours. HMVEC Matrigel cultures 
were bathed with either endothelial basal media (EBM) without growth factors or serum, 
complete EGM2-MV (EBM + growth factors, +5% serum), or serum-free HPC 
expansion media, or serum-free HPC-conditioned media collected after 3 or 6 days of 
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expansion. To assess whether direct cell contact could augment endothelial cell function, 
HMVEC were also co-cultured on growth factor reduced Matrigel in direct co-culture 
with 1x105 ex vivo-expanded HPC in EBM. The number of complete branch points in the 
tubule networks formed by HMVEC was enumerated on an inverted microscope by 
blinded manual counts of complete branch points using four fields of view in triplicate 
wells at 6, 24 and 48 hours. 
3.2.8 Identification of secreted angiogenic proteins during HPC-
HMVEC co-culture 
Conditioned EBM (without serum or growth factors) was harvested after 72h of culture 
of 4x104 HMVEC or 8x104 HPC to assess cytokines secreted by each cell type under 
basal culture conditions. To identify angiogenic proteins differentially secreted when 
cross-talk between EC and HPC was permitted, HMVEC and HPC were co-cultured 
together to generate EBM media conditioned by both cell types in direct co-culture 
simultaneously. Angiogenesis-associated proteins were detected in EC-, HPC-, and 
EC/HPC co-culture-conditioned media samples using a human angiogenesis antibody 
array C1000 kit and chemiluminescence imaging of the membranes as per manufacturer 
instructions (Human Angiogenesis Antibody Array C1000, RayBiotech, Norcross, GA, 
USA). Mean signal intensities for each protein detected was normalized to signal 
intensity of negative and positive control spots to adjust for differences in exposures 
between arrays and between samples as outlined in manufacturer guidelines. Relative 
fold-changes in protein levels in conditioned media were calculated by densitometry 
comparing array signal density between 3 different biological samples using Image J 
software.  
3.2.9 Murine femoral artery ligation and intramuscular transplantation 
of expanded HPC 
To induce unilateral hindlimb ischemia, surgical ligation and complete resection of the 
right femoral artery and vein was performed on anesthetised NOD/SCID (Jackson 
Laboratory, Bar Harbor, ME) or NOD/SCID/MPSVII mice as previously described in 
detail in Putman et al. in Appendix 1 and elsewhere (Chapter 2, Appendix 1)19,24. Within 
24 hours of surgery, mice were transplanted by intramuscular injection at three sites into 
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the right (surgical/ischemic) adductor muscle with 50μL saline as vehicle control, 20x106 
unsorted UCB MNC, 1x105 UCB ALDHhi cells, 1x105 ALDHlo cells, or 5x105 ex vivo-
expanded HPC. Total cell doses injected were selected based on frequency of ALDHhi 
cells in unpurified UCB MNC and based on the frequency of cells that retained high 
ALDH-activity after 6 days of culture.  
3.2.10 Quantification of hindlimb perfusion using laser Doppler 
perfusion imaging 
Anesthetized mice were stabilized at 37°C for 5 minutes on a heat pad before blood flow 
in the lower hindlimbs (ankle to toe) was quantified using laser Doppler perfusion 
imaging (LDPI, Moor Instruments, Devon, UK). The perfusion ratio of the 
ischemic/surgical limb compared to the uninjured/control limb was assessed after surgery 
to confirm induction of acute ischemic injury with a perfusion ratio (PR<0.1) <10% 
compared to the normal limb. Subsequent LDPI measurements were taken in each mouse 
at 3, 7,14, 21, and 28 days after transplantation to track recovery of perfusion temporally.  
3.2.11 Gait analysis to assess recovery of limb use after injury  
Noldus CatWalk software and equipment (CatWalk 7.1, Noldus, Wageningen, 
Netherlands) was used to quantify usage of the hindlimb after femoral artery ligation-
induced injury. Baseline limb usage was determined by relative print intensity in the right 
versus left hindlimb, before and after surgery. PBS or expanded HPC-transplanted mice  
mice were reassessed for limb usage at 3, 7, 14, 21, and 28 days after transplantation by 
running on the CatWalk system. Relative usage of the injured right hindlimb was 
quantified by normalizing print intensity of the right hindlimb compared to the 
contralateral uninjured leg at each time point.  
3.2.12 Assessment of hindlimb muscle vascularization  
Adductor muscles from transplanted mice were were harvested, embedded in optimum 
cutting temperature medium (Tissue Tek, Sakura Finetek, Tokyo, Japan), frozen, and 
cryosectioned. Muscle sections were fixed in 10% formalin (Sigma), and blocked with 
mouse-on-mouse reagent (Vector Labs, Burlingame, CA). Adductor muscle blood vessel 
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density in ischemic and nonischemic limbs was quantified at 7 and 28 days after 
transplantation by quantifying mouse CD31+ blood vessels using rat anti-mouse CD31 
(1:100; BD Biosciences) and peroxidase-labeled anti-rat secondary antibodies (Vector 
Labs) visualized using 3,3'–diaminobenzidine substrate (Vector), and counterstained 
with hematoxylin. Blood vessel density was counted in a blinded fashion from nine 
photomicrographic fields per sample using light microscopy. 
3.2.13 Statistics 
Analysis of significance was performed by one-way ANOVA with Tukey’s multiple 
comparison tests for progenitor frequency assays, EC survival/proliferation assays, 
cytokine array screens, and vessel density histology. Two-way repeated measures 
ANOVA with Bonferroni post-hoc tests were used for LDPI and Matrigel tube forming 
time courses. Catwalk limb usage data were analysed using an unpaired Student’s t-test. 
All statistical analyses were performed using Graphpad Prism software. 
3.3 Results 
3.3.1 Ex vivo expansion of UCB ALDHhi cells 
Lineage-depleted (Lin–) human UCB MNC with low side scatter and high (ALDHhi, 
2.4±0.4% of Lin– cells) or low (ALDHlo, 16.2±3.6% of Lin– cells) aldehyde 
dehydrogenase activity were selected based on diamniobenzaldehyde (DEAB) inhibition 
gating controls (n=18, Figure 3.1). Next, the FACS-purified UCB ALDHhi cells were 
plated on fibronectin-coated dishes in serum-free X-vivo-15 media supplemented with 
10ng/ml of each recombinant human TPO, SCF, and FLT3L. After 6 days in culture, 
there was a 20.0±5.6 fold increase in total cell number. 13.2±2.4% of expanded cells 
(Table 3.1, n=4) maintained high ALDH activity amounting to a 2.6-fold expansion of 
total ALDHhi cells over 6 days ex vivo expansion.  
After 6 days culture under expansion conditions, resulting hematopoietic cells were 
assessed for changes in cell surface marker expression compared to freshly isolated UCB 
ALDHhi cells. Expanded progeny showed a decreased frequency of cells expressing the 
hematopoietic progenitor marker CD34 (29.5±2.7%) compared to freshly isolated 
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ALDHhi cells (92.5±2.7%, Table 3.1 n=4). Similarly, expanded cells showed a 
diminished frequency of cells expressing prominin 1 (CD133) from 73.0±1.2% to 
10.2±1.8%, and the receptor tyrosine kinase for SCF (c-kit/CD117) from 33.5±8.1% to 
2.9±0.6% (Table 3.1, n=4). However, taking into account the 20-fold expansion in total 
cell number, the total number of CD34+ cells was increased 6.4-fold, the total number of 
CD133+ cells was increased 2.8-fold, and the total number of CD117+ cells was increased 
1.7-fold after 6 days expansion. Culture expanded cells maintained high expression of the 
early myeloid progenitor marker Siglec-3 (CD33, 96.2±0.07%) compared to parental 
UCB ALDHhi cells (96.1±0.8%, Table 3.1, n=4). Finally, after 6 days ex vivo culture 
there was no increase in the expression of mature lineage-specific markers for monocytes 
(0.3±0.1% CD14+, Table 3.1, n=4), macrophages (0.4±0.2% Mac-1/CD11b+), B cells 
(0.0±0.0% CD19+, Table 3.1 n=4), or T cells (0.1±0.1% CD3+, Table 3.1 n=4). 
Collectively, these data indicate that ex vivo culture of UCB ALDHhi cells results in the 
expansion of the total number of primitive cells that retained early myeloid phenotype 
without increasing cell surface marker expression associated with mature monocyte or 
macrophage lineages. 
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Figure 3.1. Ex vivo expansion of hematopoietic progenitor cells from lineage 
depleted UCB ALDHhi cells.  
Following ficoll-paque centrifugation and bead-labeled antibody negative selection of 
mature lineage markers (A) human UCB mononuclear cells were selected according to 
size (forward scatter) and granularity (side scatter). Inhibition of ALDH activity by 
DEAB prevents accumulation of Aldefluor fluorescence. Cells with low side scatter 
selected based on low (ALDHlo) or high (ALDHhi) Aldefluor™ fluorescence (n=18). (B) 
Schematic overview of ex vivo expansion of hematopoietic progenitor cells (HPC). (C) 
Representative FACS plots of measures of retention of high ALDH activity in ex vivo-
expanded HPC (n=4). 
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Table 3.1. Cell surface marker phenotype 
changes after ex vivo expansion of HPC. 
Lineage Marker 
UCB 
ALDHhi 
cells (%) 
ex vivo 
expanded 
HPC (%) 
Hematopoietic 
Progenitor   
ALDH 100 13.2±2.4 
CD34 92.5±2.7 29.5±4.4 
CD38 75.9±4.9 43.9±7.5 
CD133 73.0±1.2 10.2±1.8 
CD117 33.5±8.1 2.9±0.6 
Myeloid   
CD33 96.1±0.8 96.2±0.7 
Monocyte   
CD14 2.8±0.9 0.3±0.1 
B cell   
CD19 0.8±0.2 0.0±0.0 
T cell   
CD3  3.0±1.5 0.1±0.1 
 
  
112 
 
 
3.3.2 Ex vivo expansion of ALDHhi UCB cells increases the total 
number of hematopoietic progenitor cells.  
Fresh UCB ALDHhi cells and 6 day expanded progeny were plated at limiting dilution in 
semi solid methylcellulose media with hematopoietic growth factors to enumerate 
clonogenic hematopoietic colony formation before and after 6 days ex vivo expansion. 
Notably, the ex vivo-expanded HPC retained significant multipotent myeloid colony 
forming capacity (Figure 3.2A). In freshly isolated UCB ALDH cells, approximately 1 in 
3 cells showed hematopoietic colony forming function in methylcellulose. After ex vivo 
culture, HPC progeny displayed a reduced frequency of colony forming units at 
approximately 1 in 8 cells. At 20.0±5.6-fold total cell expansion this amounts to a 7.5-
fold increase in total hematopoietic colony forming cells after 6 days ex vivo culture. Ex 
vivo-expanded HPC also showed a significant decrease in the overall frequency of 
erythroid blast forming units (BFU-E, macrophage (CFU-M) and granulocyte (CFU-G) 
colony forming units (Figure 3.2A, n=4, p<0.05). Furthermore, ex vivo expansion caused 
a shift in myeloid lineage specification away from granulocytic differentiation towards 
erythroid differentiation (Figure 3.2B,C). Taken together, these data illustrate that ex vivo 
culture of UCB ALDHhi cells effectively increases the total number of hematopoietic 
progenitor cells (HPC) available for further application. 
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Figure 3.2. Ex vivo expanded HPC retain myeloid multipotency.  
(A) Following 6 days of serum free culture expanded HPC retain diminished progenitor 
cell marker phenotype. (C) HPC plated in semi-solid methylcellulose media show 
myeloid multipotency at diminished levels compared to (B) freshly isolated ALDHhi 
cells. (*p<0.05, n=5). 
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3.3.3 Expanded HPC retain a vascular regenerative transcription 
profile 
Affymetrix microarray identified multiple transcripts with significantly changed 
expression levels (>1.5 fold increase, p<0.01) in 3 ex vivo-expanded HPC samples 
compared to 3 parental, uncultured UCB ALDHhi cell samples. Confirming cell surface 
phenotype as measured by flow cytometry, ex vivo-expanded HPC expressed 
significantly less KIT (CD117, p=8.31x10-6) and PROM1 (CD133, p= 6.88x10-4) 
compared to UCB ALDHhi cells. Interestingly, despite significant reduction in CD34 
expression at the cell surface there was no significant reduction in CD34 transcript levels 
in HPC compared to UCB ALDHhi cells. The raw data was next filtered to focus on 
transcripts coding for secreted proteins with documented biological functions that 
potentially modulate endothelial cell survival and pro-angiogenic processes that were 
significantly upregulated after ex vivo expansion (n=3, Table 3.2). Ex vivo-expanded HPC 
showed upregulation of several transcripts which code for secreted growth factors known 
to modulate vascular regeneration including epidermal growth factor (EGF), vascular 
endothelial growth factor A and B  (VEGF-A, VEGF-B), and angiopoietin 1 (ANGPT1, 
Table 3.2). Furthermore, HPC expressed significantly higher levels of transcripts for 
proteins that modulate vascular growth factor signaling including 
ribonuclease/angiogenin inhibitor-1 (RNH1, angiogenin regulator) and insulin-like 
growth factor binding protein 3 (IGFBP3, insulin-like growth factor modulator, Table 
3.2). Ex vivo expansion of HPC from UCB ALDHhi cells also increased expression of 
transcripts associated with matrix modifying proteins, including tissue inhibitor of 
metalloproteinases 1 and 3 (TIMP-1, TIMP-3, Table 3.2). Collectively, these data suggest 
that ex vivo-expanded HPC retain a vascular regenerative transcription profile. 
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Table 3.2. Transcripts for secreted proteins associated with vascular regeneration 
upregulated in ex vivo-expanded HPC 
Gene 
Symbol Common Name Biological Function Molecular Function 
Fold-
Change 
vs. UCB 
ALDHhi  
p-value 
vs. UCB 
ALDHhi 
EGF 
epidermal growth 
factor 
promotes endothelial cell 
proliferation, survival, differentiation, 
and migration 
EGF receptor 
activation 6.5 4.6x10-4 
TIMP3 
tissue inhibitor of 
metalloproteinases 
3 
prevents matrix remodeling, 
stabilizing preexisting vasculature 
inhibition of MMP 
activity 2.9 1.2x10-5 
RNH1 
ribonuclease/ 
angiogenin 
inhibitor 1 
promotes cell survival under stress 
conditions, decreases apoptosis 
modulates cellular 
localization, regulatory 
activity of angiogenin 2.5 7.7x10-7 
VEGFA 
vascular 
endothelial growth 
factor A 
primary regulator and activator of 
angiogenesis, autocrine signaling 
promotes vascular homeostasis 
VEGFR2 receptor 
activation 2.5 1.1x10-3 
ANGPT1 angiopoietin 1 
stabilizes the blood vasculature by 
suppressing EC responses during 
vascular stress  
TIE2 receptor 
activation 2.0 2.4x10-3 
TIMP1 
tissue inhibitor of 
metalloproteinases 
1 
MMP-independent functions include 
inhibition of apoptosis, induction of 
angiogenesis and cell proliferation 
inhibition of MMP 
activity; stimulating the 
Akt survival pathway 1.9 5.6x10-4 
VEGFB 
vascular 
endothelial growth 
factor B 
critical for blood vessel survival under 
pathological conditions, non-essential 
role in vessel formation 
VEGFR1 receptor 
activation 1.5 2.3x10-4 
IGFBP3 
insulin-like 
growth factor 
binding protein 3 inhibits endothelial cell apoptosis,  
modulates IGF 
signaling 1.5 4.8x10-4 
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3.3.4 Expanded HPC support endothelial cell tubule formation in 
vitro.  
To assess whether these expanded HPC supported EC tubule forming function via 
paracrine actions, human microvascular endothelial cells (HMVEC) were plated on a thin 
gel of growth factor reduced matrigel bathed in growth factor+/serum+ endothelial 
growth medium (EGM2-MV, Figure 3.3A), or growth factor-/serum– endothelial basal 
media (EBM, Figure 3.3B), to serve as positive and negative controls for tubule 
formation respectively. In addition, HMVEC were exposed to basal HPC expansion 
media (X-vivo 15 + cytokines) or day 3 or day 6 HPC conditioned media (Figure 3.3D). 
Finally, HMVEC were co-cultured directly with expanded HPC in EBM (Figure 3.3C). 
Interestingly, HPC-conditioned media showed no effect on tubule formation compared to 
basal media controls (n=8). However, after 6 hours of direct co-culture with ex vivo-
expanded HPC, HMVEC formed significantly more branch points compared to HMVEC 
grown in EBM or X-vivo 15 vehicle controls (p<0.01, Figure 3.3D, n=4). Furthermore, 
direct co-culture with HPC supported tubule formation equivalent to HMVEC grown in 
positive control conditions containing EGM fully supplemented with growth factors and 
serum. Importantly, HPC plated alone on growth factor reduced matrigel did not result in 
tubule formation. Together, this data shows that direct co-culture with HPC promotes EC 
tubule formation under growth factor-free and serum-free conditions. 
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Figure 3.3. Ex vivo-expanded HPC support tubule formation by HMVEC in serum-
free, growth factor reduced conditions.  
EC were seeded onto growth factor-reduced Matrigel supplemented with endothelial 
basal media with (A) 5% serum and EC growth factors, (B) basal EC media, (C) 5x103 
expanded HPC in direct co-culture, xvivo15 basal, or day 3 or day 6 HPC conditioned 
media. Photomicrographs were taken at 6h (A-C), 24h, and 48h and branch points were 
enumerated by blinded counts (Scale bar = 500 μm). (D) Summary of complete branch 
points counts per well. (**p<0.01). 
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3.3.5 Expanded HPC support HMVEC survival under growth factor-
free, serum-free conditions 
HMVEC were grown on plastic in EGM2 media fully supplemented with serum and 
growth factors (EGM2-MV, Figure 3.4A), or in basal endothelial cell media (EBM) 
without serum or growth factors (Figure 3.4B) or in non-contact transwells containing ex 
vivo-expanded HPC in EBM (Figure 3.4C). Under fully supplemented conditions (EGM2 
+ serum + cytokines) HMVEC demonstrated a 4-fold increase in cell number in 72 hours, 
whereas culture in serum and growth factor depleted basal conditions resulted in a 2-fold 
reduction in cell number. HPC co-culture prevented HMVEC cell loss after 72 hours 
under basal growth factor-free, serum-free conditions (Figure 3.4D, n=5-8, p<0.05).  
To further address the paracrine support of endothelial cell survival under growth factor-
free, serum-free conditions, HMVEC were plated in HPC conditioned media and cells 
were enumerated after 72 hours using the CyQuant system. Similar to the transwell co-
culture results, HMVEC grown in day 3 or day 6 conditioned media showed the 
prevention of cell loss associated under growth factor-free, and serum-free conditions 
(Figure 3.4E, n=6-7, p<0.05).  
Due to the pro-survival responses elicited in HMVEC when exposed to HPC secreted 
factors, HMVEC were also harvested after 24 hours culture in EGM2-MV, EBM, or in 
non-contact transwell co-culture with HPC and assessed for apoptosis using 7-
aminoactinomycin D (7AAD) combined with annexin V-staining measured by flow 
cytometry (Figure 3.4F, n=4-6). HPC co-culture significantly reduced the frequency of 
dead cells (% 7AAD+ cells) compared to EBM-cultured controls (Figure 3.4G, n=4-6, 
p<0.05). However, HPC co-culture only modestly reduced the frequency of early 
apoptotic cells (% 7AAD-/Annexin V+). In contrast, HPC conditioned media did not 
alter total cell death or apoptosis rates compared to EBM or X-vivo 15 vehicle controls 
(Figure 3.4G). Collectively, these data indicate that HPC co-culture supported the 
survival of EC in serum-free, growth factor-free conditions. 
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Figure 3.4. Ex vivo-expanded UCB HPC and conditioned media support the survival 
of endothelial cells under serum-starved conditions.  
(A-C) 4x104 HMVEC were cultured for 72 hours in basal media (EBM2) with or without 
growth factors (EGF, VEGF, FGF, IGF-1) and serum (5%) supplementation. Into each 
culture a hanging 1μm pore transwell was suspended above the EC and filled with 8x104 
day 6 expanded HPC or basal media (Scale bar = 200μm). (D) Non-contact co-culture 
with D6 expanded HPC promoted the survival of EC under growth factor-free, serum-
starved conditions (*p<0.05, n=5-8, in duplicate). (E) 3x103 EC were cultured in HPC 
expansion basal media (Xvivo 15) with or without EC growth factors (EGF, VEGF, FGF, 
IGF-1) and serum (5%) supplementation. Day 3 or Day 6 conditioned medium (X vivo 
15 base) collected during HPC expansion supported survival of EC under serum and 
growth factor-free conditions (n=6-7 in triplicate, *p<0.05). (F) Representative plots 
showing flow cytometric detection of Annexin V/7AAD survival status of endothelial 
cells 24 hours after culture. (G) Summary statistics for cell survival status at 24 hours. 
(different letter denotes *p<0.05). 
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3.3.6 HMVEC co-culture with HPC increased the secretion of pro-
survival signals 
HMVEC and HPC were grown in basal endothelial cell media (EBM) alone, or in direct 
co-culture with both cell types in basal EBM. After 72 hours, the conditioned media from 
each culture condition was collected and screened for secreted protein content using 
antibody array. When grown in basal endothelial media without serum or growth factors 
both HMVEC and ex vivo-expanded HPC secreted growth factors, chemokines, matrix 
modifying proteins and secreted receptor proteins associated with endothelial cell 
function during angiogenesis (Figures 3.5, 3.6, n=3). Notably, co-culture of HPC with EC 
significantly increased levels of several growth factors associated with vascular 
regeneration including epidermal growth factor (EGF, Figure 3.5, n=3, p<0.05) and 
angiopoietin-2 (Figure 3.6, n=3, p<0.05). Moreover, HPC co-culture increased the 
amount of angiopoietin-2 secreted into the media significantly more than the additive 
signals of HMVEC or HPC cultured alone, indicating a potential cellular crosstalk 
regulating increased angiopoietin 2 secretion (n=3, p<0.05). Many chemokines which 
have been implicated in the recruitment of inflammatory cell types to areas of ischemia 
were also significantly increased during HPC co-culture including 
GROα,β,γ/CXCL1,2,3, IL8/CXCL8, and RANTES/CCL5 (Figure 3.5, n=3, p<0.05). 
Several matrix modifying proteins were significantly upregulated during HPC co-culture 
including tissue inhibitor of metalloproteinases 1 and 2 (TIMP-1, TIMP-2, Figure 3.5, 
n=3, p<0.05) and matrix metalloproteinase-9 (MMP-9, Figure 3.6, n=3, p<0.05). TIMP-2 
was significantly upregulated in co-culture compared to the additive signals of HMVEC 
and HPC alone (n=3, p<0.05). Overall, HPC co-culture with HMVEC in unsupplemented 
media increased the paracrine and autocrine secretion of several angiogenesis-associated 
growth factors, chemokines and matrix modifying proteins. 
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Figure 3.5. HMVEC co-culture with HPC increases secretion of pro-survival 
signals: Part 1.  
(A) Chemiluminescent imaging of RayBio® Membrane-Based Antibody Human 
Angiogenesis Array C1000 was used to screen and compare expression levels of 
angiogenesis-associated cytokines, growth factors, proteases, and soluble receptors 
secreted in basal endothelial media after 72 in culture. (B) HMVEC grown in basal 
unsupplemented media co-cultured with ex vivo-expanded HPC are exposed to higher 
levels of pro-survival signals (n=3, *p<0.05). 
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Figure 3.6. HMVEC co-culture with HPC increases secretion of pro-survival 
signals: Part 2.  
(A) Chemiluminescent imaging of RayBio® Membrane-Based Antibody Human 
Angiogenesis Array C1000 was used to screen and compare expression levels of 
angiogenesis-associated cytokines, growth factors, proteases, and soluble receptors 
secreted in basal endothelial media after 72 in culture. (B) HMVEC grown in basal 
unsupplemented media co-cultured with ex vivo-expanded HPC are exposed to higher 
levels of pro-survival signals (n=3, *p<0.05). 
  
127 
 
 
  
128 
 
3.3.7 Expanded HPC enhance recovery of limb perfusion after 
transplantation into ischemic limbs 
Previously in Chapter 2, I demonstrated that freshly isolated UCB ALDHhi cells support 
recovery of perfusion and revascularization in the ischemic hindlimb of mice after 
intravenous transplantation into mice with unilateral hindlimb ischemia (Chapter 2)19. To 
confirm these findings with UCB ALDHhi cells and to assess whether expanded HPC 
could impact the recovery of perfusion in vivo, freshly isolated UCB ALDHhi cells and ex 
vivo-expanded HPC were transplanted intramuscularly into immune deficient NOD/SCID 
mice with acute unilateral hindlimb ischemia after femoral artery ligation surgery. 
Hindlimb perfusion was assessed by laser Doppler perfusion imaging (LDPI) and the 
perfusion ratio of the ischemic limb versus the contralateral control limb was determined 
weekly for up to 28 days. After femoral artery ligation surgery, the perfusion ratio (PR) 
of the treatment leg was less than 10% of the control leg in all transplanted mice 
(PR≤0.1). Mice treated with intramuscular phosphate buffered saline (PBS, Figure 3.7A) 
vehicle control established the baseline recovery of perfusion (PR=0.49±0.03 at 28 days 
after treatment). Mice with ischemic adductor muscle transplanted intramuscularly with 
freshly isolated 20x106 UCB MNC or 1x105 purified UCB ALDHlo cells showed no 
significant changes in recovery of perfusion compared to PBS controls (Figure 3.7D). In 
contrast, mice that were treated by intramuscular transplantation of 1x105 purified UCB 
ALDHhi cells (Figure 3.7B, Day 7 PR=0.45±0.09) or 5x105 ex vivo-expanded HPC 
(Figure 3.7C, Day 7 PR=0.40±0.02) showed significantly accelerated recovery of 
perfusion of the ischemic limb compared to PBS vehicle controls (Figure 3.7A, Day 7 
PR=0.25±0.02) within 7 days after transplant (Figure 3.7D). At a frequency of 13.2% of 
expanded HPC retaining high ALDH activity, mice transplanted with 5x105 HPC receive 
an equivalent dose of 6.6x104 ALDHhi cells, a lower effective dose of ALDHhi cells. 
Importantly, improved perfusion at day 7 translated to a significant increase in perfusion 
at later time points (days 14-28) compared to PBS injected controls. Collectively, these 
data confirm that transplantation of UCB ALDHhi cells promote recovery or perfusion in 
the ischemic hindlimb of mice after femoral artery ligation. Furthermore, the data 
indicates that ex vivo expansion of HPC from UCB ALDHhi cells does not diminish 
vascular regenerative function.  
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To further assess recovery from acute ischemic injury, limb use by gait analysis of 
transplanted mice was assessed using Noldus™ Catwalk 7.1 software. Mice treated by 
intramuscular injection of ex vivo-expanded HPC showed significantly increased usage of 
the ischemic limb at 7 days after transplant compared to PBS treated control mice (Figure 
3.7E). These findings demonstrate that the recovery of perfusion in mice transplanted 
with UCB ALDHhi cells or ex vivo-expanded HPC is accompanied by augmented 
recovery of limb usage in the injured limb. 
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Figure 3.7. Direct intramuscular injection of UCB ALDHhi cells augment perfusion 
of ischemic limbs. 
(A-C) Representative LDPI following right femoral artery ligation and tail vein injection 
of PBS vehicle control, 20x106 unsorted UCB MNC, 1x105 ALDHhi cells, 1x105 ALDHlo 
cells, or 5x105 ex vivo-expanded HPC monitored for 28 days (n=7-15). Numbers in 
bottom left of each LDPI image indicate perfusion ratio of the ischemic versus the non-
ischemic hindlimb from ankle to toe. (D) Summary of mean perfusion ratio ± SEM as 
above. Transplantation of UCB ALDHhi cells promoted robust, maintained recovery of 
perfusion in ischemic mouse hindlimbs by day 7 post-transplantation as compared to 
saline injected controls (*p<0.05,**p<0.01). (E) Noldus™ catwalk paw print intensity at 
day 7 post transplantation showed that mice transplanted with HPC regained use of their 
ischemic leg faster than saline vehicle controls (n=6). 
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3.3.8 Intramuscular transplantation of HPC prevents loss of 
endogenous blood vessels after acute ischemic injury 
Ischemic and control adductor muscle were cryosectioned and stained for CD31 
expression to enumerate the blood vessels present at 7 and 28 days after injury. Within 7 
days of femoral artery ligation, saline-treated control mice showed a significant loss of 
the CD31+ positive vessels in the ischemic limb (61.9±2.1 CD31+ vessels/mm2) compared 
to the contralateral control limb (69.9±0.8 CD31+ vessels/mm2, p<0.05, n=7, Figure 
3.8C). This loss of vascularization in the ischemic limb (62.5±1.6 CD31+ vessels/mm2, 
Figure 3.8D) of saline treated mice was consistent at 28 days after induction of ischemic 
injury compared to normal limb (69.4±0.6 CD31+ vessels/mm2, Figure 3.8D). Mice 
treated by intramuscular injection of UCB MNC or ALDHlo cells showed no difference in 
ischemic limb vascularization compared to PBS controls (Figure 3.7). Mice transplanted 
with ex vivo-expanded HPC showed prevention of CD31+ cell loss at 7 (72.3±0.6 CD31+ 
vessels/mm2, Figure 3.8C) and 28 days after treatment (68.1±1.8 CD31+ vessels/mm2, 
Figure 3.8D). Purified ALDHhi cells from fresh UCB similarly showed a reduction in the 
loss of vascularization in the ischemic muscle at 28 days after treatment (71.8±2.3 CD31+ 
vessels/mm2, Figure 3.8D). These findings suggested that UCB ALDHhi cells and ex vivo-
expanded HPC prevent the loss of CD31+ vessels in the ischemic hindlimb of mice after 
ischemic injury. 
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Figure 3.8. Intramuscular transplantation of ex vivo-expanded cord blood 
hematopoietic progenitor cells prevents loss of vascularization of ischemic hindlimb 
muscle after acute ischemic injury.  
(A, B) Representative photomicrographs of CD31 staining in ischemic adductor muscle 
sections taken 28 days after right femoral artery ligation and intramuscular injection of 
PBS, ALDHhi cells, or HPC. (C, D) Summary of mean vessel density ± SEM in the 
ischemic or non-ischemic limb at (C) 7 days, or (D) 28 days after transplantation. Mice 
that were transplanted with fresh UCB ALDHhi cells or ex vivo-expanded HPC 
demonstrated increased vascularization of the surgical limb. (*p<0.05). 
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3.4 Discussion 
In this study I demonstrate that human UCB-derived cells with high ALDH activity can 
be readily expanded in serum free conditions without diminishing vascular regenerative 
function after direct intramuscular transplantation in vivo. After 6 days ex vivo culture in 
clinically relevant serum free conditions, 20-fold expansion of total hematopoietic cell 
number was obtained with substantial expansion of total myeloid progenitor cell number. 
Our findings show that ex vivo-expanded HPC maintained an angiogenic vascular 
regenerative phenotype by mRNA transcriptional profile. Furthermore, we demonstrate 
the HPC responded to EC cell signals in culture and increase secretion of angiogenic 
growth factors, matrix-modifying proteins and chemokines that recruit support cells to 
the site of injury, inflammation and hypoxia.  
This vascular regenerative phenotype of HPC was confirmed by demonstration that HPC 
supported endothelial cell survival and tubule formation in growth factor-free, serum-free 
co-culture culture conditions. Importantly, transplantation of ex vivo-expanded HPC into 
immune-deficient mice with femoral artery ligation–induced hindlimb ischemia promoted 
recovery of perfusion and prevented loss of vascularization in the hindlimb similar to 
previously characterized UCB ALDHhi cells (Chapter 2)19. Thus, we propose that ex vivo 
expansion of UCB ALDHhi cells represents a clinically applicable means of effectively 
increasing the number myeloid progenitor cells for cardiovascular disease therapy 
without reducing vascular regenerative function.  
After 6 days of serum free expansion culture UCB ALDHhi cells expanded 20-fold in 
total cell number. Of these expanded HPC, only 13.2±2.4% retained high ALDH activity, 
amounting to a total 2.6 fold expansion of ALDHhi cells over 6 days ex vivo expansion. 
Based on other progenitor cell surface marker expression our 6-day expansion protocol 
also produced a 6.4-fold expansion of CD34+ cells, a 2.8-fold expansion of CD133+ cells 
and a 1.7-fold expansion in the number of total CD117+ cells, despite a decrease in the 
relative frequency of cells expressing progenitor markers. The general decrease in 
progenitor marker expression frequency despite total progenitor cell number is consistent 
with other published hematopoietic cell expansion protocols20,25,26. Furthermore, it is 
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possible that the number of CD117 expressing cells is higher than detected by flow 
cytometry as after prolonged culture in high concentrations of SCF, the ligand for 
CD117/c-Kit, leads to receptor internalization and recycling as is the case with many 
receptor tyrosine kinases27. Relative decreases in hematopoietic progenitor marker 
expression were confirmed by microarray results showing significantly lower expression 
of both CD117/c-Kit (KIT) and CD133 (PROM1) transcripts. Thus, we demonstrate here 
that ex vivo expansion of UCB ALDHhi cells effectively increases the number of 
angiogenic myeloid ALDHhi/CD34+/CD133+/CD117+ progenitors cells available for cell 
therapy applications. 
It has recently been shown that decreasing autocrine inhibitory signaling during HPC 
expansion by use of a batch-fed system, it is possible to significantly increase the 
expansion of hematopoietic stem and progenitor cells28,29. It is plausible that by applying 
new, more efficient methods of ex vivo HPC expansion, and by the use of novel 
molecules to prevent progenitor differentiation, it will be possible to further increase the 
number of hematopoietic cells that retain vascular regenerative function for cell therapy 
applications outside of transplantation for haematological disorders. This is an important 
area of development for applications employing UCB-derived cells in an allogeneic 
setting, because available cell number currently prohibits clinical application. 
We also demonstrated that co-culture of HPC with endothelial cells in growth factor-free, 
serum-free, basal endothelial cell media led to increased survival of endothelial cells as 
measured by cell counts and by viability dye measures in vitro. Furthermore, 
intramuscular transplantation of HPC into the ischemic hindlimb of mice augmented 
recovery of perfusion and prevented loss of capillary density within the ischemic muscle 
tissue. As such, HPC conditioned media contained secreted EGF and co-culture with EC 
increased the concentrations of EGF significantly compared to EC cultured alone. 
Moreover, EGF transcript levels were increased 6.5-fold in ex vivo-expanded HPC 
compared to fresh UCB ALDHhi cells. The observed pro-survival effect on endothelial 
cells in both in vitro and in vivo contexts is consistent with potential paracrine stimulatory 
effects by secreted EGF on endothelial cells. Endothelial cells express epidermal growth 
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factor receptor (EGFR)30-32 and EGFR activation has been shown to activate the PI3K/Akt 
pathway thereby regulating endothelial cell survival33. 
Furthermore, we show that ex vivo-expanded HPC retain a vascular regenerative, 
angiogenic transcriptional and secretory profile beyond EGF expression. After culture, 
HPC showed upregulation of important regulators of endothelial cell function including 
angiopoietin 1 (ANGPT1) and vascular endothelial growth factors A and B (VEGF-A, 
VEGF-B). During homeostasis in vivo EC-EC contacts are stabilized and cell survival is 
promoted by perivascular cells who secrete angiopoietin 1 and activate theTie2 receptor 
on endothelial cells34,35. Vascular endothelial growth factor A (VEGF-A) is the primary 
regulator of the angiogenic cascade by which endothelial cells become activated to 
proliferate and migrate in response to hypoxia or injury36. Furthermore, VEGF-A 
signaling has been shown to be necessary for EC survival signaling in homeostatic 
quiescence and in hypoxic conditions36,37. Additionally, VEGF-B signaling has been 
demonstrated to be critical for blood vessel survival under pathological conditions 
promoting not only EC survival but increasing survival of mural smooth muscle cells or 
pericytes38. ANG2 is expressed by EC and its expression is increased under hypoxic 
conditions34,39. ANG2 is stored in endothelial Weibel–Palade bodies which are secreted in 
response to inflammation and mediate endothelial cell activation34,40,41. However, in the 
absence of VEGF, angiopoietin 2 induces destabilization and regression of the 
vasculature. During hypoxia, which promoted both ANG2 and VEGF secretion, 
neovascularization is induced by a VEGF mediated pro-angiogenic program referred to 
as the “angiogenic switch”34,39. HPC co-culture increased secreted ANG2 levels in 
conditioned media significantly indicating a potential role for HPC in increasing 
activation of endothelial cells during inflammation and hypoxia. Taken together, these 
data indicate that ex vivo-expanded HPC maintain the transcriptional prolife and 
secretory functions necessary to support vascular stabilization after ischemic injury 
pushing the EC cell program from regression to survival and stabilization.  
HPC co-culture with HMVEC also increased the secretion of TIMP-1 and TIMP-2 in 
vitro. Moreover, TIMP1 transcript was upregulated in HPC after ex vivo expansion from 
UCB ALDHhi cells. Increased TIMP expression been shown in hematopoietic progenitor 
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cells and myeloid cells previously, and play a role in modifying the extracellular matrix 
in response to vascular injury or hypoxia42. Broadly, TIMPs inhibit MMP-mediated 
remodelling of the extracellular matrix and basement membrane, an important step in 
both vascular regression and angiogenesis. TIMPs promote the stability of blood vessels 
by preventing breakdown of the supportive extracellular matrix and promoting basement 
membrane deposition36,43. Beyond the normal activity of TIMPs regulating MMP activity, 
TIMP-1 has been shown to have MMP-independent functions which include inhibition of 
apoptosis, induction of angiogenesis and cell proliferation44. In particular, TIMP-1 has 
specifically been shown to prevent TNF-α mediated apoptosis in EC though the Akt 
pathway45. Both the MMP-independent  and MMP-mediated effects of TIMP-1 on EC 
and the vasculature promote endothelial cell survival by supressing cell death are 
consistent with our in vitro and in vivo findings showing less cell death in HPC-EC co-
culture conditions. 
Ex vivo HPC expansion led to increases in transcripts associated with modulating 
vascular growth factor signaling ribonuclease/angiogenin inhibitor 1 (RNH1) and insulin-
like growth factor binding protein 3 (IGFBP3). RNH1 has been shown to promote cell 
survival in stress conditions by decreasing apoptosis and modulating the cellular 
localization and activity of angiogenin which is promoter of angiogenesis46. IGFBP3 has 
been demonstrated to inhibit endothelial cell apoptosis by an IGF-independent 
mechanism47. Thus, angiogenin and IGFBP3 may represent important regulators EC 
function and the effects of these two regulators may also contribute to the pro-survival 
mechanism consistent with our findings. 
Co-culture of HPC with EC increased secreted levels of several chemokines including 
members of the CXC and CC families, GRO/CXCL1-3, IL-8/CXCL8, and 
RANTES/CCL5. GRO and CXCL8 are known to play a role in chemokine-mediated 
regulation of angiogenesis and regulate recruitment of neutrophils, macrophages and 
lymphocytes to the site of injury48-52. Interestingly, MMP-9 was also secreted by ex vivo-
expanded HPC. MMP-9 is thought to be important in activating the angiogenic switch, 
playing a role in increasing VEGF bioavailability by freeing it from deposits within the 
extracellular matrix53. MMP-9 has been further implicated in vascular regeneration by 
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playing a role in promoting vasculogenesis54. Notably, MMP-9 has been implicated in the 
mobilization of circulating angiogenic cells that also modulate a pro-angiogenic niche in 
areas of hypoxia. Collectively, the cumulative effects of these molecular mediators all act 
to increase the potential recruitment of circulating cells from the host, which can help 
mediate a vascular regenerative program at the site of injury. These proposed 
mechanisms could play a plausible role in vivo in vascular regeneration seen after 
transplantation of HPC into ischemic tissues.  
Our lab has previously described a subset of hematopoietic progenitor cells with from 
human BM high ALDH activity that play a role in paracrine support of vascular 
regeneration (Chapter 2)18,24,55. Perin et al. have recently reported phase I/II clinical trials 
using autologous BM-derived ALDHhi cells for the treatment of critical limb ischemia 
secondary to peripheral artery disease and ischemic heart failure56,57. Both studies 
demonstrated the safety of ALDHhi cells in patients with cardiovascular disease. 
Importantly, in patients with critical limb ischemia, intramuscular injection of autologous 
BM ALDHhi promoted improved Rutherford category scores and reduced resting pain. 
Furthermore patients treated by ALDHhi cell transplant showed modest but significantly 
improved ankle to brachial index scores indicating improved perfusion of the lower limb. 
Finally, patients who were treated with BM ALDHhi cells reported significantly improved 
quality of life after treatment56. These data demonstrate that ALDHhi cells are a viable 
clinical cell population for the treatment of ischemic disease, and our data further 
suggests that this population may be expanded using clinically applicable conditions to 
increase the number of pro-vascular progenitor cells available for transplantation.  
Notably however, there is emerging evidence that application of autologous bone marrow 
progenitor cells in patients with diabetes or cardiovascular disease might be problematic. 
There exists convincing evidence for decreased frequency and reduced regenerative 
function for circulating and bone marrow progenitor cells in patients with chronic 
diabetes, cardiovascular disease and increasing age58-61. Unfortunately, the patients who 
would most benefit from vascular regenerative therapy are generally of increasing age 
and overwhelming affected by diabetes and cardiovascular disease1, making the 
development of allogeneic transplantation strategies desirable. As such, human umbilical 
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cord blood represents an allogeneic source is readily available and may possess distinct 
advantages over autologous bone marrow as source of cells for vascular regenerative 
therapy. Most notably, umbilical cord blood is early in ontogeny and free of chronic 
disease and age related dysfunctions. We have also shown here that ex vivo culture of 
UCB derived ALDHhi cells permits expansion of the number of cells available for 
therapy. However, it is possible that similar ex vivo expansion strategies could be applied 
to autologous bone marrow transplants in patients as an alternative in order bypass the 
need for immune suppression in the allogeneic setting. Nonetheless, we propose that 
UCB ALDHhi cells represent a readily available, and expandable HPC population with 
robust vascular regenerative properties. Therefore, expanded UCB-derived ALDHhi cells 
represent an excellent candidate population for the development of allogeneic cell 
therapy for ischemic disease.  
Our current work demonstrates that is possible to increase the number of hematopoietic 
progenitor cells available from UCB ALDHhi cells for applications in vascular 
regeneration without losing regenerative function. We propose that purification of BM or 
UCB based on high aldehyde dehydrogenase activity followed by ex vivo expansion to 
increase the progenitor pool poses a promising clinical approach to developing cell 
therapy for vascular regeneration and the treatment of ischemic disease.  
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Chapter 4 
4 High Aldehyde Dehydrogenase Activity Identifies a 
Subpopulation of Multipotent Stromal Cells with Increased 
Vascular Regenerative Function  
BM MSC are a population of progenitor cells that expand readily in ex vivo cultures with 
promising potential for vascular regenerative cellular therapies. However, our lab has 
demonstrated that different MSC lines from different donors showed variable efficacy to 
promote regeneration. Furthermore, the Hess lab had previously shown that re-selection 
of MSC that retained high ALDH activity after culture increased islet regenerative 
capacity. Therefore the objective of the studies presented in this chapter was as follows: 
• To characterize the differentiative and vascular regenerative functions of MSC 
subpopulations selected after expansion for low versus high ALDH activity. 
The studies presented in Chapter 4 use some of the general findings from Chapters 2 and 
3 and other work by the Hess laboratory, specifically that selection of cells with high 
ALDH activity isolates a population of cells with increased vascular regenerative 
potential, as the basis for an approach to prospectively identify a subset of MSC that 
might be superior candidates for future development of cellular therapy for CVD.  It uses 
the in vitro models established in Chapters 2 and 3 to establish proof of concept for 
proposed future in vivo studies with populations of MSC purified by ALDH activity 
level.   
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4.1 Introduction 
Despite significant progress and advances to improve clinical management, 
cardiovascular disease (CVD) remains the leading cause of premature death worldwide 
and represents a huge burden on the health care systems in North America1-5.  Ischemia is 
characterized by insufficient blood flow to a given tissue or organ and includes both acute 
conditions like myocardial infarction and stroke and chronic ischemic conditions like 
atherosclerotic arterial disease.  Direct and indirect costs of medical management and 
treatment of CVD is a growing burden on global health care systems, estimated to now 
cost in excess of $310 billion annually in the United States alone3,4,6-8.   
Multipotent stromal cells (MSC) also referred to as mesenchymal stromal stem cells can 
be isolated from bone marrow (BM) and other tissues.  MSC are defined by their ex vivo 
culture method; they must be plastic adherent, express the markers CD73 (ecto 5’ 
nucleotidase), CD90 (Thy-1), and CD105 (endoglin) after culture and must not express 
hematopoietic markers like CD45 or CD141,2,7-10.  Additionally, MSC must demonstrate 
definitive multipotency, by ability to differentiate into osteocytes, adipocytes and 
chondrocytes1-5.  
Broadly, MSC are considered as good candidates for allogeneic cell therapy applications 
because of their low immunogenicity; they do not express MHC class II (HLA-DR) nor 
co-stimulatory molecules like CD40, CD80 and CD863,4,6-8.  Furthermore, MSC have 
been shown to demonstrate multi-tissue engraftment and little proliferative capacity after 
transplantation, reducing risk of transplantation related malignancies1,2,7-10.  In general, 
MSC contributions towards regenerative therapy is primarily through the modulation of 
the tissue microenvironment as opposed to cell replacement6,8,11.  Indeed MSC have been 
demonstrated to readily support many repair processes including vascular regeneration1,8-
10. MSC have also been shown to augment cardiomyocyte1,10-14 and EC1,10,15,16 survival, 
and secrete VEGF-A, FGF-2, ANG-1, and MCP-11,10,12-14,17. MSC have also been recently 
identified as a component of vascular pericytes that express CD146 in multiple human 
organs in situ and help stabilize newly formed vessels when co-transplanted with ECs in 
vivo15,16,18-20. MSC have furthermore been shown to play an important role in 
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immunomodulation presenting interesting potential paracrine applications in auto-
immune disease and inflammatory conditions17,18,21-23. Taken together these unique 
properties underscore the considerable promise of MSC from human BM or UCB as a 
potential source for vascular regenerative cell therapies.  
BM MSC represent a readily available population of progenitor cells that expand 
efficiently in ex vivo cultures with promising potential for vascular regenerative cellular 
therapies.  However, an outstanding limitation to the successful implementation of MSC-
mediated regeneration in various clinical therapeutic settings is major inter-donor 
variability in MSC function.  The Hess laboratory have previously shown that 
transplanted BM MSC populations show substantial donor variation in ability to support 
regeneration of pancreatic islets in a streptozotocin-induced beta cell deletion model of 
diabetes19,20.  Other groups have demonstrated donor variation in MSC in terms of 
osteogenic differentiative capacity21,23,24.  Furthermore, MSC have been shown to undergo 
replicative senescence under differentiative growth conditions and subsequent reduction 
in regenerative function over prolonged culture in several systems19,25.  This decline in 
MSC function over extended ex vivo culture also demonstrates notable inter-donor 
variability24.   To improve cell therapy using MSC, it is desirable to identify prospective 
markers to identify subpopulation with increased regenerative capacity. 
Our laboratory has previously demonstrated that aldehyde dehydrogenase (ALDH), a 
cytosolic enzyme involved in retinoic acid synthesis and in cellular self-protection 
against oxidative stress is a useful marker of primitive progenitor cells associated with 
increased vascular regenerative function (Chapter 2)26,27.  Indeed the Hess laboratory have 
shown that selection of BM mononuclear cells with high ALDH activity isolates an 
enriched starting population of mixed hematopoietic, endothelial and mesenchymal 
progenitor cells that supported robust recovery of perfusion and increased vascularization 
after femoral artery ligation-induced ischemic injury in an immunodeficient mouse 
model26.  Furthermore, the Hess laboratory has demonstrated the MSC derived from BM 
cells with high ALDH activity support increased regeneration in the diabetic pancreas19.   
Thus, we hypothesized that MSC subpopulations with increased ALDH activity will 
improve vascular regenerative function via the paracrine support of endothelial cell 
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activation and neo-vessel forming function. In this chapter, we present preliminary 
characterization of the differentiation and vascular regenerative properties of MSC 
subpopulations with high versus low ALDH activity sorted after expansion.   
4.2 Methods 
4.2.1 BM MSC derivation and culture 
BM aspirates were acquired with informed consent during routine pre-screening for BM 
donation by Dr. Anargyros Xenocostas at the London Health Sciences Centre in London, 
Ontario, Canada.  The mononuclear cell fraction was isolated using ficoll centrifugation.  
BM mononuclear cells were then depleted of residual red blood cells by lysis in 
ammonium chloride.  Mononuclear cells were plated at 2.7x105 cells/cm2 on tissue culture 
treated plastic dishes in fully-supplemented Amniomax C-100 media (Gibco, Grand 
Island, NY). Culture media was changed 48 hours after plating to allow adherent stromal 
cells to adhere to plastic. Thereafter, growth media was changed 3 times per week for 
maintenance and cell expansion. Adherent MSC colonies were detectable by light 
microscopy within 2 weeks of plating.  MSC were harvested by trypsin and subsequently 
passaged at 4.7x103 cells/cm2 for expansion culture.  After passage 2-3, MSC were 
harvested using trypsin and suspended in FBS + 10% DMSO for cryopreservation.  
Thawed MSC were seeded at 4.7x103 cells/cm2 in Amniomax to reestablish MSC culture 
and subsequently passaged prior to reaching 80% confluence until sufficient cell numbers 
were accrued for experiments. 
4.2.2 Isolation of MSC subpopulations based on ALDH activity 
To assay BM MSC for relative ALDH activity, growth media was aspirated, cells were 
washed with PBS and cells were collected after trypsin-mediated detatchment. After cell 
counting, MSC were assayed for ALDH activity using Aldefluor reagent at 10x106 
cells/mL as per manufacturer instructions (Stemcell Technologies, Vancouver, BC). 
Fluorescence activated cell sorting (FACS) was performed to isolate cells with high 
(ALDHhi) or low (ALDHlo) ALDH activity to >99% purity. ALDHlo gating was set by 
using DEAB inhibition of ALDH activity in control samples. Sorted cells were 
subsequently washed in PBS to allow efflux of Aldefluor substrate via reactivation of 
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inhibited ABC-transporters prior to plating at 2.7x105 cells/cm2 on tissue culture treated 
plastic dishes in fully supplemented Amniomax C-100 media as described above. 
4.2.3 Cell surface marker phenotype analysis 
BM MSC were harvested with trypsin, collected in PBS+5%FBS and assayed for ALDH 
activity level by labeling with Aldefluor as above.  Subsequently, cells were stained with 
anti-human antibodies for MSC marker expression CD73, CD90, CD105. To confirm that 
MSC populations are negative for hematopoietic markers MSC were also labelled with 
antibodies raised against monocyte marker CD14, and pan-leukocyte marker CD45.   
Finally, to further characterise MSC sub populations Aldefluor labelled MSC were 
labelled with antibodies for pericyte marker CD146 and LNGFR (CD271, Miltenyi 
Biotech, Auburn CA).  All other antibodies were obtained from BD Biosciences 
(Missisauga, ON). Viable, 7-amino-actinomycin D (7AAD, BD Bioscience)-excluding 
cells were assessed for ALDH-activity and cell surface marker expression using an LSRII 
flow cytometer at the London Regional Flow Cytometry Facility and analyzed using 
FlowJo software (Treestar, Ashland, OR). All gating was performed based on 
fluorescence minus-one controls (FMO.) 
4.2.4 in vitro adipogenesis assay 
To test differentiation of MSC into the adipose lineage, active ALDHhi or ALDHlo MSC 
cultures were harvested using trypsin and reseeded in 12 well plates at 1x104 cells/cm2 
and grown for 2-4 days to near confluency in Amniomax media. Amniomax media was 
aspirated and cells were washed with PBS before replacement with adipogenesis 
differentiation media (Gibco). Adipogenesis media was changed every 3-4 days for 14 
days.  After 14 days of adipocyte induction, cultures were fixed in formalin and subjected 
to Oil Red O staining to label intracellular lipid stores. Cells were counterstained with 
hematoxylin to visualise cell nuclei. Relative induction of adipogenesis was quantified by 
percentage red pixels of total in photomicrographs measured using ImageJ software.  
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4.2.5 in vitro osteogenesis assay 
To assess differentiation of MSC into osteocytes, active ALDHhi or ALDHlo MSC 
cultures were harvested using trypsin and reseeded in 12 well plates at 5x103 cells/cm2 
and grown for 2-4 days to near confluency in Amniomax. Amniomax media was 
aspirated and cells were washed with PBS before replacement with osteogenesis 
differentiation media (Gibco).  Osteogenesis media was changed every 3-4 days for 21 
days.  After 21 days of osteocyte induction, cultures were fixed in formalin and processed 
for Alizarin Red S staining to detect calcification of osteocytes.   
4.2.6 in vitro chondrogenesis assay 
To assess differentiation of MSC into chondrocytes, active ALDHhi or ALDHlo MSC 
cultures were harvested using trypsin, counted, pelleted and resuspended at 1.6x107 
cells/mL of Amniomax. To create MSC micromass cultures 5μL aliquots of the 
concentrated cell solution were carefully seeded in multiwall plates. After establishment 
and 2 hours of incubation in high humidity conditions at 37°C, chondrogenesis 
differentiation media (Gibco) was added to the micromass cultures.  Chondrogenesis 
media was changed every 2-3 days for 21 days. After 21 days of chondrocyte induction 
micromasses were collected and embedded in optimum cutting temperature medium and 
frozen. Cryosections were prepared at 8μm and fixed in formalin prior to Alcian Blue 
staining to detect proteoglycans produced by chondrocytes. Cryosections were 
counterstained with Nuclear Fast Red to identify nuclei in chondrocyte micromasses.  
4.2.7 Generation of BM ALDHlo and ALDHhi MSC conditioned media  
After FACS isolation, ALDHhi or ALDHlo MSC were seeded at 4.7x103 cells/cm2 and 
grown in Amniomax for 3 days at 37°C to reestablish culture.  After 3 days the 
Amniomax media was aspirated and replaced with serum-free, growth factor-free, 
endothelial basal media (EBM, Lonza, Basel, Switzerland).  After an additional 48 hours 
in EBM culture without supplement, ALDHhi MSC- or ALDHlo MSC-conditioned media 
was collected and filtered at 0.2μm and frozen for later use.  
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4.2.8 HMVEC Culture 
Human dermal microvascular endothelial cells (HMVEC) were grown in endothelial 
basal medium-2 (EBM2, Lonza) supplemented with single-quots to make endothelial 
growth medium (EGM2-MV, Lonza) containing fetal bovine serum (5% FBS), epidermal 
growth factor (EGF), vascular endothelial growth factor (VEGF), basic fibroblast growth 
factor (FGF-B), insulin-like growth factor-1 (IGF-1), and ascorbic acid. Cells were 
seeded at 4.7x103 cells/cm2.  For maintenance culture, EGM2-MV was changed every 2-
3 days when required 
4.2.9 CyQUANT endothelial cell proliferation assays 
HMVEC were seeded at 3x103 cells/well in 96 well plates using 100μL of fetal bovine 
serum and growth factor supplemented endothelial growth media (EGM2-MV, 
GF+/Serum+, Lonza), basal endothelial media with or without growth factors and serum,  
(GF+/Serum-, GF-/serum+, or GF-/serum-), or in ALDHhi MSC- or ALDHlo MSC-
conditioned basal endothelial media.  Cultures were maintained for 72 hours at 37°C 
before each well carefully inverted and blotted to remove media from each well.   The 
whole 96-well microplate was then frozen at -70°C for later use.  To quantitate increased 
DNA content representative of increased cell division, adherent cells were lysed by 
addition of lysis buffer with CyQUANT GR dye in each well for 2-5 minutes at room 
temperature, and protected from light as per manufacturer instructions (Molecular Probes, 
Eugene, OR, USA).  Fluorescent signal in each well was assessed by fluorescence 
microplate reader at 480nm excitation and 520nm emission maxima.  Cell number in 
each well was interpolated from a standard curve generated with known number of 
HMVEC per well.   
4.2.10 Fluorescent cell labeling for co-culture studies 
HMVEC were labeled using CellTracker Green CMFDA  (Molecular Probes), at a 
concentration of 2μM in PBS+ PBS+5%FBS. ALDHhi or ALDHlo MSC tagged using 
CellTracker Red CMPTX (Molecular Probes) at a concentration of 3μM in PBS+5%FBS. 
Growth medium was aspirated from cell culture flasks and washed with PBS. After 
washing, cells were incubated in appropriate dye solution for 15-45 min, at 37°C. The 
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dye solution was then aspirated and replaced with normal growth medium, followed by 
incubation at 37°C for at least 30 min prior to harvest for co-culture experiments.   
4.2.11 HMVEC and MSC co-culture tubule formation assays on 
Geltrex basement membrane extract 
Geltrex reduced growth factor basement membrane extract (Gibco) was coated as a thin 
gel on a 24-well plate at a volume of 100μL per well, followed by incubation at 37°C for 
1-2 hours to allow the gel to set. The appropriate conditioned medium from ALDHhi 
versus ALDHlo MSC, or from EGM-2 or EBM controls was then added at a volume of 
400μL per well. EBM was added to negative control and experimental wells and EGM2-
MV was added to positive control wells. CellTracker Green CMFDA tagged HMVEC, 
with previously established cells under EGM2-MV conditions, were harvested for 
secondary culture and 4.5x104 cells were added to each well. CellTracker Red CMPTX-
dyed MSC were harvested and labeled with Aldefluor and sorted into ALDHlo and 
ALDHhi MSC as described above.  CMPTX-tagged ALDHhi and ALDHlo MSC 
populations and were added to experimental wells, at 9x103 ALDHhi MSC or ALDHlo 
MSC per well. Endothelial cell tubule formation was assessed at 6 hours and 24 hours 
after plating by phase contrast and fluorescent micrographs. Tubule branch points were 
enumerated using 4 different fields of view by a blinded observer. All co-culture assays 
were performed in duplicate.  
4.2.12 Murine femoral artery ligation and intramuscular 
transplantation of expanded MSC 
To assess the effects of MSC in vascular regeneration in vivo we induced acute unilateral 
hindlimb ischemia by surgical ligation and complete resection of the right femoral artery 
and vein on anesthetised NOD/SCID (Jackson Laboratory, Bar Harbor, ME) mice as 
previously described (Chapter 2, Appendix 1)27,28. Within 24 hours of surgery, mice were 
transplanted by intramuscular injection at three sites into the right (surgical/ischemic) 
adductor muscle with 50μL saline as vehicle control or 5x105 BM MSC.   
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4.2.13 Quantification of hindlimb perfusion using laser Doppler 
perfusion imaging 
Anesthetized mice were stabilized at 37°C for 5 minutes on a heating pad before blood 
flow in the lower hindlimbs (ankle to toe) was quantified using laser Doppler perfusion 
imaging (LDPI, Moor Instruments, Devon, UK). The perfusion ratio of the 
ischemic/surgical limb compared to the uninjured/control limb was assessed after surgery 
to confirm induction of acute ischemic injury with a perfusion ratio (PR<0.1) of <10% 
compared to the normal limb.  Subsequent LDPI measurements were taken in each mouse 
at 3, 7,14, 21,and 28 days after transplantation to track recovery of perfusion temporally.   
4.2.14 Statistics 
Data and results are reported as mean values ± SEM. Statistical comparisons were made 
using a Student’s t-test for adipogenesis induction and one-way ANOVA test followed by 
Tukey’s Post-Hoc tests for all other assays. 
4.3 Results 
4.3.1 BM MSC phenotype by ALDH activity level 
Human BM-derived MSC cultures were established and assayed for ALDH activity using 
Aldefluor and FACS.  Sorted MSC subpopulations with high (37.4±3.2% ALDHhi, Figure 
4.1) and low (45±4.2% ALDHlo, Figure 4.1) ALDH activity were isolated based upon 
DEAB-inhibited controls.  Both ALDHhi and ALDHlo MSC displayed robust expression 
of characteristic stromal markers CD73, CD90, CD105 (Figure 4.2, Table 4.1) but did not 
express hematopoietic marker CD45 (Figure 4.2D, Table 4.1) or monocyte marker CD14 
as detected by flow cytometry (Table 4.1).  Furthermore, both ALDHhi and ALDHlo MSC 
highly expressed pericyte marker CD146 and LNGFR/CD271 (Figure 4.2E, Table 4.1).  
Taken together, these data indicated that both subpopulations BM MSC express  MSC 
cell surface markers, fulfilling an important determinant in the minimal criteria for MSC 
as set by the International Society for Cellular Therapy2.  
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Figure 4.1. Bone marrow MSC purified according to high and low levels of ALDH 
activity using Fluorescence Activated Cell Sorting. 
(A) DEAB inhibits ALDH activity and establishes a negative gate to mark the ALDHlo 
MSC subset. ALDHlo and ALDHhi MSC subsets sorted by FACS. (B) Representative 
photomicrographs of MSC FACS sorted in to (B) ALDHhi and (C) ALDHlo populations 
and plated in Amniomax media and grown by plastic adherence (n=14). 
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Figure 4.2. Bone marrow MSC with high and low levels of ALDH activity display 
MSC markers.  
Bone Marrow subpopulations with high and low ALDH activity were isolated by FACS 
and analyzed for cell surface marker expression associated with MSC phenotype. Both 
ALDHhi and ALDHlo MSC showed high levels of (A) CD73, (B) CD90, and (C)  CD105 
expression. Both populations were negative for hematopoietic marker (D) CD45. Both 
ALDH populations expressed pericyte marker (E) CD146. All gates were set by 
fluorescence-minus-one controls (FMO). 
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Table 4.1. Bone marrow MSC with high and low 
levels of ALDH activity display MSC markers. 
Lineage Marker ALDHhi  MSC (+%) ALDH
lo  
MSC (+%) 
Hematopoietic   
CD45 0.2±0.2 0.3±0.3 
CD14 0.3±0.3 2.0±1.8 
MSC   CD73 97.9±0.9 92.4±5.0 
CD90 82.0±11.4 80.3±12.1 
CD105 64.2±10.2 50.6±15.0 
Pericyte   CD146 76.5±7.3 67.4±13.4 
Other   CD271 73.3±20.4 69.5±8.5 
(n=3-6)  
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4.3.2   Both BM MSC ALDHhi and ALDHlo subpopulations 
demonstrate multipotent stromal cell differentiation 
Human BM-derived MSC were separated into subpopulations by level of ALDH activity 
by FACS and were subjected to in vitro differentiation conditions to characterize 
mesenchymal multipotency.  Both ALDHhi and ALDHlo MSC formed Oil Red O positive-
staining adipocytes after 14 days culture in adipogenesis induction media (Figure 4.3).  
Notably, ALDHhi MSC (Figure 4.3A,C) demonstrated significantly increased frequency 
of adipocyte induction compared to ALDHlo MSC (Figure 4.3B,D) as measured by 
percent Oil Red O positive staining by culture area (Figure 4.3E, p<0.05, n=4).  Both 
ALDHhi (Figure 4.4A,C) and ALDHlo MSC (Figure 4.4A,C) also demonstrated induction 
of osteocyte formation as assayed by Alizarin Red S detection of calcium deposition after 
21 days in osteogenesis media for 21 days (Figure 4.4).   Furthermore, both ALDHhi 
(Figure 4.5A) and ALDHlo MSC (Figure 4.5B) demonstrated induction of chondrocyte 
differentiation in micromass culture in chondrogenesis media for 21 as measured by 
detection of proteoglycan deposition by chondrocytes using Alcian Blue staining in 
cryosections (Figure 4.5).  Taken together, these data indicate that subpopulations of BM 
MSC with both high and low levels of ALDH activity demonstrate mesenchymal 
multipotency consistent with the defining minimal criteria2.  
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Figure 4.3. Bone marrow-derived ALDHhi MSC show increased adipogenesis.  
(A,C) ALDHlo MSC and (B,D) ALDHhi MSC were grown for 14 days in adipogenesis 
differentiation media prior to Oil Red O staining. Representative (A,B) bright field and 
(C,D) phase contrast photomicrographs of cell cultures stained with Oil Red O and 
hematoxylin. (E) ALDHhi MSC show greater induction of adipocyte formation as 
measured by % red pixels indicating positive Oil Red O staining after 14 days in 
adipogenesis medium compared to ALDHlo MSC (n=4, p<0.05). 
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Figure 4.4. Bone marrow-derived ALDHhi and ALDHlo MSC differentiate into 
osteocytes.  
(A,C) ALDHlo MSC and (B,D) ALDHhi MSC were grown for 21 days in osteogenesis 
differentiation media prior to Alizarin Red S staining. Representative (A,B) bright field 
and (C,D) phase contrast photomicrographs of cell cultures stained with Alizarin Red S. 
Both ALDHhi and ALDHlo MSC induction of osteocyte formation as measured by % red 
pixels indicating calcium deposition in osteocytes (n=4). 
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Figure 4.5 ALDH activity level does not affect chondrocyte differentiation by MSC.  
Both bone marrow-derived (A) ALDHlo and (B) ALDHhi MSC showed robust formation 
of chondrocytes after 21 days micromass culture in chondrogenesis medium. Induction of 
chondrogenesis in micromass cryosections was confirmed by Alcian blue staining 
indicating proteoglycan deposition. Nuclear Fast Red counterstaining labels nuclei. 
  
166 
 
 
  
167 
 
4.3.3 ALDHhi MSC demonstrated increased support of endothelial cell 
proliferation 
To test differences in paracrine support of support of endothelial cell proliferation 
ALDH-purified ALDHhi or ALDHlo MSC subpopulations were cultured in GF-free 
serum-free endothelial basal media to generate MSC-conditioned media used for 
HMVEC growth studies.  Dermal-origin HMVEC were cultured on plastic in basal 
endothelial media with or without GFs (EGF, VEGF-A, FGF, IGF-1) and 5%FBS, or in 
ALDHhi MSC-conditioned or ALDHlo MSC-conditioned media generated without serum 
or growth factor supplementation.  Conversely, HMVEC grown without either or both 
serum and growth factors showed no proliferation over 72hours.  HMVEC cultured in 
GF+/FBS+ endothelial growth media demonstrated approximately 3.5 fold increase in 
cell number over 72 hours as measured by CyQuant quantification. Notably, ALDHhi 
MSC-conditioned media significantly increased proliferation of HMVEC compared to 
ALDHlo MSC-conditioned media and basal endothelial media (p<0.01, n=5). 
Interestingly, there was notable variation in HMVEC proliferative responses between BM 
donor source. Pairwise comparisons of ALDHhi vs. ALDHlo MSC-conditioned media 
within all other donor samples showed significant increases in EC proliferation in 
ALDHhi–treated cultures (p<0.05, n=5).  Intriguingly, BM45 MSC conditioned media 
was most effective at promoting proliferation in both ALDHhi and ALDHlo 
subpopulations further illustrating inter-donor variability in the induction of HMVEC 
growth.   Taken together these data demonstrate the purification of BM MSC based on 
high ALDH activity isolated a subpopulation of MSC with increased paracrine secretory 
support of EC expansion.  
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Figure 4.6. ALDHhi MSC conditioned media supports proliferation of endothelial 
cells.  
Representative photo-micrographs of human micro-vascular endothelial cells (HMVEC) 
grown in (A) growth factor+/serum+ EGM2 media, (B) basal growth factor-free/serum-
free, (C) ALDHhi MSC-conditioned media or (D) ALDHlo MSC-conditioned media. (E) 
Compared to ALDHlo MSC-conditioned basal media, and basal media, ALDHHi MSC 
conditioned media increased HMVEC proliferation. (F) Induction of HMVEC 
proliferation varies according to the individual donor bone marrow source from which the 
MSC were derived. (E) Different letters denote significant differences in mean (p<0.01, 
n=5). 
  
169 
 
 
  
170 
 
4.3.4 ALDHhi and ALDHlo MSC augmented HMVEC tubule stability  
To assess the potential for MSC-mediated support of endothelial cell tube formation, 
CellTracker Green CMFDA fluorescent-tagged HMVEC were plated on growth factor 
reduced Geltrex in basal endothelial media without serum or growth factor 
supplementation.  ALDH sorted MSC subpopulations were fluorescently labelled with 
CellTracker Red CMPTX and co-cultured with EC at a ratio of 1 MSC:5 EC.  Within 6 
hours of co-culture, red-labelled MSC were detected in association with newly formed 
endothelial cell tubules, consistent with perivascular wrapping function of MSC (Figure 
4.7G,H). Direct co-culture of HMVECs with either ALDHlo or ALDHhi MSC did not 
significantly increase tubule branch point formation by HMVECs at 6 hours relative to 
negative control basal endothelial cell media (Fig. 4.7A-H,Q, n=3). Moreover, the 
number of branch points formed by HMVEC in MSC co-cultures was reduced compared 
to the number of branch points formed by HMVEC alone in growth factor- and serum-
supplemented media (Figure 4.7Q).  However, after 24 hours of co-culture, only ALDHhi 
MSC supported significantly increased endothelial cell tubule formation compared to 
basal conditions (Figure 4.7R). Moreover, ALDHhi MSC co-culture promoted tube 
formation at equivalent levels to HMVEC cultured alone in growth factor and serum 
supplemented endothelial growth media.  ALDHlo MSC co-culture did not significantly 
alter HMVEC tubule formation compared to controls or ALDHhi MSC co-culture (Figure 
4.7R, n=3).  These data demonstrated that purification of MSC with high ALDH activity 
isolates a population of cells with increased support of endothelial cell tubule 
stabilization.  
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Figure 4.7. Co-culture with bone marrow-derived ALDHhi and ALDHlo MSC 
augments HMVEC tubule formation.  
Representative photomicrographs of tubule and branch point formation by HMVECs 
after (A-H) 6 hours or (I-P) 24 hours culture in basal media (EBM, A,E,I,M), positive 
control media (EGM2-MV, B,F,J,N), EBM with ALDHlo MSC co-culture (C,G,K,O), or 
EBM with ALDHhi MSC co-culture (D,H,L,P). Scale bar = 300μm. (Q) Co-culture with 
ALDHhi and ALDHlo MSC significantly augmented tubule branch point formation 
relative to basal media at 6 hours. (R) ALDHhi MSC-conditioned media supported 
maintenance of significantly more branch points compared to ALDHlo at 24 hours. Data 
are expressed as mean ± SEM. (Q,R) Different letters denote significant difference, 
p<0.05, n=3. 
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4.3.5 Intramuscular injection of BM MSC promotes accelerated 
recovery of perfusion after acute ischemic injury.  
To establish proof of concept in vivo and to assess the functional role of transplanted 
MSC in vascular regeneration, NOD/SCID mice were subjected to unilateral femoral 
artery ligation and transplanted by intramuscular injection of BM MSC (non-sorted) into 
the injured leg adductor muscle. Mice were monitored for recovery of perfusion using 
laser Doppler perfusion imaging for 28 days.  Seven days after treatment of PBS vehicle-
injected control mice had recovered a perfusion ratio  (PR, ischemic limb/normal limb) of 
0.25±0.03 (Figure 4.8A, n=7). However, mice treated with heterogeneous BM MSC 
showed significantly augmented rate of recovery of perfusion (PR=0.52±0.07) within 7 
days compared to PBS-treated mice (Figure 4.8A, p<0.01, n=6).  Although perfusion was 
increased in MSC transplanted mice at days 7 and 14, significantly improved perfusion 
was not maintained at later time points (Days 21 and 28). Two different BM MSC donor 
sources were used.  At day 7 post-treatment mice injected with BM20 MSC (Figure 4.8B, 
PR=0.67±0.06, n=3) showed significantly augmented recovery of perfusion compared to 
both PBS (Figure 4.8B, PR=0.25±0.03, n=7, p<0.01) and BM18 MSC (Figure 4.8B, 
PR=0.37±0.03, n=3, p<0.01) treated mice.  Notably, mice treated with BM18 MSC 
showed no significant differences in recovery of perfusion compared to PBS controls. 
Taken together, these data indicate that BM MSC support the recovery of perfusion in the 
ischemic hindlimb of immune deficient mice after acute injury. However, inter-donor 
variability in the induction of recovered perfusion by different MSC lines was evident. 
This in vivo model will form the basis for future investigations to determine the in vivo 
vascular regenerative potential of ALDHlo or ALDHhi MSC sub-populations and to 
further identify other phenotypes of BM MSC samples associated with increased 
regenerative function.   
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Figure 4.8. Bone marrow MSC show differential support of vascular regeneration 
by donor source.  
LDPI was used to quantify perfusion in the hind limb following right femoral artery 
ligation and intramuscular injection PBS vehicle control (n=7), or 5x105 BM MSC (n=6) 
monitored for 28 days. (A) Perfusion ratio of the ischemic versus the non-ischemic 
hindlimb from ankle to toe in all transplanted mice as described above. Compared to 
saline controls, transplantation of BM MSC promotes recovery of perfusion in ischemic 
mouse hindlimbs by day 7 post-transplantation. (B) Data presented in (A) sub-divided by 
MSC donor, MSC from BM20 showed increased support of perfusion recovery compared 
to donor BM18 MSC. Data are expressed as mean ± SEM, *p<0.01 v PBS, #p<0.01 v 
BM18 MSC.  
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4.4 Discussion  
In this chapter, we demonstrate that BM MSC can be sub-fractionated into populations 
based upon the level of ALDH enzyme activity.  Both ALDHhi and ALDHlo MSC display 
the characteristic cell surface marker phenotype typical of mesenchymal stromal cells 
devoid of hematopoietic cell contamination. Moreover, both ALDHhi and ALDHlo 
subpopulations display robust mesenchymal multipotency, demonstrating differentiation 
capacity to adipocytes, osteocytes and chondrocytes under lineage specific differentiation 
conditions.  We show that the MSC subpopulation with high ALDH activity after culture 
expansion demonstrates increased paracrine support of endothelial cell proliferation in 
vitro, under serum-free, growth factor free conditions.  Furthermore, we demonstrated 
that ALDHhi MSC also augmented endothelial cell tubule formation, stabilizing tube-like 
structures possibly through perivascular wrapping.  We propose that high ALDH activity 
provides a clinically relevant, FACS-selectable, and prospective marker to identify MSC 
subpopulations with increased vessel supportive functions for the development of 
improved cell therapies for ischemic disease.   
The Hess laboratory and others have previously identified cells high levels of ALDH 
activity as a marker which selects hematopoietic (Chapter 2)26,27,29-35, endothelial (Chapter 
2)26,27,36-38, neural39,40, and mesenchymal19,26 cells with primitive, stem/progenitor cell 
phenotype and function.  Our lab has previously demonstrated that initial selection of 
ALDHhi mixed progenitor cells from BM26 or UCB (Chapter 2)27 demonstrate increased 
support of endothelial cell function in vitro and enhanced vascular regeneration in vivo. 
The Hess laboratory have shown that while MSC-like cells can be derived from the 
ALDHlo BM cells, these cells do not demonstrate full multi-lineage differentiation, and 
are restricted primarily to the adipocytes lineage26. In contrast, MSC grown from ALDHhi 
BM mononuclear cells represent true MSC, which expand efficiently in ex vivo culture 
and demonstrate full multipotecy forming fat, bone and cartilage26. Furthermore, the 
frequency of mesenchymal colony forming cells is significantly higher in the ALDHhi 
population of human BM compared to ALDHlo BM26.   Together these findings led us to 
hypothesize that high ALDH activity might be a good prospective marker to further 
purify an ALDHhi MSC subset with increased capacity for vascular regeneration after 
177 
 
expansion ex vivo.  Importantly, both the ALDHlo and ALDHhi subsets of expanded MSC 
demonstrated extensive expression of CD146, a cell surface marker previously associated 
with perivascular wrapping function for MSC isolated from multiple human tissues in 
situ16. 
The findings that BM ALDHhi cell promote recovery of hindlimb ischemia in mice was 
used as preclinical justification for initiating clinical trials in patients with critical limb 
ischemia, the most severe form of peripheral arterial disease (PAD)(NCT00392509)41. 
Intramuscular transplantation of freshly isolated (uncultured) autologous BM ALDHhi 
cells at multiple sites in the ischemic limb was compared directly compared to unpurified 
autologous BM MNC in PAD patients with a Rutherford score of 4 (resting pain without 
significant ulceration) or 5 (resting pain with unresolved ulceration or necrosis)41.  
Results of this pioneering study demonstrated safety and patients that received 
autologous BM ALDHhi cells showed improved Rutherford category and reduced resting 
pain.  Furthermore patients in the ALDHhi treatment group showed improved ankle to 
brachial index scores more rapidly than the MNC group indicating improved perfusion of 
the lower limb.  However, patients in both cohorts reported significantly improved 
quality of life indices.41 More recently, a phase 2 placebo-controlled randomized clinical 
study has been initiated to investigate transplantation of BM ALDHhi cells to improve 
symptoms of intermittent claudication (NCT01774097).  The Hess laboratory have 
previously shown that the BM ALDHhi progenitor cells are primarily (>90%) comprised 
of hematopoietic precursor cells that efficiently form myeloid colonies in vitro, and are 
also highly enriched in CD45- progenitor cells that generate multipotent fibroblast 
colonies (1 CFU-F in 1500 BM ALDHhi cells) that expand efficiently and adherent to 
plastic. Furthermore, MSC have been widely investigated in clinical trials for 
cardiovascular disease.  As a readily ex vivo expandable population of cells from BM, 
MSC have been proposed as excellent candidates for cell therapy due to their robust 
paracrine activities and perivascular wrapping functions.  Indeed in diabetic rat models, 
BM MSC have been demonstrated to promote vascular repair and wound healing42-44.   
Moreover, a randomized controlled clinical trial was undertaken to compare BM MNC 
and BM MSC therapy in diabetic patients with critical limb ischemia45.  This study 
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showed that both BM MNC and MSC were safely administered by intramuscular 
administration and both BM MNC or BM MSC promoted improvements in perfusion, 
tissue oxygenation, and pain free walking time at 24 weeks post treatment45.   Notably, 
greater cell numbers could be generated during the ex vivo expansion of BM MSC 
compared to the fresh BM MNC, indicating the appeal of ex vivo expansion to increase 
cell numbers for transplantation.  
However, a number of preclinical models have shown that BM MNC and MSC from 
patients with diabetes or cardiovascular disease show diminished function for vascular 
regeneration46-49.  For this reason, cell therapy approaches using BM MSC combined with 
ex vivo expansion are appealing as ex vivo expansion and targeted intra-muscular 
transplantation may restore MSC vascular regenerative function, or alternatively, you 
could potentially source BM from healthy donors for use in an allogeneic context.  In 
addition, the establishment of national registries to cryopreserve and HLA-phenotype 
UCB samples may provide a renewable source of vascular regenerative MSC from early 
ontogeny and devoid of chronic cardiovascular disease co-morbidities.  Moving forward 
towards essential experiments that will establish proof-of-concept, I propose that ALDH 
activity presents a useful functional marker to identify MSC subpopulations with 
increased vascular regenerative potential.   Furthermore, selection of ALDHhi MSC might 
also be helpful in screening cell lines to identify sample with increased or diminished 
vascular regenerative potential. Taken together I propose that BM-derived MSC with 
high ALDH activity represent a promising candidate for further development of cell 
therapy for cardiovascular disease broadly and for critical limb ischemia and peripheral 
arterial disease specifically.    
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Chapter 5 
5 Summary and Discussion 
5.1 Summary of Major Findings 
The overall objective of this thesis was to expand our understanding of the role of human 
progenitor cells in vascular regeneration as a means to improve the outcome of potential 
cell therapy applications in ischemic cardiovascular disease. Towards this end, I have 
characterized a population of umbilical cord blood derived progenitors purified by 
selection of cells with high ALDH activity, a mixed stem and progenitor cell population 
with enhanced regenerative functions. Using complementary in vitro and in vivo models, 
I have demonstrated the vascular regenerative effects of UCB ALDHhi cells. Furthermore, 
I have demonstrated that it is feasible to increase the number of these useful, pro-
angiogenic hematopoietic cells for vascular regenerative therapy by clinically applicable, 
serum-free ex vivo expansion without diminishing vascular regenerative activity. 
Building upon the abundant pre-clinical promise of MSC for vascular regenerative 
therapies and the concept of high ALDH activity as a marker of cells with increased 
progenitor cell and vascular regenerative phenotypes, I further demonstrated that MSC 
with high ALDH activity demonstrate the support of endothelial cell function in vitro, 
further reinforcing the use of ALDH as a prospective marker of multiple progenitor cell 
lineages with enhanced vascular regenerative functions. Taken together, my studies have 
demonstrated the viability of high ALDH activity as a useful marker for the isolation and 
purification of blood and BM-derived cell types with increased efficacy in treatment of 
ischemic disease (Figure 5.1). 
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Figure 5.1 Summary of thesis findings. 
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5.1.1 Chapter 2 – UCB ALDHhi cells induce vascular regeneration  
The aims of my studies in chapter 2 were to characterize the capacity of UCB ALDHhi 
cells to support vascular function in vitro in models of endothelial cell co-culture and in 
vivo in a murine model of acute unilateral hind limb ischemia. Our lab had previously 
demonstrated that selection of BM cells with high ALDH activity isolates a 
subpopulation of cells that reconstitute hematopoiesis1,2, show widespread tissue 
distribution3, and recruit to areas of ischemia after intravenous transplantation4. 
Furthermore, the Hess lab have demonstrated that BM ALDHhi cells augment re-
vascularization of the ischemic limb in transplanted mice after acute ischemic injury4. 
Numerous studies have demonstrated that patients affected by CVD and/or diabetes have 
decreased numbers of circulating pro-angiogenic cells, and furthermore these few 
circulating have diminished efficacy in supporting vascular regeneration5-11. For this 
reason my studies focused on the investigation of UCB as an alternate source of ALDHhi 
pro-angiogenic progenitor cells for allogeneic transplantation approaches to augment the 
diminished efficacy and frequency of circulating cells for vascular regeneration in 
patients with CVD where autologous transplantation may be of limited effectiveness.  
At the onset of these studies, I hypothesized that transplantation of human UCB ALDHhi 
HPC would promote vascular regeneration of ischemic limbs in immune-deficient mice 
with unilateral hind limb ischemia via paracrine mechanisms. I demonstrated that 
selection of UCB ALDHhi cells isolates a population with increased myeloid HPC 
phenotype by cell surface marker expression and by colony forming cell capacity in vitro. 
Furthermore, my studies demonstrated that isolation of cells with high ALDH activity 
from UCB enriches and selects for rare CD45–ECFC within the more heterogenous MNC 
population. I showed that the UCB ALDHhi population demonstrated a pro-angiogenic 
transcription profile compared to UCB cells with low ALDH activity. Indeed, 
transcription of several important vascular regeneration-associated cytokines including 
ANG1 and VEGF-A were expressed at significantly higher levels in ALDHhi cells than in 
UCB ALDHlo cells. In co-culture with EC, UCB ALDHhi cells promoted the survival of 
EC under growth factor-free, serum-free conditions. Moreover, in co-culture with EC on 
growth factor-reduced matrigel, UCB ALDHhi cells supported augmented EC tubule 
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formation. Importantly, intravenous transplantation of UCB ALDHhi cells in an immune-
deficient mouse model of acute unilateral hind limb ischemia significantly augmented 
recovery of perfusion and increased vascularization in the ischemic limb compared to 
vehicle-transplanted controls. Notably, the value of purification of the ALDHhi progenitor 
cell subset was shown by increased recovery of perfusion and vascularization compared 
to transplantation of heterogeneous UCB MNC containing an equivalent dose of ALDHhi 
cells. After intravenous transplantation of UCB ALDHhi cells mice showed low levels of 
human cell engraftment specifically in the ischemic muscle. Preparative irradiation to 
reduce human cell rejection did not enhance recovery of perfusion by enhancing 
engraftment or hematopoietic reconstitution. Indeed, irradiated mice showed increased 
recruitment of human cells to the BM consistent with previously demonstrated 
hematopoietic reconstituting capacity1,2. Transplantation of UCB ALDHhi cells into 
irradiated mice showed delayed, less robust recovery of perfusion or vascularization in 
the ischemic hindlimb compared to non-irradiated mice consistent with decreased early 
recruitment of transplanted ALDHhi cells to the ischemic muscle. Indeed, our lab has 
previously shown that tail vein injected BM-derived ALDHhi cells recruit specifically to 
the ischemic hind limb within 6-24 hours after femoral artery ligation surgery indicating 
the chemotactic nature of ALDHhi cells in response to ischemic damage stimuli4. We 
concluded that although increased engraftment and survival of ALDHhi cells in the 
ischemic hindlimb was predicted to improve revascularization, permanent or long-term 
residence in the ischemic limb was not required to achieve potent recovery of small 
capillary function. 
My work in chapter 2 demonstrated that purification of ALDHhi cells from UCB is a 
viable, readily available and less invasive alterative source of ALDHhi cells to BM. Due 
to the early ontogeny of UCB, it will not have any CVD or age-associated morbidities 
that might impair the most effective applications of cell therapy. The evidence that 
purified ALDHhi cells were more effective than transplantation of heterogeneous MNC 
containing as many ALDHhi cells indicates the importance of prospective selection 
strategies to isolate cell types with increase vascular regenerative function while 
depleting cells with either no benefit or potentially inhibitory effects. Overall, these 
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studies indicated that UCB ALDHhi cells are a promising candidate for future 
development of cell therapies for the treatment of CVD and more specifically for PAD 
and CLI.  
5.1.2 Chapter 3 – ex vivo expanded UCB HPC retain pro-angiogenic 
capacity 
Building directly upon the findings of chapter 2, my second aim was to address a primary 
shortcoming of the use of blood derived ALDHhi cells. Namely, selection of ALDHhi cells 
for use in a human setting may be hindered by the number of cells available for transplant 
because the ALDHhi population is very rare accounting for less than 0.5% of total MNC 
in UCB and less than 1% in total BM MNC4,12. The first goal in chapter 3 was to develop 
an ex vivo expansion protocol which could increase the number of cells available for 
therapy without untoward differentiation that may decrease the effectiveness of the cells 
for vascular regeneration. Thus my aim for the studies presented in chapter 3 was to 
optimize the ex vivo expansion of UCB ALDHhi hematopoietic cells under clinically 
relevant serum-free conditions and to characterize vascular regenerative functions of the 
expanded progenitor cells in vitro. In addition, I wanted to investigate the paracrine 
mechanisms by which expanded hematopoietic progenitor cells derived from UCB 
ALDHhi contribute to revascularization after direct intramuscular injection into the 
ischemic limb. The hypothesis for these studies was that ex vivo expansion of UCB 
ALDHhi cells would increase the number of pro-angiogenic hematopoietic progenitor 
cells for application in vascular regeneration without decreasing EC-supportive functions.  
I demonstrated that ex vivo expansion of UCB ALDHhi cells in clinically relevant, serum-
free media with recombinant human TPO, FLT3L, and SCF for 6 days imparted a 20-fold 
expansion of early myeloid cells retaining hematopoietic progenitor phenotype without 
increasing the number of mature monocytes or macrophages. Moreover, after ex vivo 
expansion from UCB ALDHhi cells, the resultant progeny retained hematopoietic 
progenitor colony forming function in vitro and maintained a pro-angiogenic 
transcriptional profile similar to freshly isolated UCB ALDHhi parental cells. In fact, the 
expanded HPC population showed upregulation of several important vascular 
regeneration-associated transcripts including significant upregulation of EGF, VEGF-A 
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and ANG1. In direct co-culture with HMVEC, ex vivo-expanded HPC augmented tubule 
formation in serum-free growth factor reduced conditions. Furthermore, HPC-
conditioned media and co-culture of HPC with HMVEC promoted increased survival of 
HMVEC in growth factor-free serum-starved conditions. I demonstrated that during co-
culture with HMVEC, in basal unsupplemented media, HPC increased secretion of the 
vascular regenerative growth factors EGF and ANG2. Furthermore HPC co-culture 
increased secretion of chemokines that have been shown to play a role in modulating 
recruitment of other support cells that are implicated in vascular regeneration in response 
to injury or hypoxia including GRO/CXCL1-3, IL-8/CXCL8, and RANTES/CCL5. 
Finally, HPC co-culture also increased secretion levels of matrix modifying proteins, 
MMP-9, TIMP-1 and TIMP-2. These pro-angiogenic and matrix-modifying proteins have 
been implicated in the induction of angiogenic sprouting in vivo and in vascular 
stabilization and extracellular matrix remodeling respectively.  
Using our well established immune-deficient mouse model of acute hindlimb ischemia, I 
demonstrated that intramuscular injection of ex vivo-expanded HPC augmented recovery 
of perfusion and increases vascularization of the ischemic muscle. Furthermore, I showed 
that this improved vascular repair after femoral artery ligation in mice treated with ex 
vivo expanded UCB HPC also resulted in improved recovery of limb usage compared to 
vehicle controls. This indicates the usefulness of cell therapy for vascular regeneration 
reaches beyond improvements in blood flow to ischemic tissue and includes accelerated 
limb usage during recovery. Adequate perfusion and limb usage in ischemic tissues is an 
important factor in moderating quality of life improvements in patients afflicted with 
peripheral artery disease and critical limb ischemia. Taken together, my work in Chapter 
3 demonstrated that it is possible to increase the number of pro-angiogenic hematopoietic 
cells using clinically relevant expansion conditions. Importantly, I demonstrated that this 
expansion of cell number does not decrease the efficacy for vascular regeneration 
compared to the parental UCB ALDHhi cell population. Collectively, the findings from 
Chapters 2 and 3 demonstrated that UCB is a readily available, expandable source of 
progenitor cells with vascular regenerative potential, presenting a promising candidate 
cell population for development of cell therapies for ischemic PAD.  
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5.1.3 Chapter 4 – MSC with high ALDH activity  
Multipotent stromal cells can be isolated from bone marrow (BM) and many other 
tissues. Broadly, MSC are considered good candidates for allogeneic cell therapy 
applications because of their established safety after infusion, low immunogenicity and 
potential immunomodulatory effects. Moreover, MSC are considered to be excellent 
cellular sources of regenerative cytokines for many tissue repair processes and 
specifically they have been shown to secrete pro-angiogenic factors13-17. Implementation 
of MSC therapy has been somewhat hindered by variability in MSC function between 
donor source and by lack of prospective markers for selection of samples with the 
optimal regenerative potential for a given application. Our laboratory has previously 
demonstrated that selection of high ALDH activity isolates an increased frequency of 
MSC from BM MNC4 and as MSC differentiate in prolonged ex vivo culture, ALDH 
activity and regenerative capacity is reduced. Furthermore, my earlier studies from 
Chapters 2 and 3 have shown that high ALDH activity identifies hematopoietic cells with 
increased vascular regenerative potential. For these reasons I hypothesized that selection 
of MSC subpopulations with high ALDH activity after expansion culture would identify 
a population of MSC with enhanced vascular regenerative functions.  
In Chapter 4, I demonstrated that after expansion ex vivo, both ALDHhi and ALDHlo MSC 
subpopulations expressed the cell surface markers characteristic of MSC, CD73, CD90, 
and CD105, and were devoid of contaminating hematopoietic cells and monocytes. 
Moreover, I showed that both MSC sub-populations expressed the pericyte marker 
CD14618 and the prospective MSC marker low affinity nerve growth factor receptor 
(LNGFR) also called CD27119. Furthermore, I demonstrated that both ALDHhi and 
ALDHlo subsets of expanded MSC demonstrate mesenchymal multipotency, showing 
growth factor induced differentiation into bone, fat and cartilage. Thus, both ALDHhi and 
ALDHlo MSC met the strict definition of MSC set forth by the International Society for 
Cellular Therapy20.  
Adapting the in vitro co-culture systems I developed in Chapters 2 and 3, I demonstrated 
that ALDHhi MSC showed greater support of endothelial cell proliferation in basal 
conditions compared to ALDHlo MSC. Moreover, using fluorescent tagging and co-
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culture with HMVEC, I demonstrated that ALDHhi MSC demonstrated increased vessel 
integration/association and provided structural support for the stabilization of EC tubule 
formation in vitro compared to ALDHlo MSC. Based on my findings in Chapter 4, I 
propose that BM-derived MSC with high ALDH activity represent an excellent candidate 
for further development of cellular therapies for cardiovascular disease. Moreover, after 
intramuscular injection of unpurified, culture expanded MSC into immune deficient mice 
with unilateral hindlimb ischemia I showed evidence for inter-donor sample variability in 
the capacity of BM MSC to promote vascular regeneration. These findings confirmed the 
need for further study to identify additional prospective markers to identify MSC with 
effective vascular regenerative function.  
5.2 Clinical Applications 
The findings presented in this thesis provide substantial pre-clinical justification for 
further investigations of potential application of purified UCB ALDHhi cells, ex vivo-
expanded HPC derived from UCB ALDHhi cells, and MSC subpopulations with high 
ALDH activity. Indeed, Phase I/II clinical trials headed by Perin and colleagues have 
demonstrated the safety and efficacy of autologous BM ALDHhi cells by intramyocardial 
injection in patients with heart failure and by intramuscular injection in patients with 
critical limb ischemia21,22. My work demonstrates the potential application of UCB-
derived ALDHhi cells in allogeneic transplant strategies both by intravenous and 
intramuscular injection. Specifically in patients with severe PAD, transplantation of BM-
derived ALDHhi cell has been demonstrated to support the recovery of perfusion and 
improved disease outcome, decreasing Rutherford score and resting pain with 
concomitant increases in self reported quality of life21. These promising findings 
demonstrate the potential for application of ALDHhi cells broadly for CVD and 
specifically for patients with PAD and CLI.  
Purification by high ALDH activity does not represent the only subpopulation of BM 
MNC that has been investigated at the clinical level; autologous BM CD34+ have been 
previously assessed in patients with moderate to severe CLI23. These studies also 
demonstrated safety and suggested a promising trend towards reduced amputation and 
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improved clinical indices23. However, I postulate that ALDH may represent a superior 
marker to isolate a subpopulations of cells as it isolates not only the hematopoietic 
progenitor cell types as would CD34 selection, but also isolates increased frequency of 
MSC and ECFC4,12. However, to date the majority of cell therapy trials for CVD have 
investigated heterogenous BM MNC populations. Despite the mixed results in BM MNC 
therapy for acute myocardial infarction, meta-analyses have shown small benefits in left 
ventricle ejection fraction24. Furthermore, the clinical trials investigating application of 
BM MNC for PAD and CLI have shown some promise despite the small sample size of 
trials completed25-27. As larger trials are completed, higher-powered analyses will be 
needed clarify disease outcome improvements, and our preclinical data suggests that 
prospective purification of pro-angiogenic progenitors and concomitant removal of 
potentially interfering inflammatory cells could potentially help improve trial outcomes.  
Interestingly, it has been demonstrated that MSC derived from a type 2 model diabetic 
(db/db) mice showed decreased frequency, recruitment and efficacy in the support of 
wound healing in diabetic mice compared to wild type controls28. Furthermore, MSC 
isolated from rats with STZ-induced diabetes showed diminished differentiation, 
paracrine cytokine secretion, and anti-apoptotic activity compared to healthy controls29. 
However, studies have shown that using ex vivo growth factor (IGF and FGF2) activation 
of diabetic-derived MSC has been shown to abrogate disease associated dysfunction 
suggesting possible rejuvenation strategies to augment autologous MSC for CVD patients 
may be possible30. Moreover, pretreatment of MSC from type 2 (db/db) diabetic mice 
with EGF has been shown to abrogate diabetes-related dysfunction and to support 
recovery of perfusion in mouse model of hindlimb ischemia31. These finding point 
towards the potential benefit of a combined cell therapy approach using HPC co-
transplantation with HLA-matched MSC. Indeed, our pre-clinical characterization of pro-
angiogenic effectors showed that HPC secrete EGF and EGF-family cytokines that are 
expected improve MSC-mediated vascular regenerative effects in vivo. Using a similar 
approach, clinical trials using co-administration of expanded BM MSC with BM MNC in 
patients with moderate to severe PAD showed safety and suggested improvements in 
both hemodynamic and clinical indices32.  
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Broadly, most cell therapies investigated for ischemic disease at the clinical level 
encompass autologous approaches, despite accumulating evidence of disease associated 
progenitor cell dysfunction in the patients with CVD8,9,28,29,33,34. Thus, the preclinical work 
presented in this thesis may represent important findings regarding possible alternative 
allogeneic sources (namely UCB) of purified angiogenic supportive progenitor cell types 
untouched by chronic CVD co-morbidities. In addition, despite demonstrating safety in 
multiple applications, arguably many of the clinical trials completed to date have been 
underpowered to properly assess efficacy in treatment of CVD25,26,35,36. While many have 
shown promising trends improving disease outcomes, further study is required to 
properly identify the best candidate and delivery techniques for future cell therapy for 
CVD37. To date, there have been few significant clinical trials investigating application of 
allogeneic BM MSC or UCB cells for PAD27. Notwithstanding, the findings presented in 
this thesis and by other research groups demonstrate the abundant promise shown in pre-
clinical experiments for possible allogeneic cell therapy with BM MSC14,38 or UCB-
derived cells12,39-42 for PAD and CVD broadly. As such, I propose that purified UCB 
ALDHhi cells, their ex vivo-expanded HPC progeny, and the ALDHhi subset of expanded 
BM MSC all represent promising candidates for future cell therapy applications.  
5.2.1 Angiogenic Hematopoietic Cells 
It is important to note that UCB ALDHhi cells represent a heterogeneous progenitor cell 
population, that contained enriched frequency of both hematopoietic and endothelial 
colony forming cells4,12. Throughout this thesis I have taken great care to delineate the 
contributions of supportive hematopoietic progenitors from the potential contributions of 
non-hematopoietic endothelial progenitor cells or EPC. Indeed, confusion in the field still 
exists because many populations that have been termed “EPC” are in fact hematopoietic 
cell types that do not give rise to mature EC. Yoder et al. have established the phenotype 
of the true, non-hematopoietic progenitor cells which they termed ECFC, defined by 
cobblestone morphology, late outgrowth after plating from blood and no expression of 
hematopoietic markers CD45 or CD146. Others have called ECFC the late blood 
outgrowth EPC in contrast to the early outgrowth cells which should be more properly 
called circulating angiogenic cells (CAC) or colony forming unit-Hill cells (CFU-
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Hill)43,44. The population of cells that Asahara et al. termed EPC in the seminal 1997 
manuscript45, and early outgrowth CAC in fact more closely resemble heterogeneous 
populations of VEGF-activated monoctyes46-49. Nonetheless, culture-expanded CAC 
populations derived primarily from CD14+ monocytes have been shown to be an 
important circulating angiogenic cell type40,50,51. UCB ALDHhi cells and ex vivo-expanded 
HPC do not contain notable CD14+ monocytes, an important distinction between UCB 
ALDHhi cells and CAC broadly. In addition our ALDHhi cell-derived HPC are generated 
using traditional hematopoietic expansion conditions whereas CAC are expanded using 
angiogenic growth factors. Both CAC and CFU-Hill cells have been shown to play a role 
in paracrine support of angiogenesis and vascular regeneration44,47,48. More generally, 
ALDHhi cells are different from CAC or CFU-Hill cells in that ALDHhi selection depletes 
mature macrophages and lymphocytes, which are known to be constituent cells types of 
those other angiogenic cell populations. However, both CFU-Hill and CAC include 
hematopoietic progenitor cells, which would have high ALDH activity, indicating some 
overlap in these pro-angiogenic but non-vessel integrated cellular populations. Since 
selection of high ALDH activity isolates cells with progenitor cell function, it remains 
possible that ALDHhi cells or expanded HPC differentiate into mature effectors like 
monocytes or macrophages in vivo which may contribute to improved revascularization 
and perfusion after transplantation. However, whether the vascular regenerative effects of 
UCB ALDHhi cells or expanded HPC is mediated directly by the transplanted cells or by 
differentiated progeny after transplantation remains to be elucidated after future studies.  
5.3 Future Directions 
Our screening approach to identify secreted soluble factors that might modulate vascular 
regeneration was limited by availability of panel candidate factors. To identify a more 
global profile of blood-derived progenitor cell paracrine factors that modulate vascular 
regeneration,  I propose the development of a proteomic approach to identification of the 
complete secretome of UCB ALDHhi cells, expanded HPC or ALDHhi MSC. Other 
groups have done similar proteomic screening to identify the secretome of human 
embryonic stem cells52, EPC46,53, and to identify stem cell-mediated cytokine deposition 
in extracellular matrix54,55. Identification of a global secretory profile of angiogenic 
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hematopoietic cells including UCB ALDHhi cells and ex vivo-expanded HPC will help 
determine the mechanisms by which blood cell-mediated vascular regeneration can occur 
and will help direct future development of rational cell, peptide or drug therapies for 
CVD.  
Beyond identification of the paracrine and juxtacrine factors that regulate angiogenic 
blood cell-mediated vascular interactions in ischemic disease, I propose that future cell 
therapy clinical trails should only be undertaken on cell types with better characterized 
molecular mechanisms of action to prevent unnecessary expenditures on suboptimal 
cellular populations. For this reason, gain and loss-of-function studies on critical 
paracrine mediators should be performed on candidate cellular populations to develop a 
more in depth understanding of cell-mediated vascular regeneration after acute and under 
chronic ischemic conditions. Better understanding of the molecular mediators regulating 
effective regeneration could also direct possible future applications of autologous cell 
therapies with ex vivo or correction of CVD-associated angiogenic cell dysfunction.  
A limitation of my mouse model for investigating potential cell therapy for CAD or PAD 
is that femoral artery ligation induces an acute ischemic injury and does not recapitulate 
the atherosclerotic chronic disease condition. The most common mouse models used to 
assess atherosclerosis are the apolipoprotein E-deficient (ApoE-/-) and low density 
lipoprotein receptor knockout (LDLR-/-)56-58. The ApoE knockout model is characterized 
by spontaneous development of atheromatous lesions, the development of which is 
accelerated on a Western diet57. More recently, investigations have combined the ApoE 
knockout mice model of atheroscelosis with the acute injury model of femoral artery 
ligation59. Moreover, one group demonstrated that transplantation of CD34+/M-cadherin+ 
BM-derived progenitor cells promoted increased arteriogenesis in the ischemic hindlimb 
of ApoE-/- mice with surgically-induced unilateral hindlimb ischemia. These findings 
indicate that a population of hematopoietic progenitor cells promotes vascular 
regeneration in a chronic atheromatous model of hindlimb ischemia. I propose 
investigating application of UCB ALDHhi cells, HPC, and ALDHhi MSC in similar 
models of chronic ischemic disease to further confirm my findings. 
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Recently, progress has been made in advancing the effectiveness of ex vivo expansion of 
hematopoietic stem and progenitors cells. A notable example of these novel factors are 
the aryl hydrocarbon receptor antagonists which have been shown to dramatically 
increase the expansion of hematopoietic stem cells60. Moreover, the Sauvageau lab has 
recently identified many new factors involved in HSC regulation61. Beyond new small 
molecule and protein mediators of HSC/HPC expansion, novel ex vivo culture techniques 
have augmented our ability to increase the number of progenitor cells available after 
expansion. The Zandstra group demonstrated recently that using a batch-fed culture 
system which reduces accumulation of autocrine inhibitory factors that dampen 
expansion significantly increases expansion rates of HPC62,63. Use of these novel 
expansion strategies will augment our ability in the future to increase the number of cells 
available for cell therapy in disease conditions beyond simple HSC transplantation for 
hematological disorders.  
As the key cellular mediators of progenitor cell vascular regeneration are better 
characterized and the molecular mechanisms are elucidated it will become increasingly 
feasible to consider ex vivo bio-engineering approaches to develop de novo blood vessels 
for clinical application. As new scaffolds are identified and characterized such as 
decellularized blood vessel explants64, our increased understanding of the important cell 
types in vascular regeneration will help advance possible autologous seeding with BM or 
blood-derived cells before scaffold implantation. Moreover, it is important to recognize 
that sufficient vascularization is necessary for long-term successful engraftment of many 
tissue transplant strategies broadly65. Thus, it will be increasingly important to understand 
possible autologous or allogeneic cell sources that may augment vascularization of tissue 
grafts. Indeed, in the practice of reconstructive plastic surgery it is well recognized that 
proper vascularization is a limiting factor in the implementation of many promising tissue 
engineering applications66-68. This demonstrates the importance of a better understanding 
of the cellular mediators of vascular regeneration beyond vascular disease as a key 
component of regenerative medicine broadly. The work presented in my thesis has 
advanced our understanding of the particular subpopulations of blood derived cells that 
help mediate a vascular regenerative niche and demonstrated the effectiveness of UCB 
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ALDHhi cells, ex vivo-expanded HPC and ALDHhi MSC for regenerative medicine 
applications.  
5.4 Conclusions 
Overall, the findings presented in this thesis demonstrate that UCB cells with high ALDH 
activity are a readily available population of pro-angiogenic cells which can be expanded 
in ex vivo culture and present a promising source for cell therapy applications in 
treatment of CVD. Moreover, I demonstrated that high ALDH activity identifies 
subpopulations of progenitor cells with increase vascular regenerative functions from 
UCB HPC and also from BM MSC. My work has advanced the development of further 
preclinical characterization of candidate cell populations and biomarkers for the future 
development of allogeneic and autologous cell therapy.  
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Appendix 1. Isolation of Human Umbilical Cord Blood Aldehyde Dehydrogenase 
Expressing Progenitor Cells That Modulate Vascular Regenerative Functions in 
vitro and in vivoiii 
David M. Putman and David A. Hess 
 
                                                
iii This appendix has been previously published and is reproduced here with permission.  
Putman DM, Hess DA. Isolation of Human Umbilical Cord Blood Aldehyde Dehydrogenase Expressing 
Progenitor Cells that Modulate Vascular Regenerative Functions In Vitro and In Vivo. Current Protocols in 
Stem Cell Biology. 2013. 25:2A.10.1–2A.10.19 
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ABSTRACT 
This unit describes the isolation and application of human umbilical cord blood 
progenitors cells to modulate vascular regenerative functions using in vitro co-culture 
systems and in vivo transplantation models.  Using aldehyde dehydrogenase as a marker 
of stem cell function, blood-derived progenitors can be efficiently purified form human 
umbilical cord blood using flow cytometry.  We describe in vitro approaches to measure 
cell-mediated effects on the survival, proliferation and tube forming function of 
endothelial cells using growth rate assays and Matrigel tube forming assays. 
Additionally, we provide a detailed protocol for inducing acute unilateral hindlimb 
ischemia in immune-deficient mice to assess progenitor cell modulated effects on 
vascular regeneration by tracking the recovery of blood flow using non-invasive laser 
Doppler perfusion imaging.  Collectively, we present combined in vitro and in vivo 
transplantation strategies for the pre-clinical assessment of human progenitor cell-based 
therapies to treat ischemic disease.  
Keywords: aldehyde dehydrogenase • stem cells • umbilical cord blood • critical limb 
ischemia • angiogenesis 
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INTRODUCTION 
This section describes the isolation and application of pro-angiogenic progenitor cells 
from human umbilical cord blood (UCB) for the development of cellular therapies to 
treat ischemic vascular diseases. Angiogenesis, defined as the sprouting of new blood 
vessels from pre-existing vessels, represents a central process for tissue repair, and allows 
the delivery of circulating pro-angiogenic progenitor cells from multiple lineages to form 
a vascular regenerative microenvironment (Rafii and Lyden, 2003).  
Due to recent widespread initiatives to HLA-phenotype and cryopreserve human UCB in 
North America and Europe, UCB now represents a readily available source of progenitor 
cells for cell therapy applications. Umbilical cord blood represents a rich and renewable 
source of hematotopoietic (HPC) and endothelial (EPC) progenitor cells that demonstrate 
a variety of pro-angiogenic functions. Early in ontogeny and untouched by chronic 
vascular disease-related pathologies, human UCB contains expandable precursor 
populations of endothelial cells (EC) that represent the building blocks of neovessels 
(Asahara et al., 1999; Asahara et al., 1997) and early myeloid progenitor cells that 
provide paracrine support of EC survival and vessel forming functions (Putman et al., 
2012).  
This unit focuses on the prospective isolation and functional characterization of 
progenitor cells from human UCB. First, we describe fluorescence activated cell sorting 
(FACS) of lineage depleted UCB mononuclear cells using high aldehyde dehydrogenase 
(ALDHhi) activity, a conserved stem cell function that enriches for HPC and EPC 
frequencies. Second, we outline co-culture strategies to determine the paracrine 
communication between signal-sending progenitor lineages that support signal-receiving 
EC survival, proliferation and tube-like structure formation in vitro. Third, we describe in 
detail, human progenitor cell transplantation methodologies into immunodeficient 
(NOD/SCID) models of critical limb ischemia induced by unilateral femoral artery 
ligation and transection. These models have been optimized to permit the survival and 
function of delivered human progenitor cells in areas of ischemia, and allow the temporal 
quantification of blood flow recovery in live mice using laser Doppler perfusion imaging, 
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coupled with detailed characterization of human cell engraftment correlated with the 
induction of capillary formation in vivo. Collectively, these technologies represent 
valuable platforms to dissect the molecular cross-talk between vascular and 
hematopoietic progenitor subsets during regenerative angiogenesis. These vascular 
regenerative processes may also be manipulated to promote the repair of ischemic tissues 
including the damaged myocardium after infarct, and the recovery of vascular function 
following stroke. The protocols presented below are detailed descriptions of those 
previously published by our group (Cappocia et al., 2009, Putman et al., 2012). 
NOTE: All cell isolation and culture procedures are to be performed in a Class II 
biological safety cabinet. 
NOTE: Aseptic technique is required for handling of all the solutions and equipment in 
contact with living human cells. 
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BASIC PROTOCOL 1 
ISOLATION OF UMBILICAL CORD BLOOD PROGENITOR CELLS WITH 
HIGH ALDEHYDE DEHYDROGENASE ACTIVITY 
Using high aldehyde dehydrogenase (ALDHhi) activity, a cytosolic enzyme involved in 
retinoic acid metabolism and cellular self-protection from oxidative damage (Hess et al., 
2004; Hess et al., 2006; Cai et al., 2004; Pearce et al., 2005; Storms et al., 2005; Corti et 
al., 2006), and progenitor-associated cell surface markers (CD34, CD133), we have 
developed fluorescence activated cell sorting (FACS) strategies to enrich for progenitor 
cells from hematopoietic, endothelial, mesenchymal lineages (Capoccia et al., 2009). 
This isolation is non-toxic and relies on the principle that ALDH-activity is 
downregulated during progenitor cell differentiation (Storms et al., 1999). Thus, high 
ALDH-activity efficiently isolates highly-purified and viable progenitor subtypes for 
characterization of pro-angiogenic functions using traditional molecular approaches (cell 
surface marker analyses, Affymetrix microarray, cytokine production by ELISA or 
western blot; not discussed in this unit). Furthermore, these starting cell populations can 
be used to establish highly proliferative hematopoietic and endothelial progenitor cultures 
amenable to co-culture analyses and transplantation into immunodeficient mouse models 
of limb ischemia described in detail below. 
Materials 
50mL heparinized syringe (250U) with 16-gauge needle 
15mL or 50mL conical tubes 
liquid pipettor and sterile 25mL, 10mL, and 5mL pipettes 
1-mL and 200-µL pipettors and sterile filtered tips 
RosetteSep® human UCB progenitor enrichment cocktail (Stem Cell Technologies (SCT), 
cat. no. 15026) 
peripheral buffered saline (PBS) + 2% fetal bovine serum (FBS HyClone) 
Ficoll-Hypaque gradient (density 1.077 g/L, SCT) 
Sterile glass pipettes 
EasySep® Red Cell Lysis Buffer (SCT, cat. no. 20110) 
Beckman GPR centrifuge with horizontal rotor 
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hemacytometer and inverted light microscope (Zeiss), or automated cell counter 
Isolation of UCB Lineage Depleted Mononuclear Cells 
1. Using a 50mL heparinized syringe, draw 50mL of human UCB by venipuncture 
from the umbilical vein of clamped placental and umbilical cord obtained 
immediately after live birth. UCB can be stored at room temperature for up to 24 
hours prior to cell processing without a significant loss of viability. 
2. To deplete mature T-lymphocytes, B-lymphocytes, monocytes, NK-cells and red 
blood cells (optional), transfer UCB sample from syringe into 2-50mL conical 
tubes and add RosetteSep™ Human UCB Progenitor Enrichment cocktail at 
10µL/mL and incubate for 20 min at room temperature.  
 
RosetteSep™ is comprised of tetrameric antibody complexes recognizing CD2, 
CD3, CD14, CD16, CD19, CD24, CD56, CD66b and glycophorin A. Unwanted 
mature cells are pelleted with red blood cells after Ficoll-Hypaque centrifugation 
(see below).  
3. Add an equal volume of room temperature PBS and mix well. 
4. Slowly layer 10mL UCB/PBS mixture on the surface of 5mL of Ficoll-Hypaque 
solution at room temperature. For large volume samples 30mL UCB/PBS mixture 
can be layered on the surface of 15mL Ficoll Hypaque solution.  
To maintain the Ficoll-Hypaque / blood interface, hold the receiving tube at a 45º 
angle and allow the UCB mixture to carefully flow down the side of the tube to 
settle on the top of the Ficoll-Hypaque without mixing. 
5. Centrifuge for 20-30 min at 450 x g, at 20ºC, with no brake.  
Human UCB progenitor cells are enriched in the cloudy mononuclear cell layer, 
above the pelleted RBC and Ficoll-Hypaque and below the clear plasma layer.  
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6. Using a sterile pipette, carefully remove the mononuclear cell layer by gently 
swirling the pipette tip as cells are drawn, and transfer mononuclear cell layer to a 
fresh 15mL or 50mL conical tube. 
7. Wash cells by adding excess PBS + 2% FBS (>3 times the volume of the 
mononuclear cell layer) and centrifuge for 7 min at 240 x g, at 20ºC, with the 
brake on. After centrifugation, aspirate the supernatant, and resuspend the cell 
pellet in PBS + 2% FBS, repeat this step 2 times. 
The washing step described above is required to reduce platelet contamination 
and cellular debris from the mononuclear cell layer and wash remaining Ficoll-
Hypaque solution from the sample.  
8. If visible red cell contamination occurs in the washed mononuclear cell sample 
(pink tinge in soluion), lyse residual RBC by adding 25mL of 1X red cell lysis 
buffer solution. Allow to stand for 5 min at room temperature, add 25mL of PBS 
+ 2% FBS, and centrifuge for 7 min at 240 x g. After centrifugation, aspirate the 
supernatant and resuspend the cell pellet in PBS + 2% FBS, repeat this step 2 
times. 1-2 rounds of red cell lysis may be required. 
Some UCB samples may contain a significant amount of nucleated red blood cells 
that resist lysis. However, after 2 rounds of lysis and washing the red 
cell:leukocyte ratio should be <2:1, and manual hemacytometer counts will allow 
for an accurate quantification of lineage depleted mononuclear cell numbers. 
9. After the final wash, resuspend the purified mononuclear cells in 1mL of 
Aldefluor™ assay buffer. Count viable cell numbers by trypan blue exclusion 
using a hemocytometer or an automated cell counter.  
A typical 50mL UCB sample contains 200-300 x 106 undepleted mononuclear 
cells. After RosetteSep™ (as above) the total mononuclear cell number is reduced 
to 5-50x106 lineage depleted cells allowing for a more efficient isolation of 
ALDH-expressing cells by FACS as described below. 
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SUPPORT PROTOCOL 1 
CELL SEPARATION BASED ON ALDEHYDE DEHYDROGENASE ACTIVITY 
The Aldefluor™ reagent kit is used to identify UCB progenitor cells that exhibit high 
activity levels of the intracellular enzyme ALDH. Activated Aldefluor™ reagent is an 
aminoacetaldehyde moiety conjugated to a Bodipy fluorochrome (BAAA). BAAA is 
lipid soluble and freely diffuses into intact and viable mononuclear cells. In the presence 
of ALDH, BAAA is converted into Bodipy-aminoacetate (BAA-) anion, and trapped 
within the cell due to its negative charge, allowing the accumulation of fluorescent 
product proportional to the amount of active ALDH within the cell. BAA- can be cleared 
from the cell acting as a substrate for ATP-binding cassette (ABC) transporters. During 
the Aldefluor reaction, active efflux of BAA- is minimized by an efflux inhibitor 
contained within the Aldefluor assay buffer. After cell sorting, this pharmacological 
inhibition can be removed by washing in PBS. Aldeflour reagent is not cytotoxic. Thus, 
viable progenitor cells with high ALDH activity can be purified from highly 
heterogeneous cell populations without affecting progenitor cell functions in subsequent 
assays. A specific inhibitor of ALDH, diethylaminobenzaldehyde (DEAB), is used to 
control for background fluorescence. The Aldefluor™ separation protocol detailed below 
has been optimized for human umbilical cord blood, but is also applicable to the isolation 
of ALDHhi cells from human bone marrow. 
Materials 
Aldefluor™ kit (Stem Cell Technologies, cat. no. 01700) containing: 
 Dry Aldefluor™ reagent, 50 μg 
DEAB inhibitor, 1.5 mM, in 95% ethanol, 1 mL 
2N HCl, 1.5 mL 
DMSO, 1.5 mL 
Aldefluor™ Assay Buffer, 4 x 25 mL 
High-speed fluorescence activated cell sorter, FACS Aria III (Beckton Dickenson) 
5mL conical tubes with 500µL PBS+5%FBS (for sorted cell collection) 
NOTE: Store kit reagents at 4 – 8ºC as per manufactures instructions. Do not freeze. 
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NOTE: The following protocols have been optimized for lineage depleted UCB samples. 
The protocol has been slightly modified from the manufacturers instructions to conserve 
reagents. 
Aldefluor Activation  
1. Assemble all kit reagents and warm to room temperature before use. 
2. Add 25µL of DMSO to the vial with dry Aldefluor™ reagent, mix well with 
pipettor, and let stand at room temperature for 1 minute. 
The dry Aldefluor™ reagent is an orange red powder that changes to a bright 
yellow green upon addition of DMSO. 
3. Add 25µL of 2N HCl to the Aldefluor™ vial, mix well with pipettor, and incubate 
the mixture for 15 minutes at room temperature. 
4. Add 350µL of Aldefluor™ buffer and mix well. The final concentration of the 
solubilized Aldefluor reagent is 300µM. 
5. Divide the Aldefluor™ reagent into aliquots and store at -20ºC until needed for 
the Aldefluor™ assay. 
Aldefluor™ Assay 
1. Adjust the cell sample to 5-10x106 cells/mL in Aldefluor™ assay buffer. 
2. Add 5µL of DEAB inhibitor to the DEAB control tube. Recap the tube and the 
DEAB vial immediately. 
DEAB is provided in 95% ethanol and will evaporate if not capped after use. 
3. Add 5µL of Aldefluor™ per mL of cell suspension. Mix immediately and add 
0.5mL of the cell and Aldefluor™ mixture to the DEAB control tube and recap 
each tube. Incubate each tube for 30 min at 37°C (do not exceed 60 min). 
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The ALDH enzymatic reaction begins immediately upon the addition of the 
activated substrate to the cell suspension. Because the DEAB tube is important in 
establishing the sort gates for the ALDHlo versus the ALDHhi populations, it is 
important that the aliquot of Aldefluor™ reacted cells is added to the DEAB 
control tube without delay. 
4. After incubation, centrifuge tubes at 450 x g for 7 min and remove supernatant. 
Resuspend each tube in 0.5mL of Aldefluor™ assay buffer  
5. Count viable cell numbers using trypan blue exclusion using a hemocytometer or 
an automated cell counter. For optimal sorting concentration adjust Aldefluor™ 
treated cell suspension to 30-40x106 cells/mL in Aldefluor™ assay buffer and 
store on ice or at 4°C until cell sorting. 
If cell sorting using ALDH activity in combination with cell surface markers 
(CD34, CD133, etc) is to be performed, aliquot 0.5 mL of Aldefuor™ treated cells 
to individual tubes and add 2-5µL of PE- or APC conjugated antibody to cell 
suspension. To prevent efflux of Aldefluor™ product it is important to perform 
antibody incubation (20-30 min) in Aldefluor™ assay buffer. Whenever possible 
keep the cells on ice or at 4°C to minimize fluorescent product efflux. 
Cell Sorting Based on ALDH activity 
1. Generate a side scatter (SSC) versus forward scatter (FSC) dot plot. In setup 
mode, place the DEAB control sample on the flow cytometer and adjust the 
voltages to center the nucleated cell populations to the to the center of the SSC 
versus FSC plot. Create region (R1) that includes the nucleated cell population 
and excludes anucleated erythrocytes and cell debris based on the UCB FSC 
versus SSC profile (Fig. 1A).  
Granular cells show high SSC and FSC. Nucleated cells (monocytes, 
macrophages, T-lymphocytes, B-lymphocytes, and progenitor cells) show low 
212 
 
SSC with intermediate FSC. Platelets, erythrocytes and cell debris show low 
SSC and FSC (Fig. 1A). 
2. Create a SSC versus Aldefluor™ fluorescence dot plot (Fig. 1B) gated on R1. In 
set-up mode, adjust the Aldefluor™ fluorescence photomultiplier tube voltage 
so that the stained cells in the DEAB control tube are centered in the third log 
decade on the dot plot (Fig. 1B). Create a region R2 that includes DEAB-
inhibited cells with low SSC and low Aldefluor™ fluorescence. Switch the flow 
cytometer to data acquisition mode and collect 100,000 events in the R1 region. 
Even in the DEAB-inhibited sample, all live nucleated cells will demonstrate 
Aldefluor™ fluorescence. Thus, the DEAB analyses (Aldefluor™ fluorescence 
in the presence of DEAB inhibitor) is a necessary control to distinguish 
background cellular fluorescence (ALDHlo cells) versus cells with high ALDH-
activity (ALDHhi cells) using the test sample. 
3. In set-up mode, place the test sample on the flow cytometer. Without adjusting 
the photomultiplier voltage, create a region (R3) that includes low SSC cells 
with bright Aldefluor™ fluorescence (ALDHhi cells). Switch the flow cytometer 
to data acquisition mode and collect 100,000 events in the R1 region. 
4. In sorting mode with the sample chiller on, load ALDHlo cell and ALDHhi cell 
collection tubes each containing 500µL Aldefluor™ assay buffer, and collect 
the ALDHloSSClo cells (R1 and R2) and ALDHhiSSChi cells (R1 and R3) at 
10,000-20,000 events per second (Fig. 1C). 
5. After cell sorting, perform a purity check on the collected ALDHlo cell versus 
ALDHhi cell tubes. Cell populations should be >99% pure. 
6. Centrifuge sorted cell tubes at 240 x g for 7 min and aspirate supernatant. Wash 
cells with 5mL PBS + FBS to remove ABC-transporter inhibition and allow the 
efflux activated Aldefluor™ from viable cells.  
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Sorted cell populations are undamaged by cell sorting and ready for use in the 
in vitro co-culture or in vivo transplantation experiments described below. In 
addition, UCB ALDHhi cells can be used to establish highly-proliferative 
cultures of hematopoietic progenitor cells (Fig. 1D) in X-Vivo 15 basal media + 
10ng/mL SCF, TPO, Flt-3 ligand (Lonza, cat. no. 04-744Q) on fibronectin 
coated plates, or endothelial progenitor cells (Fig. 1E) in EGM-2 media + 
EGF, IGF, FGF, VEGF (Lonza, cat. no. CC-3162) on fibronectin-coated plates. 
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Appendix 1. Figure 1. Flow cytometric isolation of human UCB mixed progenitor 
cells using high aldehyde dehydrogenase activity.  
(A-C) Representative flow cytometry plots showing the selection of ALDHlo versus 
ALDHhi mononuclear cells after lineage depletion. (D) Representative photomicrograph 
of human hematopoietic progenitors from ALDHhi UCB in culture.  (E) Representative 
photomicrograph of endothelial progenitor cells in plastic adherent culture. 
 
  
215 
 
  
216 
 
BASIC PROTOCOL 2 
CO-CULTURE OF UCB ALDHhi CELLS TO ASSESS PARACRINE EFFECTS 
ON ENDOTHELIAL CELL SURVIVAL, PROLIFERATION, AND FUNCTION  
This protocol was adapted to characterize paracrine and juxtacrine support provided UCB 
progenitor cells on mature endothelial cell survival, proliferation and tubule formation in 
vitro (Putman et al., 2012).  However, these co-culture systems could easily be adapted to 
test the potential vascular regenerative paracrine functions of any cell type of interest. 
NOTE: For this protocol human microvascular endothelial cells (HMVEC) are selected 
to model capillary or small vessel pro-angiogenic responses. Conversely, human 
umbilical vein endothelial cells (HUVEC) are used to model pro-angiogenic responses by 
larger vessel-resident endothelial cells. 
Materials 
Endothelial cells (HUVEC or HMVEC expanded in adherent culture, ATCC) 
EBM-2 Basal Medium (Lonza, cat. no. CC-3156)  
EGM-2 MV SingleQuot Kit & Growth Factors (Lonza, cat. no. CC-4147) 
 Contains a cocktail of growth factors (EGF, VEGF, FGF, IGF-1) and fetal bovine 
serum (5% FBS) supplements to be added to basal media. 
Tissue culture treated dishes/plates (Corning; 75cm2 flasks for expansion, cat. no. 
430641, 12 well plate – 3512, 24-well plate – 3524 for co-culture assays) 
Phosphate Buffered Saline (PBS, prepared ahead) 
Trypsin Solution (Gibco, TrypLE™ Express (1X), no Phenol Red, cat. no. 12604-013) 
Phosphate Buffered Saline + 5% fetal bovine serum (PBS+FBS, prepared ahead) 
ALDH-activity purified UCB cells (ALDHhi and ALDHlo from Basic Protocol 1) 
50mL conical centrifuge tubes 
Hanging polycarbonate transwell inserts (3µm pore, Corning, Cat. no. 3402) 
Matrigel™ Basement Membrane Matrix - Growth Factor Reduced (BD Biosciences, cat. 
no. 356231) 
Pipettors and 1000µL, 200µL, 20µL sterile tips 
Beckman GPR centrifuge with horizontal rotor 
hemacytometer and inverted light microscope or automated cell counter 
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Cell Culture Incubator at 37°C, 5% CO2 
Endothelial Cell Harvest 
1. Aspirate growth media (EGM2-MV) and gently rinse culture dish with 10mL 
pure PBS (no FBS). 
2. Add 1mL Trypsin solution to culture dish and swirl to cover surface. Incubate at 
room temperature or 37°C for 2-5 min to dissociate adherent HMVEC. 
3. If cells do not lift easily from the growth surface you can force cell into 
suspension by hitting the base of the flask against the palm of your hand.  
4. Once cells have lifted from flask (check visually on inverted light microscope) 
add 10mL PBS + 5% FBS solution and mix by repeated pipetting. Check flask to 
ensure no cells are left behind uncollected. 
5. Collect cells into a 50mL conical tube and centrifuge at 240 x g for 7 minutes. 
6. Aspirate supernatant and resuspend cells in 1 mL of EBM2 (Basal EC Media). 
7. Count cells using trypan blue exclusion using a hemocytometer and light 
microscope or automated cell counter.  
8. Distribute cells into a 50mL tube for each media condition to be used.  
Adjust the ratio of cell suspension added to each tube depending on number of 
wells needed for assay: 
I. GF+ Serum+ (EGM2-MV; fully supplemented) 
Positive control conditions for optimal EC survival and growth. 
II. GF- Serum- (EBM2; unsupplemented basal media) 
Negative control conditions for baseline EC survival. 
III. GF+ Serum- (EBM-2 + growth factors) 
Suboptimal conditions for EC growth without serum. 
IV. GF- Serum+ (EBM-2 + 5% FBS) 
Suboptimal conditions for EC growth without growth factors. 
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9. Spin all tubes at 240 x g for 7 minutes. 
10. Aspirate supernatants and resuspend cells in appropriate media at 106 cells/mL 
Endothelial Cell Growth Rate Assay 
1. Seed 40x103 HMVEC per well in tissue culture-treated 12-well plate. 
Cell densities have been optimized for a 12 well plate format and should be 
adjusted accordingly for culture in 6 or 24 well plates. 
2. Under each growth condition, add 105 ALDHhi or ALDHlo cells into porous 3µm 
hanging transwells suspended above the HMVEC in the 12 well plate (Fig. 2A). 
3. Incubate cell culture dishes at 37°C for 72 hours. 
4. At 24, 48, and 72 hours, observe cells under stereomicroscope and record 
photomicrographs (Fig. 2B).   
5. Enumerate trypan blue excluding HMVEC by blinded hemocytometer counts or 
automated cell counting to determine the total number and frequency of viable 
versus dead cells. 
Matrigel Tubule Formation Assay 
1. Thaw matrigel overnight in ice bucket in fridge. 
2. Plate 200μL into each well of a 24 well plate. Carefully, pipet Matrigel to evenly 
cover the base of the well. 
It is important to prechill your plate and pipet tips in the fridge to prevent the 
Matrigel from solidifying prematurely. Keep plate on an ice block, and Matrigel 
in ice bucket. Shake the dish if needed to evenly coat well. 
3. Incubate plate at 37°C for at least 30 minutes to allow matrigel layer to set before 
plating cells. 
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4. Add appropriate media to each well up to a total volume 400μL. 
EGM2-MV; positive control 
EBM2; negative control and basal media for cell supplementation 
5. Seed 50x103 HMVEC to each Matrigel-coated well. 
6. Add 20x103 ALDHhi or ALDHlo cells. 
7. Observe under stereomicroscope and obtain photomicrographs of 3 fields of view 
per well of matrigel at 24, 48 and 72 hours (Fig. 2C). 
8. Enumerate number of branch points per field of view and quantify average tube 
length using image analysis software such as ImageJ. 
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SUPPORT PROTOCOL 2 
PREPARING CONDITIONED MEDIA TO ASSESS PARACRINE SUPPORT OF 
ENDOTHELIAL CELL FUNCTION  
If desired, basic protocol 2 can be adapted for use with cell-conditioned basal media, 
prepared in advance, in place of direct co-culture in hanging transwell inserts (Fig. 2A). 
These assays demonstrate the added benefit of assessing only paracrine effects without 
the possibility of cell migration through the transwell.   
1. Seed standardized number of ALDHlo or ALDHhi cells into appropriate sized 
culture dish containing EBM-2, basal media without serum or growth factors. 
For optimal cell density, seed 400-500x103 cells in a T75-flask (10-15mL), 150-
200x103 cells in a T25 flask (3-5mL), or 50x103 cells in a 6 well plate (1mL). 
2. Incubate culture for 24-48 hours at 37ºC.  
3. Using a pipet collect conditioned media into a 50mL conical centrifuge tube and 
spin at 450 x g for 5-7 minutes.  
4. Collect supernatant and aliquot conditioned media into polystyrene tubes.  
5. Store conditioned media at -30ºC until use.  
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Appendix 1. Figure 2. Co-culture assays to assess cell-mediated effect on survival 
proliferation tube forming capacity of endothelial cells  
(A) Schematic overview of hanging transwell co-culture and cell conditioned media 
assays to assess endothelial cell proliferation. (B) Representative photomicrograph of 
human endothelial cells cultured on plastic. (C) Representative photomicrograph of 
human endothelial cells growing on a thin layer of matrigel to assess modulation of tube-
like structure formation.  
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BASIC PROTOCOL 3 
MURINE FEMORAL ARTERY LIGATION AND EXCISION AND 
QUANTIFICATION OF VASCULAR REGENERATION IN VIVO  
This protocol outlines a surgical procedure for inducing unilateral acute hindlimb 
ischemia in immunodeficient mice. This protocol includes a double ligation with 
complete resection of the fermoral artery and vein. This procedure induces more severe 
ischemia than single ligation or non-resecting models. We have used immune deficient 
NOD/SCID mice (Jackson Laboratory, Bar Harbor, ME) to allow the survival and 
function of xenotransplanted human progenitor cells with reduced rejection due to 
complete knockout of T- and B-lymphocyte function (SCID mutation) and reduced innate 
immunity (NOD mutaton).  However, this protocol can be applied to any 
immunodeficient mouse strain (NUDE, NOD/SCID IL-2R g null, NOD/SCID/MPSVIII 
mice) noting that there are strain specific differences in the magnitude and rate of 
recovery of perfusion following human cell transplantation. 
NOTE: The procedures described for the transplantation of human progenitor cells into 
highly immunodeficient mouse models of limb ischemia requires a dedicated barrier 
facility with an aseptic surgical and monitoring suite and sterile housing using hepa-
filtered ventilated racks.  
Materials 
Ketamine hydrochloride (100mg/mL, 60-70mg/kg) 
Xylazine (20mg/mL, 2-4 mg/kg) 
Eye lubricant (Allergan Refresh Lacrilube) 
Surgical scissors and forceps 
Sterile cotton tipped applicator  
5-0 Silk Sutures  
Nexaband® Liquid Topical Tissue Adhesive (Abbott Animal Health) 
Microsugical inverted microscope (Nikon SMZ2B)  
Microinjection Syringes 
Mobile Laboratory Animal Anesthesia System (VetEquip, cat. no. 901807) 
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Electric hair clippers (Wahl) 
Hair removal cream (Nair) 
Bacteriostatic soap 
Isopropyl alcohol 
Betadine solution 
Sterile cotton tipped applicators  
Cautery tool (Alcon Surgical Optemp II) 
Bupreorphine (0.1 mg/kg, subcutaneous) 
Heat Pad 
Laser Doppler imager (Moor LDI2) 
OCT tissue embedding medium 
Tissue moulds 
Liquid nitrogen 
Dry ice 
Cryostat microtome 
Mouse anti-human HLA-A,B,C antibody (1:500, Beckton Dickenson, cat. no. 557347) 
Rat anti-mouse CD31 antibody (1:100 Beckton Dickenson, cat. no. 550274) 
vWF antibody (1:200 Millipore, cat. no. AB7356) 
DAPI reagent 
Immunofluorescent Microscope (Zeiss AxioScope™ or similar) 
Anesthesia 
3 Induce initial anesthesia by intraperitoneal injection of ketamine hydrochloride 
(60-70mg/kg) and xylazine (2-4mg/kg) solution. 
For ease of use and to reduce the number of injections needed prepare a working 
solution of ketamine and xylazine in saline or sterile water to use to 
intraperitoneal injection. 
4 Place mouse into anesthesia induction chamber and fill chamber with 2-5% 
isoflurane in 100% O2 at a flow rate of 0.8L/min. 
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5 Once mouse is unresponsive to external stimuli by foot pinch, place mouse on 
surgical surface in supine position and immobilize the right hindlimb by taping the foot to 
the surgical surface. 
6 Maintain anesthesia for the duration of the surgical procedure using a nose cone 
with 1-2% isoflurane in 100% O2 at a flow rate of 0.8L/minute. 
Surgery 
1. Apply bepanthene ophthalmic ointment to the eyes to prevent drying during 
surgery. 
2. Shave the hair from the lower limb and inguinal region using an electric shaver 
for bulk hair removal. Completely remove residual hair from lower limb by 
applying Nair hair removal cream briefly (1 min). 
3. Wipe away excess hair removal cream and clean the skin and prepare surgical 
field with three rounds of bacteriostatic soap wash followed by isopropyl alcohol 
swab and betadine scrub.  
From here forward the protocol is most easily completed using a dissecting 
microscope. 
4. Carefully make a 10-15mm longitudinal incision in the skin following the femoral 
vessel from the inguinal crease distally down the midpoint of the thigh using 
surgical scissors and forceps.  
5. Use moistened sterile cotton tipped applicator and surgical scissors to gently clear 
subcutaneous fat away to expose the femoral artery and vein and associated 
neurovascular bundle (Fig. 3A).  Locate the superficial epigastric artery branch 
point as a landmark. 
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6. Using the cautery tool, cauterize transversely the subcutaneous fat and the 
superficial epigastric artery. This will expose the muscle and neurovascular 
bundle underneath.  
7. Carefully separate the femoral nerve from the femoral artery and vein starting 
near the groin and moving distally towards the knee using forceps and scissors.  
Avoid damaging the femoral nerve while separating it from the vessels. 
8. Thread silk suture under the femoral artery and vein and gently slide it proximally 
toward the groin to maximize the length of the femoral artery and vein to be 
excised. Ligate the artery and vein using double surgical knots.  
9. Thread silk suture under the femoral artery and vein and gently slide it proximally 
to the bifurcation of the popliteal and saphenous arteries that descend into the calf. 
Ligate the artery and vein using double surgical knots.  
10. Using the cautery tool, cauterize the collateral vessels that emerge from the 
femoral artery between the ligation sites.  
11. Carefully resect and excise the femoral artery and vein bundle between ligation 
sites with surgical scissors. Typically, it is possible to excise a 5mm segment of 
the femoral artery and vein between ligation sites. Carefully check the ligation 
site for full occlusion and for any signs of bleeding. 
12. Close skin incision using silk sutures and/or Nexaband tissue glue. 
13. For post-operative pain management, administer buprenorphine (0.1mg/kg) by 
subcutaneous injection. 
14. Transfer mouse to recovery cage with direct access to water and food and monitor 
the mice for 30-60 min ensuring they emerge from anesthesia and retain use of the 
surgical limb. 
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It is expected that the mice will show reduced mobility and use of the ischemic 
limb after surgery. Mice will demonstrate a notable limp for 24-48 hours post-
operatively. Gradually, mice will recover full mobility in the surgical limb. Be 
sure to monitor the incision sites daily for up to 7 days and look for signs of 
bleeding or excessive grooming that may result in the re-opening of the incision. 
If signs of incision damage occur, move mouse to a separate cage without 
littermates to allow healing. 
15. Allow mice to recover for 24 hours before administration of the compound or cell 
type of interest to assess effects on the recovery of blood flow by laser Doppler 
perfusion imaging of the mouse hindquarters as described below.   
Useful administration techniques include intravenous tail vein injection to deliver 
cells or compounds to the general circulation to study the recruitment of injected 
cells to the ischemic region. Alternatively, direct intramuscular injection into the 
ischemic adductor or gastrocnemius muscle can be used to bypass the 
inefficiencies of cellular recruitment to the ischemic region. 
Laser Doppler Perfusion Imaging (LDPI) Analyses 
NOTE: LDPI timepoints and a representative example of the recovery of limb perfusion 
after intravenous injection of 2x105 UCB ALDHhi cells is shown in Fig. 3B. 
1. Induce anesthesia as described in the surgery section above. 
Depending on the strain of mouse used the injection of xylazine and ketamine to 
induce anesthesia may not be necessary and induction using inhaled anesthesia 
may be sufficient. 
2. Completely remove any residual hair from lower limb by applying hair removal 
cream briefly. 
Excess hair re-growth will interfere with the accuracy of the laser Doppler 
measurements. Typically, residual hair removal will be required every 1-2 weeks 
depending on mouse strain and fur color. 
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3. Transfer mouse to 37ºC draped heating plate for 5 minutes to stabilize body 
temperature. 
It is important to ensure stable body temperature in the mouse before LDPI 
scanning as decreased body will significantly alter blood flow in the hindlimbs. 
4. Maintain anesthesia with 1-2% isoflurane in 100% oxygen at 0.8L/min. 
Carefully maintain anesthetic depth to prevent scan artifact from the mouse 
moving if too lightly anesthetized or from falsely low measurement of blood flow 
if too deeply anesthetized. 
5. Place mouse in supine position under laser Doppler perfusion imager and extend 
hindlimbs.  Follow manufacturer instructions for proper calibration of laser and 
measurement of superficial blood flow using consistent settings between 
subsequent measures at later time points.  
6. Using the LDPI software acquire the perfusion image data. Adjust the background 
threshold to display LDPI flux measurements on the mouse hindquarters from the 
waist to the tips of the toes. 
7. To quantify relative blood flow in the ischemic versus the control limb set a 
region of interest on each leg between the toes and heel (Fig. 3A), and measure 
the units of flux in the ischemic limb versus the non-ischemic limb.  
8. To ensure consistent induction of acute unilateral hindlimb ischemia by the 
surgical procedures described above. Relative perfusion in the ischemic limb of 
NOD/SCID mice should be <10% of the perfusion flow in the control limb.   
9. Repeat measurement of blood flow using the identical protocol at each time point 
to track the recovery of perfusion over a 28 day time course.  
We recommend performing LDPI at post-transplantation day 0, 3, 7, 14, 21, and 
28 (Fig. 3B) in 8-10 mice per cohort to allow for statistical comparison between 
the recovery of perfusion in control (PBS injected) versus cellular transplanted 
treatments. 
Collection of Muscle Samples for Histological Analysis  
1. At the predetermined end point of your experiment, euthanize the mice by 
cervical dislocation under anesthesia or by CO2 inhalation. 
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Depending on the purpose of the experiment we routinely euthanize mice from 
each transplantation cohort at day 7; to address the recruitment of human cells to 
the ischemic region and to generate a snapshot of active vascular regenerative 
processes, at day 14 to address the survival of human cells in the ischemic region 
at the midpoint of the regenerative process, and at day 28 to document the overall 
extent of vascular recovery. At each endpoint extensive histochemical analyses 
can be performed (see below) at the site of surgery in the quadriceps muscle and 
distally in the gastrocnemius muscle. We routinely monitor human cell 
engraftment and survival, the recovery of capillary density and small neovessel 
formation, the induction of EC proliferation and prevention of apoptosis in the 
ischemic region, in order to fully document the cellular mechanisms of vascular 
recovery. 
2. Remove skin and fasciae from the legs and lower limbs of the mouse.  Using 
dissection scissors remove the superficial thigh muscles by making an incision 
beginning laterally across the knee and carefully peeling and cutting back the 
muscle from along the femur up towards the groin.  
3. Embed the muscle in OCT compound in tissue mould blocks.  Align embedded 
tissue so that the lateral cut across the knee or ankle is along the base of the block.  
4. Dissect the gastrocnemius (calf) muscle by making incisions along the tendons 
inserting at the ankle and cut proximally along the lower leg bones towards the 
knee. 
5. Embed the calf muscle in OCT compound in tissue mould blocks. Align 
embedded tissue so that the lateral cut across the knee is along the base of the 
block.  
Careful placement of each muscle sample in the tissue block allows efficient 
cross-sectional cuts through the muscle fibers during cryosectioning 
6. Quickly freeze muscle sections suspended in OCT using liquid nitrogen flash 
freeze or by placing trays on a dry ice block.  
7. Frozen tissue can be stored at -20ºC for up to 7 days. For long-term storage, 
transfer to a -80ºC freezer. 
8. Cut 10-15μm sections using a cryostat microtome at -14ºC to -18C.   Store dry 
sections at -20ºC. Transfer dry frozen sections to -80ºC freezer for long-term 
storage.  
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Human Cell Engraftment and Blood Vessel Density in Hindlimb Muscle 
Sections 
1. Following standard immunohistochemistry or immunfluorescence protocols 
(http://www.vectorlabs.com/catalog.aspx?prodID=1375) detect transplanted cell 
recruitment/engraftment using HLA-A,B,C expression to identify human cells. 
2. Similary, immunostain for mouse CD31 expression to visualize murine capillary 
beds using immunofluorescent microscopy counterstained with DAPI or light 
microscopy counterstained with hematoxylin to mark nuclei (Fig. 3C).  
3. Similarly, immunostain for mouse vWF expression to visualize larger murine 
arterioles using immunofluorescent microscopy counterstained with DAPI or light 
microscopy counterstained with hematoxylin to mark nuclei (Fig. 3D). 
This labels endothelial cells of larger higher shear stress vessels such as 
arterioles.  Whereas CD31 staining can be inconsistent in larger vessels vWF 
reliably identifies larger vessels in muscle sections (Pusztaszeri et al. 2006).   
4. Enumerate HLA-A,B,C+ human cells, CD31+ capillary structures, and vWF+ 
arterioles by blinded manual counts of 3 fields of view in each of 3 sections for 
each muscle sample. 
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Appendix 1. Figure 3. Transplantation model of acute unilateral hindlimb ischemia.  
(A) Diagram of the vasculature of the mouse hindlimb from the inguinal crease to the 
bifurcation of the femoral artery into the saphenous and popliteal arteries which descend 
into the calf and lower limb. Ligation sites for femoral artery ligation surgery are 
indicated. Representative laser Doppler perfusion images of mouse hindquarters before 
and after ligation and transection of femoral artery and vein. Regions of interest are 
selected from ankle to toe to quantify relative perfusion in the surgical limb. (B) Outline 
and suggested timing for tracking recovery of perfusion in the ischemic limb after 
surgical induction of acute ischemia. Number in lower left quadrant of each laser Doppler 
perfusion image is the ratio of perfusion in the ischemic limb to the perfusion in the 
control limb.  (C,D) Representative photomicrographs of ischemic adductor muscle 
sections stained for (C) CD31and (D) vWF. 
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COMMENTARY 
Background Information 
Ischemic disease is characterized by the reduction of blood flow to the heart or peripheral 
tissues and encompasses life-threatening disorders such as ischemic heart disease and 
critical limb ischemia. Despite advances in the management of these conditions, ischemic 
disease remains a leading causes of morbidity and mortality worldwide (Dotsenko, 2010; 
Bozdag-Turan et al., 2011). Thus, exogenous stimulation of blood vessel formation by 
cell transplantation is under intense investigation for the treatment of ischemic disease. 
Numerous studies have established the potential of transplanted bone marrow-derived 
mononuclear cells implicated in the co-ordination of regenerative angiogenesis, and have 
generated a number of clinical trials investigating treatment of cardiac (Janssens et al., 
2006; Wollert et al., 2004; Schachinger et al., 2006) and limb ischemia (Tateishi-Yuyama 
et al., 2002; Higashi et al., 2004) by transplantation. Although these studies have 
demonstrated safety in the autologous setting, they have shown only modest 
improvements in clinical endpoints (Rosenzweig, 2006). In addition, recent studies in 
patients with chronic diabetes or vascular disease-related pathologies demonstrate 
compromised progenitor cell content and function (Werner et al., 2007; Werner et al., 
2005; Fadini et al., 2006; Jialal et al.). Thus, the purification of pro-angiogenic cellular 
sub-types from non-autologous sources, and characterization of specific sub-type 
contributions during the coordination of vascular repair is warranted to improve current 
cell-based therapies for ischemic diseases. 
Using high aldehyde dehydrogenase-activity, a conserved stem cell function involved in 
the protection of long-lived cells from oxidative insult, we have identified a purified mix 
of progenitors from human BM (Capoccia et al., 2009), and from UCB (Putman et al.). 
We have shown that iv-transplanted ALDHhi mixed progenitor cells can stimulate the 
recovery of perfusion in mice with femoral artery ligation-induced limb ischemia 
(Putman et al.). However, few transplanted cells showed permanent integration into 
newly generated vascular networks. Rather, ALDHhi cells transiently recruited to the 
ischemic limb and orchestrated murine capillary formation via unidentified secretory 
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mechanisms. This concept termed “stem cell-mediated vascular regeneration” has 
become a central process for tissue repair, and provided proof-of-concept for FDA-
approval of clinical trials using autologous BM-derived ALDHhi cells to treat ischemic 
heart failure and critical limb ischemia. 
 
Critical Parameters and Troubleshooting 
Table 1. Troubleshooting Guide for Common Problems 
Problem Possible Cause Potential Solution 
BASIC PROTOCOL 1: Purification of UCB progenitors based on ALDH activity 
Incomplete red blood cell 
lysis 
High frequency of 
nucleated red blood cells 
Perform a second round of 
lysis in ammonium chloride 
solution 
Clogging during sort Too much debris or 
clumping cells 
Keep cells on ice and filter 
immediately before sorting  
BASIC PROTOCOL 2: Co-culture of UCB progenitors in vitro 
Contact inhibition or 
overgrowth of HMVEC 
during co-culture 
Initial seeding of cells at 
too high density 
Seed cells at a lowered 
density. Shorten incubation 
endpoint 
BASIC PROTOCOL 3: Femoral artery ligation and transplantation in vivo 
Bleeding during surgery Rupture of blood vessel Euthanize mouse  
Excessive necrosis in 
mouse surgical limb 
Damage to femoral nerve Euthanize mouse, take care 
not to damage the femoral 
nerve during surgery 
Mouse slow to recover after 
anesthesia 
Excessive anesthesia Administer intraperitoneal 
saline, place mouse under 
heat lamp or on heat pad to 
keep warm 
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Anticipated Results 
A 40-50mL lineage-depleted UCB sample will typically contain 200-300x106 
mononucleated white blood cells. Lineage depletion using RosetteSep™ results in the 
reduction of total cell numbers to <50x106 cells for the Aldefluor™ assay and FACS. 
Approximately 2-3% of lineage depleted cells will demonstrate high ALDH activity (Fig. 
1C), and the ALDHhi population should be separated from the ALDHlo cells by greater 
than half a log scale. Depending on cell sorting efficiency a typical UCB sample will 
yield approximately 2x105-1.5x106 ALDHhi cells for functional experimentation. These 
cell numbers represent ample cell numbers to perform the co-culture experiments in a 12-
well format. Furthermore, we routinely inject 2x105 cells per mouse during 
transplantation experiments. Therefore, from a single UCB sample we obtain sufficient 
purified cell numbers to transplant 4-8 mice plus PBS controls. 
In the in vivo transplantation model, the surgically-induced reduction in perfusion may 
differ between individual mouse strains or between surgeons if the surgical technique 
differs slightly. We recommend setting a maximum perfusion ratio of 0.1 measured 
immediately after surgery as a criterion to exclude mice with potentially incomplete 
induction of limb ischemia. In our experience this level of ischemia does not induce loss 
of limb or excessive morbidity as long as there is no damage to the femoral nerve. 
LDPI performed on live anesthetized mice allows the accurate quantification of the 
recovery of perfusion in the ischemic limb over a pre-determined time course. The 
recovery of perfusion to the ischemic limb occurs rapidly over the first 7 days. Therefore, 
several LDPI measurements should be taken in the first week to closely monitor the 
kinetics of recovery. In PBS-injected control animals, the recovery of perfusion may 
plateau after 14–28 days at ≈40-50% of the non-ischemic limb depending on the recipient 
mouse strain. This baseline recovery in perfusion is sufficient to prevent limb loss and 
avoid significant morbidity and mortality.  
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Time Considerations 
Once familiar with the protocol, the processing of an UCB unit to prepare for Aldefluor 
sorting can be completed in approximately 3 hours including all incubations.  Depending 
on sorted cell concentration and equipment, a lineage depleted UCB sample can be sorted 
in 1-2 hours from set-up through shut down. An experienced flow cytometry operator is 
recommended to properly perform and troubleshoot the important steps of cell sorting. 
Similarly, an experienced animal technician can complete anesthesia, preparation and 
surgery on a mouse in 20-30 minutes.  Depending on size of LDPI taken, non-invasive 
perfusion measurement can be completed in 10-15 minutes per mouse including 
temperature stabilization. Generally, 30 minutes is sufficient time for a mouse to recover 
from anesthesia and surgery.  
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